<author><surname>Samani</surname> <given-names>NJ</given-names> </author><author><surname>van der Harst</surname> <given-names>P</given-names> </author><title>Biological ageing and cardiovascular disease</title><source>Heart</source><year>2008</year><volume>94</volume><fpage>537</fpage><lpage>539</lpage>
<author><surname>Fuster</surname> <given-names>JJ</given-names> </author><author><surname>Andr&#233;s</surname> <given-names>V</given-names> </author><title>Telomere biology and cardiovascular disease</title><source>Circ Res</source><year>2006</year><volume>99</volume><fpage>1167</fpage><lpage>1180</lpage>
<author><surname>Aviv</surname> <given-names>A</given-names> </author><title>Telomeres and human somatic fitness</title><source>J Gerontol A Biol Sci Med Sci</source><year>2006</year><volume>61</volume><fpage>871</fpage><lpage>873</lpage>
<author><surname>Kimura</surname> <given-names>M</given-names> </author><author><surname>Hjelmborg</surname> <given-names>JB</given-names> </author><author><surname>Gardner</surname> <given-names>JP</given-names> </author><title>Short leukocyte telomeres forecast mortality: a study in elderly Danish twins</title><source>Am J Epidemiol</source><year>2008</year><volume>167</volume><fpage>799</fpage><lpage>806</lpage>
<author><surname>Bakaysa</surname> <given-names>SL</given-names> </author><author><surname>Mucci</surname> <given-names>LA</given-names> </author><author><surname>Slagboom</surname> <given-names>PE</given-names> </author><title>Telomere length predicts survival independent of genetic influences</title><source>Aging Cell</source><year>2007</year><volume>6</volume><fpage>769</fpage><lpage>774</lpage>
<author><surname>Njajou</surname> <given-names>OT</given-names> </author><author><surname>Cawthon</surname> <given-names>RM</given-names> </author><author><surname>Damcott</surname> <given-names>CM</given-names> </author><title>Telomere length is paternally inherited and is associated with parental lifespan</title><source>Proc Natl Acad Sci U S A</source><year>2007</year><volume>104</volume><fpage>12135</fpage><lpage>12139</lpage>
<author><surname>Bekaert</surname> <given-names>S</given-names> </author><author><surname>De Meyer</surname> <given-names>T</given-names> </author><author><surname>Rietzschel</surname> <given-names>ER</given-names> </author><title>Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease</title><source>Aging Cell</source><year>2007</year><volume>6</volume><fpage>639</fpage><lpage>647</lpage>
<author><surname>Spyridopoulos</surname> <given-names>I</given-names> </author><author><surname>Erben</surname> <given-names>Y</given-names> </author><author><surname>Brummendorf</surname> <given-names>TH</given-names> </author><title>Telomere gap between granulocytes and lymphocytes is a determinant for hematopoetic progenitor cell impairment in patients with previous myocardial infarction</title><source>Arterioscler Thromb Vasc Biol</source><year>2008</year><volume>28</volume><fpage>968</fpage><lpage>974</lpage>
<author><surname>Brouilette</surname> <given-names>SW</given-names> </author><author><surname>Moore</surname> <given-names>JS</given-names> </author><author><surname>McMahon</surname> <given-names>AD</given-names> </author><title>Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study</title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>107</fpage><lpage>114</lpage>
<author><surname>van der Harst</surname> <given-names>P</given-names> </author><author><surname>van der Steege</surname> <given-names>G</given-names> </author><author><surname>de Boer</surname> <given-names>RA</given-names> </author><title>Telomere length of circulating leukocytes is decreased in patients with chronic heart failure</title><source>J Am Coll Cardiol</source><year>2007</year><volume>49</volume><fpage>1459</fpage><lpage>1464</lpage>
<author><surname>O&#8217;Donnell</surname> <given-names>CJ</given-names> </author><author><surname>Demissie</surname> <given-names>S</given-names> </author><author><surname>Kimura</surname> <given-names>M</given-names> </author><title>Leukocyte telomere length and carotid artery intimal medial thickness: The Framingham Heart Study</title><source>Arterioscler Thromb Vasc Biol</source><year>2008</year><volume>28</volume><fpage>1165</fpage><lpage>1171</lpage>
<author><surname>Okuda</surname> <given-names>K</given-names> </author><author><surname>Bardeguez</surname> <given-names>A</given-names> </author><author><surname>Gardner</surname> <given-names>JP</given-names> </author><title>Telomere length in the newborn</title><source>Pediatr Res</source><year>2002</year><volume>52</volume><fpage>377</fpage><lpage>381</lpage>
<author><surname>Akkad</surname> <given-names>A</given-names> </author><author><surname>Hastings</surname> <given-names>R</given-names> </author><author><surname>Konje</surname> <given-names>JC</given-names> </author><title>Telomere length in small-for-gestational-age babies</title><source>BJOG</source><year>2006</year><volume>113</volume><fpage>318</fpage><lpage>323</lpage>
<author><surname>Martin-Ruiz</surname> <given-names>CM</given-names> </author><author><surname>Gussekloo</surname> <given-names>J</given-names> </author><author><surname>van Heemst</surname> <given-names>D</given-names> </author><title>Telomere length in white blood cells is not associated with morbidity or mortality in the oldest old: a population-based study</title><source>Aging Cell</source><year>2005</year><volume>4</volume><fpage>287</fpage><lpage>290</lpage>
<author><surname>Ehrlenbach</surname> <given-names>S</given-names> </author><author><surname>Willeit</surname> <given-names>P</given-names> </author><author><surname>Kiechl</surname> <given-names>S</given-names> </author><title>Influences on the reduction of relative telomere length over 10 years in the population-based Bruneck Study: introduction of a well-controlled high-throughput assay</title><source>Int J Epidemiol</source><year>2009</year><volume>38</volume><issue>6</issue><fpage>1725</fpage><lpage>1734</lpage>
<author><surname>Aviv</surname> <given-names>A</given-names> </author><author><surname>Chen</surname> <given-names>W</given-names> </author><author><surname>Gardner</surname> <given-names>JP</given-names> </author><title>Leukocyte telomere dynamics: longitudinal findings among young adults in the Bogalusa Heart Study</title><source>Am J Epidemiol</source><year>2009</year><volume>169</volume><fpage>323</fpage><lpage>329</lpage>
<author><surname>Nordfj&#228;ll</surname> <given-names>K</given-names> </author><author><surname>Svenson</surname> <given-names>U</given-names> </author><author><surname>Norrback</surname> <given-names>KF</given-names> </author><author><surname>Adolfsson</surname> <given-names>R</given-names> </author><author><surname>Lenner</surname> <given-names>P</given-names> </author><author><surname>Roos</surname> <given-names>G</given-names> </author><title>The individual blood cell telomere attrition rate is telomere length dependent</title><source>PLoS Genet</source><year>2009</year><volume>5</volume><issue>2</issue><fpage>e1000375</fpage>
<author><surname>Farzaneh-Far</surname> <given-names>R</given-names> </author><author><surname>Lin</surname> <given-names>J</given-names> </author><author><surname>Epel</surname> <given-names>E</given-names> </author><title>Telomere length trajectory and its determinants in persons with coronary artery disease: longitudinal findings from the heart and soul study</title><source>PloS One</source><year>2010</year><volume>5</volume><issue>1</issue><fpage>e8612</fpage>
<author><surname>Farzaneh-Far</surname> <given-names>R</given-names> </author><author><surname>Lin</surname> <given-names>J</given-names> </author><author><surname>Epel</surname> <given-names>E</given-names> </author><author><surname>Harris</surname> <given-names>WS</given-names> </author><author><surname>Blackburn</surname> <given-names>EH</given-names> </author><author><surname>Whooley</surname> <given-names>MA</given-names> </author><title>Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease</title><source>JAMA</source><year>2010</year><volume>303</volume><fpage>250</fpage><lpage>257</lpage>
<author><surname>Aviv</surname> <given-names>A</given-names> </author><title>The epidemiology of human telomeres: faults and promises</title><source>J Gerontol A Biol Sci Med Sci</source><year>2008</year><volume>63</volume><fpage>979</fpage><lpage>983</lpage>
<author><surname>Berenson</surname> <given-names>GS</given-names> </author><author><surname>McMahan</surname> <given-names>CA</given-names> </author><author><surname>Voors</surname> <given-names>AW</given-names> </author><source>Cardiovascular Risk Factors in Children&#8212;The Early Natural History of Atherosclerosis and Essential Hypertension.</source><year>1980</year><other>New York</other><publisher>Oxford University Press</publisher><fpage>47</fpage><lpage>123</lpage>
<author><surname>Kimura</surname> <given-names>M</given-names> </author><author><surname>Stone</surname> <given-names>RC</given-names> </author><author><surname>Hunt</surname> <given-names>SC</given-names> </author><title>Measurement of telomere length by the southern blot analysis of the terminal restriction fragment lengths</title><source>Nature Protocols</source><year>2010</year><volume>5</volume><fpage>1596</fpage><lpage>1607</lpage>
<author><surname>Kuh</surname> <given-names>D</given-names> </author><title>A life course perspective on telomere length and social inequalities in aging</title><source>Aging Cell</source><year>2006</year><volume>5</volume><fpage>579</fpage><lpage>580</lpage>
<author><surname>Xu</surname> <given-names>Q</given-names> </author><author><surname>Parks</surname> <given-names>CG</given-names> </author><author><surname>DeRoo</surname> <given-names>LA</given-names> </author><title>Multivitamin use and telomere length in women</title><source>Am J Clin Nutr</source><year>2009</year><volume>89</volume><fpage>1857</fpage><lpage>1863</lpage>
<author><surname>Mov&#233;rare-Skrtic</surname> <given-names>S</given-names> </author><author><surname>Svensson</surname> <given-names>J</given-names> </author><author><surname>Karlsson</surname> <given-names>MK</given-names> </author><title>Serum insulin-like growth factor-I concentration is associated with leukocyte telomere length in a population-based cohort of elderly men</title><source>J Clin Endocrinol Metab</source><year>2009</year><volume>94</volume><fpage>5078</fpage><lpage>584</lpage>
<author><surname>Lansdorp</surname> <given-names>PM</given-names> </author><title>Stress, social rank and leukocyte telomere length</title><source>Aging Cell</source><year>2006</year><volume>5</volume><fpage>583</fpage><lpage>584</lpage>
<author><surname>Cawthon</surname> <given-names>RM</given-names> </author><title>Telomere measurement by quantitative PCR</title><source>Nucleic Acids Res</source><year>2002</year><volume>30</volume><fpage>e47</fpage>
<author><surname>Aviv</surname> <given-names>A</given-names> </author><author><surname>Valdes</surname> <given-names>AM</given-names> </author><author><surname>Spector</surname> <given-names>TD</given-names> </author><title>Human telomere biology: pitfalls of moving from the laboratory to epidemiology</title><source>Int J Epidemiol</source><year>2006</year><volume>35</volume><fpage>1424</fpage><lpage>1429</lpage>
<author><surname>Shen</surname> <given-names>J</given-names> </author><author><surname>Terry</surname> <given-names>MB</given-names> </author><author><surname>Gurvich</surname> <given-names>I</given-names> </author><title>Short telomere length and breast cancer risk: a study in sister sets</title><source>Cancer Res</source><year>2007</year><volume>67</volume><fpage>5538</fpage><lpage>5544</lpage>
<author><surname>Rufer</surname> <given-names>N</given-names> </author><author><surname>Br&#252;mmendorf</surname> <given-names>TH</given-names> </author><author><surname>Kolvraa</surname> <given-names>S</given-names> </author><title>Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood</title><source>J. Exp. Med</source><year>1999</year><volume>190</volume><fpage>157</fpage><lpage>167</lpage>
<author><surname>Zeichner</surname> <given-names>SL</given-names> </author><author><surname>Palumbo</surname> <given-names>P</given-names> </author><author><surname>Feng</surname> <given-names>Y</given-names> </author><title>Rapid telomere shortening in children</title><source>Blood</source><year>1999</year><volume>93</volume><fpage>2824</fpage><lpage>2830</lpage>
<author><surname>Frenck</surname> <given-names>RW</given-names> <suffix>Jr.</suffix> </author><author><surname>Blackburn</surname> <given-names>EH</given-names> </author><author><surname>Shannon</surname> <given-names>KM</given-names> </author><title>The rate of telomere sequence loss in human leukocytes varies with age</title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>5607</fpage><lpage>5610</lpage>
<author><surname>Sidorov</surname> <given-names>I</given-names> </author><author><surname>Kimura</surname> <given-names>M</given-names> </author><author><surname>Yashin</surname> <given-names>A</given-names> </author><title>Leukocyte telomere dynamics and human hematopoietic stem cell kinetics during somatic growth</title><source>Exp Hematol</source><year>2009</year><volume>37</volume><fpage>514</fpage><lpage>524</lpage>
<author><surname>Barbieri</surname> <given-names>M</given-names> </author><author><surname>Paolisso</surname> <given-names>G</given-names> </author><author><surname>Kimura</surname> <given-names>M</given-names> </author><title>Higher circulating levels of IGF-1 are associated with longer leukocyte telomere length in healthy subjects</title><source>Mech Ageing Dev</source><year>2009</year><volume>130</volume><fpage>771</fpage><lpage>776</lpage>
<author><surname>Hunt</surname> <given-names>SC</given-names> </author><author><surname>Chen</surname> <given-names>W</given-names> </author><author><surname>Gardner</surname> <given-names>JP</given-names> </author><title>Leukocyte telomeres are longer in African Americans than in whites: the National Heart, Lung, and Blood Institute Family Heart Study and the Bogalusa Heart Study</title><source>Aging Cell</source><year>2008</year><volume>7</volume><fpage>451</fpage><lpage>458</lpage>
<author><surname>Jeanclos</surname> <given-names>E</given-names> </author><author><surname>Schork</surname> <given-names>NJ</given-names> </author><author><surname>Kyvik</surname> <given-names>KO</given-names> </author><title>Telomere length inversely correlates with pulse pressure and is highly familial</title><source>Hypertension</source><year>2000</year><volume>36</volume><fpage>195</fpage><lpage>200</lpage>
<author><surname>Vasan</surname> <given-names>RS</given-names> </author><author><surname>Demissie</surname> <given-names>S</given-names> </author><author><surname>Kimura</surname> <given-names>M</given-names> </author><title>Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study</title><source>Circulation</source><year>2008</year><volume>117</volume><fpage>1138</fpage><lpage>1144</lpage>
<author><surname>Nawrot</surname> <given-names>TS</given-names> </author><author><surname>Staessen</surname> <given-names>JA</given-names> </author><author><surname>Gardner</surname> <given-names>JP</given-names> </author><title>Telomere length and possible link to X chromosome</title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>507</fpage><lpage>510</lpage>
<author><surname>Fitzpatrick</surname> <given-names>AL</given-names> </author><author><surname>Kronmal</surname> <given-names>RA</given-names> </author><author><surname>Gardner</surname> <given-names>JP</given-names> </author><title>Leukocyte telomere length and cardiovascular disease in the Cardiovascular Health Study</title><source>Am J Epidem</source><year>2007</year><volume>165</volume><fpage>14</fpage><lpage>21</lpage>
<author><surname>Benetos</surname> <given-names>A</given-names> </author><author><surname>Okuda</surname> <given-names>K</given-names> </author><author><surname>Lajemi</surname> <given-names>M</given-names> </author><title>Telomere length as indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity</title><source>Hypertension</source><year>2001</year><volume>37</volume><issue>part 2</issue><fpage>381</fpage><lpage>385</lpage>
<author><surname>Valdes</surname> <given-names>A</given-names> </author><author><surname>Andrew</surname> <given-names>T</given-names> </author><author><surname>Gardner</surname> <given-names>JP</given-names> </author><title>Obesity, cigarette smoking, and telomere length in women</title><source>Lancet</source><year>2005</year><volume>66</volume><fpage>662</fpage><lpage>664</lpage>
<author><surname>Kim</surname> <given-names>S</given-names> </author><author><surname>Parks</surname> <given-names>CG</given-names> </author><author><surname>DeRoo</surname> <given-names>LA</given-names> </author><title>Obesity and weight gain in adulthood and telomere length</title><source>Cancer Epidemiol Biomarkers Prev</source><year>2009</year><volume>18</volume><fpage>816</fpage><lpage>820</lpage>
<author><surname>Nordfj&#228;ll</surname> <given-names>K</given-names> </author><author><surname>Eliasson</surname> <given-names>M</given-names> </author><author><surname>Stegmayr</surname> <given-names>B</given-names> </author><author><surname>Lundin</surname> <given-names>S</given-names> </author><author><surname>Roos</surname> <given-names>G</given-names> </author><title>Nilsson PM Increased abdominal obesity, adverse psychosocial factors and shorter telomere length in subjects reporting early ageing; the MONICA Northern Sweden Study</title><source>Scand J Public Health</source><year>2008</year><volume>36</volume><fpage>744</fpage><lpage>752</lpage>
<author><surname>Gardner</surname> <given-names>JP</given-names> </author><author><surname>Li</surname> <given-names>S</given-names> </author><author><surname>Srinivasan</surname> <given-names>SR</given-names> </author><title>Rise in insulin resistance is associated with escalated telomere attrition</title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>2171</fpage><lpage>2177</lpage>
<author><surname>Scher</surname> <given-names>AI</given-names> </author><author><surname>Midgette</surname> <given-names>LA</given-names> </author><author><surname>Lipton</surname> <given-names>RB</given-names> </author><title>Risk factors for headache chronification</title><source>Headache</source><year>2008</year><volume>48</volume><issue>1</issue><fpage>16</fpage><lpage>25</lpage>
<author><surname>Niv</surname> <given-names>D</given-names> </author><author><surname>Devor</surname> <given-names>M</given-names> </author><title>Chronic pain as a disease in its own right</title><source>Pain Pract</source><year>2004</year><volume>4</volume><issue>3</issue><fpage>179</fpage><lpage>181</lpage>
<author><surname>Sicuteri</surname> <given-names>F</given-names> </author><title>Quasi-phantom head pain from functional deafferentation</title><source>Clin J Pain</source><year>1987</year><volume>3</volume><fpage>63</fpage><lpage>80</lpage>
<author><surname>Prakash</surname> <given-names>S</given-names> </author><author><surname>Shah</surname> <given-names>ND</given-names> </author><title>Delayed response of indomethacin in patients with hemicrania continua: real or phantom headache?</title><source>Cephalalgia</source><year>2010</year><volume>30</volume><issue>3</issue><fpage>375</fpage><lpage>379</lpage>
<author><surname>Marmura</surname> <given-names>MJ</given-names> </author><author><surname>Pello</surname> <given-names>SJ</given-names> </author><author><surname>Young</surname> <given-names>WB</given-names> </author><title>Interictal pain in cluster headache</title><source>Cephalalgia</source><year>2010</year><volume>30</volume><issue>12</issue><fpage>1531</fpage><lpage>1534</lpage>
<author><surname>Harris</surname> <given-names>AJ</given-names> </author><title>Cortical origin of pathological pain</title><source>Lancet</source><year>1999</year><volume>354</volume><issue>9188</issue><fpage>1464</fpage><lpage>1466</lpage>
<author><surname>Flor</surname> <given-names>H</given-names> </author><author><surname>Nikolajsen</surname> <given-names>L</given-names> </author><author><surname>Staehelin Jensen</surname> <given-names>T</given-names> </author><title>Phantom limb pain: a case of maladaptive CNS plasticity?</title><source>Nat Rev Neurosci</source><year>2006</year><volume>7</volume><issue>11</issue><fpage>873</fpage><lpage>881</lpage>
<author><surname>Lake</surname> <given-names>AE</given-names> <suffix>III</suffix> </author><title>Chronic daily headache in the absence of medication overuse: is daily or continuous pain more treatment-resistant than chronic daily headache with pain-free days?</title><source>Curr Pain Headache Rep</source><year>2005</year><volume>9</volume><issue>1</issue><fpage>4</fpage><lpage>6</lpage>
<author><surname>Vanast</surname> <given-names>WJ</given-names> </author><title>New daily persistent headaches definition of a benign syndrome</title><source>Headache</source><year>1986</year><volume>26</volume><fpage>317</fpage>
<author><surname>Li</surname> <given-names>D</given-names> </author><author><surname>Rozen</surname> <given-names>TD</given-names> </author><title>The clinical characteristics of new daily persistent headache</title><source>Cephalalgia</source><year>2002</year><volume>22</volume><issue>1</issue><fpage>66</fpage><lpage>69</lpage>
<author><surname>Takase</surname> <given-names>Y</given-names> </author><author><surname>Nakano</surname> <given-names>M</given-names> </author><author><surname>Tatsumi</surname> <given-names>C</given-names> </author><author><surname>Matsuyama</surname> <given-names>T</given-names> </author><title>Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan</title><source>Cephalalgia</source><year>2004</year><volume>24</volume><issue>11</issue><fpage>955</fpage><lpage>959</lpage>
<author><surname>Prakash</surname> <given-names>S</given-names> </author><author><surname>Shah</surname> <given-names>ND</given-names> </author><title>Post-infectious new daily persistent headache may respond to intravenous methylprednisolone</title><source>J Headache Pain</source><year>2010</year><volume>11</volume><issue>1</issue><fpage>59</fpage><lpage>66</lpage>
<author><surname>Evans</surname> <given-names>RW</given-names> </author><title>New daily persistent headache</title><source>Curr Pain Headache Rep</source><year>2003</year><volume>7</volume><issue>4</issue><fpage>303</fpage><lpage>307</lpage>
<author><surname>Choi</surname> <given-names>DS</given-names> </author><author><surname>Choi</surname> <given-names>DY</given-names> </author><author><surname>Whittington</surname> <given-names>RA</given-names> </author><author><surname>Nedeljkovi&#263;</surname> <given-names>SS</given-names> </author><title>Sudden amnesia resulting in pain relief: the relationship between memory and pain</title><source>Pain</source><year>2007</year><volume>132</volume><issue>1&#8211;2</issue><fpage>206</fpage><lpage>210</lpage>
<author><surname>Farrell</surname> <given-names>MJ</given-names> </author><author><surname>Katz</surname> <given-names>B</given-names> </author><author><surname>Helme</surname> <given-names>RD</given-names> </author><title>The impact of dementia on the pain experience</title><source>Pain</source><year>1996</year><volume>67</volume><issue>1</issue><fpage>7</fpage><lpage>15</lpage>
<author><surname>Scherder</surname> <given-names>E</given-names> </author><author><surname>Herr</surname> <given-names>K</given-names> </author><author><surname>Pickering</surname> <given-names>G</given-names> </author><author><surname>Gibson</surname> <given-names>S</given-names> </author><author><surname>Benedetti</surname> <given-names>F</given-names> </author><author><surname>Lautenbacher</surname> <given-names>S</given-names> </author><title>Pain in dementia</title><source>Pain</source><year>2009</year><volume>145</volume><issue>3</issue><fpage>276</fpage><lpage>278</lpage>
<author><surname>Pickering</surname> <given-names>G</given-names> </author><author><surname>Jourdan</surname> <given-names>D</given-names> </author><author><surname>Dubray</surname> <given-names>C</given-names> </author><title>Acute versus chronic pain treatment in Alzheimer&#8217;s disease</title><source>Eur J Pain</source><year>2006</year><volume>10</volume><issue>4</issue><fpage>379</fpage><lpage>384</lpage>
<author><surname>Kunz</surname> <given-names>M</given-names> </author><author><surname>Scharmann</surname> <given-names>S</given-names> </author><author><surname>Hemmeter</surname> <given-names>U</given-names> </author><author><surname>Schepelmann</surname> <given-names>K</given-names> </author><author><surname>Lautenbacher</surname> <given-names>S</given-names> </author><title>The facial expression of pain in patients with dementia</title><source>Pain</source><year>2007</year><volume>133</volume><issue>1&#8211;3</issue><fpage>221</fpage><lpage>228</lpage>
<author><surname>Cole</surname> <given-names>LJ</given-names> </author><author><surname>Farrell</surname> <given-names>MJ</given-names> </author><author><surname>Duff</surname> <given-names>EP</given-names> </author><author><surname>Barber</surname> <given-names>JB</given-names> </author><author><surname>Egan</surname> <given-names>GF</given-names> </author><author><surname>Gibson</surname> <given-names>SJ</given-names> </author><title>Pain sensitivity and fMRI pain-related brain activity in Alzheimer&#8217;s disease</title><source>Brain</source><year>2006</year><volume>129</volume><issue>Pt 11</issue><fpage>2957</fpage><lpage>2965</lpage>
<author><surname>Ringman</surname> <given-names>JM</given-names> </author><author><surname>Romano</surname> <given-names>JD</given-names> </author><author><surname>Medina</surname> <given-names>LD</given-names> </author><author><surname>Rodriguez-Agudelo</surname> <given-names>Y</given-names> </author><author><surname>Schaffer</surname> <given-names>B</given-names> </author><author><surname>Varpetian</surname> <given-names>A</given-names> </author><title>Increased prevalence of significant recurrent headache in preclinical familial Alzheimer&#8217;s disease mutation carriers</title><source>Dement Geriatr Cogn Disord</source><year>2008</year><volume>25</volume><issue>4</issue><fpage>380</fpage><lpage>384</lpage>
<author><surname>Takeshima</surname> <given-names>T</given-names> </author><author><surname>Taniguchi</surname> <given-names>R</given-names> </author><author><surname>Kitagawa</surname> <given-names>T</given-names> </author><author><surname>Takahashi</surname> <given-names>K</given-names> </author><title>Headaches in dementia</title><source>Headache</source><year>1990</year><volume>30</volume><issue>11</issue><fpage>735</fpage><lpage>738</lpage>
<author><surname>Nampiaparampil</surname> <given-names>DE</given-names> </author><title>Prevalence of chronic pain after traumatic brain injury: a systematic review</title><source>JAMA</source><year>2008</year><volume>300</volume><issue>6</issue><fpage>711</fpage><lpage>719</lpage>
<author><surname>Couch</surname> <given-names>JR</given-names> </author><author><surname>Bearss</surname> <given-names>C</given-names> </author><title>Chronic daily headache in the post trauma syndrome: relation to extent of head injury</title><source>Headache</source><year>2001</year><volume>41</volume><issue>6</issue><fpage>559</fpage><lpage>564</lpage>
<author><surname>Formisano</surname> <given-names>R</given-names> </author><author><surname>Buzzi</surname> <given-names>MG</given-names> </author><author><surname>Bivona</surname> <given-names>U</given-names> </author><author><surname>Matteis</surname> <given-names>M</given-names> </author><author><surname>Caltagirone</surname> <given-names>C</given-names> </author><title>Assessing cognitive and psychological patterns in posttraumatic headache following severe brain injury</title><source>J Neurotrauma</source><year>2002</year><volume>19</volume><fpage>1366</fpage>
<author><surname>Solomon</surname> <given-names>S</given-names> </author><title>Post-traumatic headache: commentary: an overview</title><source>Headache</source><year>2009</year><volume>49</volume><issue>7</issue><fpage>1112</fpage><lpage>1115</lpage>
<author><surname>May</surname> <given-names>A</given-names> </author><title>Chronic pain may change the structure of the brain</title><source>Pain</source><year>2008</year><volume>137</volume><fpage>7</fpage><lpage>15</lpage>
<author><surname>Apkarian</surname> <given-names>AV</given-names> </author><author><surname>Bushnell</surname> <given-names>MC</given-names> </author><author><surname>Treede</surname> <given-names>RD</given-names> </author><author><surname>Zubieta</surname> <given-names>JK</given-names> </author><title>Human brain mechanisms of pain perception and regulation in health and disease</title><source>Eur J Pain</source><year>2005</year><volume>9</volume><issue>4</issue><fpage>463</fpage><lpage>484</lpage>
<author><surname>Svoboda</surname> <given-names>E</given-names> </author><author><surname>McKinnon</surname> <given-names>MC</given-names> </author><author><surname>Levine</surname> <given-names>B</given-names> </author><title>The functional neuroanatomy of autobiographical memory: a meta-analysis</title><source>Neuropsychologia</source><year>2006</year><volume>44</volume><issue>12</issue><fpage>2189</fpage><lpage>2208</lpage>
<author><surname>Diesch</surname> <given-names>E</given-names> </author><author><surname>Flor</surname> <given-names>H</given-names> </author><title>Alteration in the response properties of primary somatosensory cortex related to differential aversive Pavlovian conditioning</title><source>Pain</source><year>2007</year><volume>131</volume><issue>1&#8211;2</issue><fpage>171</fpage><lpage>180</lpage>
<author><surname>Morgane</surname> <given-names>PJ</given-names> </author><author><surname>Galler</surname> <given-names>JR</given-names> </author><author><surname>Mokler</surname> <given-names>DJ</given-names> </author><title>A review of systems and networks of the limbic forebrain/limbic midbrain</title><source>Prog Neurobiol</source><year>2005</year><volume>75</volume><issue>2</issue><fpage>143</fpage><lpage>160</lpage>
<author><surname>Guidetti</surname> <given-names>V</given-names> </author><author><surname>Galli</surname> <given-names>F</given-names> </author><title>Psychiatric comorbidity in chronic daily headache: pathophysiology, etiology, and diagnosis</title><source>Curr Pain Headache Rep</source><year>2002</year><volume>6</volume><issue>6</issue><fpage>492</fpage><lpage>497</lpage>
<author><surname>Fenton</surname> <given-names>BW</given-names> </author><title>Limbic associated pelvic pain: a hypothesis to explain the diagnostic relationships and features of patients with chronic pelvic pain</title><source>Med Hypotheses</source><year>2007</year><volume>69</volume><issue>2</issue><fpage>282</fpage><lpage>286</lpage>
<author><surname>Turk</surname> <given-names>CD</given-names> </author><author><surname>Wilson</surname> <given-names>HD</given-names> </author><title>Fear of pain as a prognostic factor in chronic pain: conceptual models, assessment, and treatment implications</title><source>Curr Pain Headache Rep</source><year>2010</year><volume>14</volume><fpage>88</fpage><lpage>95</lpage>
<author><surname>Lackner</surname> <given-names>JM</given-names> </author><author><surname>Lou Coad</surname> <given-names>M</given-names> </author><author><surname>Mertz</surname> <given-names>HR</given-names> </author><author><surname>Wack</surname> <given-names>DS</given-names> </author><author><surname>Katz</surname> <given-names>LA</given-names> </author><author><surname>Krasner</surname> <given-names>SS</given-names> </author><title>Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety</title><source>Behav Res Ther</source><year>2006</year><volume>44</volume><issue>5</issue><fpage>621</fpage><lpage>638</lpage>
<author><surname>Shaw</surname> <given-names>WS</given-names> </author><author><surname>Means-Christensen</surname> <given-names>AJ</given-names> </author><author><surname>Slater</surname> <given-names>MA</given-names> </author><author><surname>Webster</surname> <given-names>JS</given-names> </author><author><surname>Patterson</surname> <given-names>TL</given-names> </author><author><surname>Grant</surname> <given-names>I</given-names> </author><title>Psychiatric disorders and risk of transition to chronicity in men with first onset low back pain</title><source>Pain Med</source><year>2010</year><volume>11</volume><fpage>1391</fpage><lpage>1400</lpage>
<author><surname>Apkarian</surname> <given-names>AV</given-names> </author><title>Pain perception in relation to emotional learning</title><source>Curr Opin Neurobiol</source><year>2008</year><volume>18</volume><issue>4</issue><fpage>464</fpage><lpage>468</lpage>
<author><surname>Giummarra</surname> <given-names>MJ</given-names> </author><author><surname>Gibson</surname> <given-names>SJ</given-names> </author><author><surname>Georgiou-Karistianis</surname> <given-names>N</given-names> </author><author><surname>Bradshaw</surname> <given-names>JL</given-names> </author><title>Central mechanisms in phantom limb perception: the past, present and future</title><source>Brain Res Rev</source><year>2007</year><volume>54</volume><fpage>219</fpage><lpage>232</lpage>
<author><surname>Wiech</surname> <given-names>K</given-names> </author><author><surname>Ploner</surname> <given-names>M</given-names> </author><author><surname>Tracey</surname> <given-names>I</given-names> </author><title>Neurocognitive aspects of pain perception</title><source>Trends Cogn Sci</source><year>2008</year><volume>12</volume><issue>8</issue><fpage>306</fpage><lpage>313</lpage>
<author><surname>Lai</surname> <given-names>CH</given-names> </author><author><surname>Hsu</surname> <given-names>YY</given-names> </author><title>A subtle grey-matter increase in first-episode, drug-naive major depressive disorder with panic disorder after 6&#160;weeks&#8217; duloxetine therapy</title><source>Int J Neuropsychopharmacol</source><year>2010</year><volume>22</volume><fpage>1</fpage><lpage>11</lpage>
<author><surname>Barrios</surname> <given-names>V</given-names> </author><author><surname>Escobar</surname> <given-names>C</given-names> </author><author><surname>Calder&#243;n</surname> <given-names>A</given-names> </author><author><surname>Llisterri</surname> <given-names>JL</given-names> </author><author><surname>Alegr&#237;a</surname> <given-names>E</given-names> </author><author><surname>Mu&#241;iz</surname> <given-names>J</given-names> </author><title>Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis</title><source>J Cardiometab Syndr</source><year>2007</year><volume>2</volume><fpage>9</fpage><lpage>15</lpage>
<author><surname>Schillaci</surname> <given-names>G</given-names> </author><author><surname>Pirro</surname> <given-names>M</given-names> </author><author><surname>Vaudo</surname> <given-names>G</given-names> </author><author><surname>Gemelli</surname> <given-names>F</given-names> </author><author><surname>Marchesi</surname> <given-names>S</given-names> </author><author><surname>Porcellati</surname> <given-names>C</given-names> </author><title>Prognostic value of the metabolic syndrome in essential hypertension</title><source>J Am Coll Cardiol</source><year>2004</year><volume>43</volume><fpage>1817</fpage><lpage>1822</lpage>
<author><surname>Liu</surname> <given-names>SJ</given-names> </author><author><surname>Guo</surname> <given-names>ZR</given-names> </author><author><surname>Hu</surname> <given-names>XS</given-names> </author><author><surname>Wu</surname> <given-names>M</given-names> </author><author><surname>Chen</surname> <given-names>FM</given-names> </author><author><surname>Kang</surname> <given-names>GD</given-names> </author><title>Risks for type-2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome the study from Jiangsu, China of 5 years follow-up</title><source>Diabetes Res Clin Pract</source><year>2008</year><volume>81</volume><fpage>117</fpage><lpage>123</lpage>
<author><surname>Elliott</surname> <given-names>WJ</given-names> </author><author><surname>Meyer</surname> <given-names>PM</given-names> </author><title>Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis</title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>201</fpage><lpage>207</lpage>
<author><surname>Bakris</surname> <given-names>GL</given-names> </author><title>Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker</title><source>J Clin Hypertens</source><year>2008</year><volume>10</volume><fpage>27</fpage><lpage>32</lpage>
<author><surname>Mancia</surname> <given-names>G</given-names> </author><author><surname>Laurent</surname> <given-names>S</given-names> </author><author><surname>Agabiti-Rosei</surname> <given-names>E</given-names> </author><author><surname>Ambrosioni</surname> <given-names>E</given-names> </author><author><surname>Burnier</surname> <given-names>M</given-names> </author><author><surname>Caulfield</surname> <given-names>MJ</given-names> </author><title>Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document</title><source>Blood Press</source><year>2009</year><volume>18</volume><fpage>308</fpage><lpage>347</lpage>
<author><surname>Bakris</surname> <given-names>G</given-names> </author><author><surname>Molitch</surname> <given-names>M</given-names> </author><author><surname>Hewkin</surname> <given-names>A</given-names> </author><author><surname>Kipnes</surname> <given-names>M</given-names> </author><author><surname>Sarafidis</surname> <given-names>P</given-names> </author><author><surname>Fakouhi</surname> <given-names>K</given-names> </author><author><surname>Bacher</surname> <given-names>P</given-names> </author><author><surname>Sowers</surname> <given-names>J</given-names> </author><title>STAR investigators. differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome</title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>2592</fpage><lpage>2597</lpage>
<author><surname>Kintscher</surname> <given-names>U</given-names> </author><author><surname>Bramlage</surname> <given-names>P</given-names> </author><author><surname>Paar</surname> <given-names>WD</given-names> </author><author><surname>Thoenes</surname> <given-names>M</given-names> </author><author><surname>Unger</surname> <given-names>T</given-names> </author><title>Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two-armed study in 14&#8201;200 patients</title><source>Cardiovasc Diabetol</source><year>2007</year><volume>6</volume><fpage>12</fpage>
<author><surname>Heidemann</surname> <given-names>C</given-names> </author><author><surname>Sun</surname> <given-names>Q</given-names> </author><author><surname>van Dam</surname> <given-names>RM</given-names> </author><author><surname>Meigs</surname> <given-names>JB</given-names> </author><author><surname>Zhang</surname> <given-names>C</given-names> </author><author><surname>Tworoger</surname> <given-names>SS</given-names> </author><title>Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women</title><source>Ann Intern Med</source><year>2008</year><volume>149</volume><fpage>307</fpage><lpage>316</lpage>
<author><surname>Sj&#246;holm</surname> <given-names>A</given-names> </author><author><surname>Nystr&#246;m</surname> <given-names>T</given-names> </author><title>Inflammation and the etiology of type 2 diabetes</title><source>Diabetes Metab Res Rev</source><year>2006</year><volume>22</volume><fpage>4</fpage><lpage>10</lpage>
<author><surname>Rubin</surname> <given-names>D</given-names> </author><author><surname>Claas</surname> <given-names>S</given-names> </author><author><surname>Pfeuffer</surname> <given-names>M</given-names> </author><author><surname>Nothnagel</surname> <given-names>M</given-names> </author><author><surname>Foelsch</surname> <given-names>UR</given-names> </author><author><surname>Schrezenmeir</surname> <given-names>J</given-names> </author><title>s-ICAM-1 and s-VCAM-1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal</title><source>Lipids Health Dis</source><year>2008</year><volume>7</volume><fpage>32</fpage>
<author><surname>Fabia</surname> <given-names>MJ</given-names> </author><author><surname>Abdilla</surname> <given-names>N</given-names> </author><author><surname>Oltra</surname> <given-names>R</given-names> </author><author><surname>Fernandez</surname> <given-names>C</given-names> </author><author><surname>Redon</surname> <given-names>J</given-names> </author><title>Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24&#8201;h ambulatory blood pressure monitoring</title><source>J Hypertens</source><year>2007</year><volume>25</volume><fpage>1327</fpage><lpage>1336</lpage>
<author><surname>Mason</surname> <given-names>RP</given-names> </author><author><surname>Marche</surname> <given-names>P</given-names> </author><author><surname>Hintze</surname> <given-names>TH</given-names> </author><title>Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine</title><source>Arterioscler Thromb Vasc Biol</source><year>2003</year><volume>23</volume><fpage>2155</fpage><lpage>2163</lpage>
<author><surname>Fogari</surname> <given-names>R</given-names> </author><author><surname>Preti</surname> <given-names>P</given-names> </author><author><surname>Zoppi</surname> <given-names>A</given-names> </author><author><surname>Mugellini</surname> <given-names>A</given-names> </author><author><surname>Corradi</surname> <given-names>L</given-names> </author><author><surname>Lazzari</surname> <given-names>P</given-names> </author><author><surname>Santoro</surname> <given-names>T</given-names> </author><author><surname>Derosa</surname> <given-names>G</given-names> </author><title>Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients</title><source>Intern Med</source><year>2008</year><volume>47</volume><fpage>1851</fpage><lpage>1857</lpage>
<author><surname>Alberti</surname> <given-names>KG</given-names> </author><author><surname>Zimmet</surname> <given-names>P</given-names> </author><author><surname>Shaw</surname> <given-names>J</given-names> </author><title>The metabolic syndrome-a new worldwide definition</title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1059</fpage><lpage>1062</lpage>
<author><surname>Hansson</surname> <given-names>L</given-names> </author><author><surname>Hedner</surname> <given-names>T</given-names> </author><author><surname>Dahl&#246;f</surname> <given-names>B</given-names> </author><title>Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials</title><source>Blood Press</source><year>1992</year><volume>1</volume><fpage>113</fpage><lpage>119</lpage>
<source>Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia</source><publisher>WHO: Geneva, Switzerland</publisher><year>2006</year>
<author><surname>Wallace</surname> <given-names>TM</given-names> </author><author><surname>Levy</surname> <given-names>JC</given-names> </author><author><surname>Matthews</surname> <given-names>DR</given-names> </author><title>Use and abuse of HOMA modeling</title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>1487</fpage><lpage>1495</lpage>
<author><surname>Law</surname> <given-names>MR</given-names> </author><author><surname>Wald</surname> <given-names>NJ</given-names> </author><author><surname>Morris</surname> <given-names>JK</given-names> </author><author><surname>Jordan</surname> <given-names>RE</given-names> </author><title>Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials</title><source>BMJ</source><year>2003</year><volume>326</volume><fpage>1427</fpage><lpage>1431</lpage>
<author><surname>Wald</surname> <given-names>DS</given-names> </author><author><surname>Law</surname> <given-names>M</given-names> </author><author><surname>Morris</surname> <given-names>JK</given-names> </author><author><surname>Bestwick</surname> <given-names>JP</given-names> </author><author><surname>Wald</surname> <given-names>NJ</given-names> </author><title>Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11&#8201;000 participants from 42 trials</title><source>Am J Med</source><year>2009</year><volume>122</volume><fpage>290</fpage><lpage>300</lpage>
<author><surname>Chrysant</surname> <given-names>SG</given-names> </author><author><surname>Melino</surname> <given-names>M</given-names> </author><author><surname>Karki</surname> <given-names>S</given-names> </author><author><surname>Lee</surname> <given-names>J</given-names> </author><author><surname>Heyrman</surname> <given-names>R</given-names> </author><title>The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study</title><source>Clin Ther</source><year>2008</year><volume>30</volume><fpage>587</fpage><lpage>604</lpage>
<author><surname>Punzi</surname> <given-names>HA</given-names> </author><title>Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide</title><source>Expert Rev Cardiovasc Ther</source><year>2009</year><volume>7</volume><fpage>229</fpage><lpage>239</lpage>
<author><surname>De Pablos-Velasco</surname> <given-names>PL</given-names> </author><author><surname>Mart&#237;nez-Mart&#237;n</surname> <given-names>FJ</given-names> </author><author><surname>Rodr&#237;guez-P&#233;rez</surname> <given-names>F</given-names> </author><title>Prevalence of obesity in a Canarian community. Association with type 2 diabetes mellitus: the Gu&#237;a Study</title><source>Eur J Clin Nutr</source><year>2002</year><volume>56</volume><fpage>557</fpage><lpage>560</lpage>
<author><surname>Borch-Johnsen</surname> <given-names>K</given-names> </author><author><surname>Wareham</surname> <given-names>N</given-names> </author><title>The rise and fall of the metabolic syndrome</title><source>Diabetologia</source><year>2010</year><volume>53</volume><fpage>597</fpage><lpage>599</lpage>
<author><surname>Ninomiya</surname> <given-names>T</given-names> </author><author><surname>Kiyohara</surname> <given-names>Y</given-names> </author><title>Albuminuria and chronic kidney disease in association with the metabolic syndrome</title><source>J Cardiometab Syndr</source><year>2007</year><volume>2</volume><fpage>104</fpage><lpage>107</lpage>
<author><surname>Gerstein</surname> <given-names>HC</given-names> </author><author><surname>Mann</surname> <given-names>JF</given-names> </author><author><surname>Yi</surname> <given-names>Q</given-names> </author><author><surname>Zinman</surname> <given-names>B</given-names> </author><author><surname>Dinneen</surname> <given-names>SF</given-names> </author><author><surname>Hoogwerf</surname> <given-names>B</given-names> </author><title>Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals</title><source>JAMA</source><year>2001</year><volume>286</volume><fpage>421</fpage><lpage>426</lpage>
<author><surname>Ibsen</surname> <given-names>H</given-names> </author><author><surname>Olsen</surname> <given-names>MH</given-names> </author><author><surname>Wachtell</surname> <given-names>K</given-names> </author><author><surname>Borch-Johnsen</surname> <given-names>K</given-names> </author><author><surname>Lindholm</surname> <given-names>LH</given-names> </author><author><surname>Mogensen</surname> <given-names>CE</given-names> </author><title>Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study</title><source>Hypertension</source><year>2005</year><volume>45</volume><fpage>198</fpage><lpage>202</lpage>
<author><surname>Bakris</surname> <given-names>G</given-names> </author><author><surname>Stockert</surname> <given-names>J</given-names> </author><author><surname>Molitch</surname> <given-names>M</given-names> </author><author><surname>Zhou</surname> <given-names>Q</given-names> </author><author><surname>Champion</surname> <given-names>A</given-names> </author><author><surname>Bacher</surname> <given-names>P</given-names> </author><title>Risk factor assessment for new onset diabetes: literature review</title><source>Diabetes Obes Metab</source><year>2009</year><volume>11</volume><fpage>177</fpage><lpage>187</lpage>
<author><surname>Chobanian</surname> <given-names>AV</given-names> </author><author><surname>Bakris</surname> <given-names>GL</given-names> </author><author><surname>Black</surname> <given-names>HR</given-names> </author><author><surname>Cushman</surname> <given-names>WC</given-names> </author><author><surname>Green</surname> <given-names>LA</given-names> </author><author><surname>Izzo</surname> <given-names>JL</given-names> <suffix>Jr</suffix> </author><title>The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report</title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>2560</fpage><lpage>2572</lpage>
<author><surname>Kaplan</surname> <given-names>NM</given-names> </author><title>The choice of thiazide diuretics: why chlorthalidone may replace hydrochlorothiazide</title><source>Hypertension</source><year>2009</year><volume>54</volume><fpage>951</fpage><lpage>953</lpage>
<author><surname>Eriksson</surname> <given-names>JW</given-names> </author><author><surname>Jansson</surname> <given-names>PA</given-names> </author><author><surname>Carlberg</surname> <given-names>B</given-names> </author><author><surname>H&#228;gg</surname> <given-names>A</given-names> </author><author><surname>Kurland</surname> <given-names>L</given-names> </author><author><surname>Svensson</surname> <given-names>MK</given-names> </author><title>Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) study</title><source>Hypertension</source><year>2008</year><volume>52</volume><fpage>1030</fpage><lpage>1037</lpage>
<author><surname>Cooper-DeHoff</surname> <given-names>RM</given-names> </author><author><surname>Wen</surname> <given-names>S</given-names> </author><author><surname>Beitelshees</surname> <given-names>AL</given-names> </author><author><surname>Zineh</surname> <given-names>I</given-names> </author><author><surname>Gums</surname> <given-names>JG</given-names> </author><author><surname>Turner</surname> <given-names>ST</given-names> </author><title>Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications</title><source>Hypertension</source><year>2010</year><volume>55</volume><fpage>61</fpage><lpage>68</lpage>
<author><surname>Alderman</surname> <given-names>MH</given-names> </author><title>New-onset diabetes during antihypertensive therapy</title><source>Am J Hypertens</source><year>2008</year><volume>21</volume><fpage>493</fpage><lpage>499</lpage>
<author><surname>Alderman</surname> <given-names>MH</given-names> </author><title>Is new-onset diabetes mellitus important? Yes, but&#8230;</title><source>High Blood Pres &amp; Cardiovasc Prev</source><year>2008</year><volume>15</volume><fpage>5</fpage><lpage>8</lpage>
<author><surname>Bakris</surname> <given-names>G</given-names> </author><author><surname>Molitch</surname> <given-names>M</given-names> </author><author><surname>Zhou</surname> <given-names>Q</given-names> </author><author><surname>Sarafidis</surname> <given-names>P</given-names> </author><author><surname>Champion</surname> <given-names>A</given-names> </author><author><surname>Bacher</surname> <given-names>P</given-names> </author><title>Reversal of diuretic-associated impaired glucose tolerance and new-onset diabetes: results of the STAR-LET study</title><source>J Cardiometab Syndr</source><year>2008</year><volume>3</volume><fpage>18</fpage><lpage>25</lpage>
<author><surname>Aguilar</surname> <given-names>D</given-names> </author><author><surname>Solomon</surname> <given-names>SD</given-names> </author><author><surname>K&#248;ber</surname> <given-names>L</given-names> </author><author><surname>Rouleau</surname> <given-names>JL</given-names> </author><author><surname>Skali</surname> <given-names>H</given-names> </author><author><surname>McMurray</surname> <given-names>JJ</given-names> </author><title>Newly diagnosed and previously known diabetes mellitus and 1&#8211;year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial</title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>1572</fpage><lpage>1578</lpage>
<author><surname>Jamerson</surname> <given-names>K</given-names> </author><author><surname>Weber</surname> <given-names>MA</given-names> </author><author><surname>Bakris</surname> <given-names>GL</given-names> </author><author><surname>Dahl&#246;f</surname> <given-names>B</given-names> </author><author><surname>Pitt</surname> <given-names>B</given-names> </author><author><surname>Shi</surname> <given-names>V</given-names> </author><title>Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients</title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>2417</fpage><lpage>2428</lpage>
<author><surname>Matsui</surname> <given-names>Y</given-names> </author><author><surname>Eguchi</surname> <given-names>K</given-names> </author><author><surname>O&#8242;Rourke</surname> <given-names>MF</given-names> </author><author><surname>Ishikawa</surname> <given-names>J</given-names> </author><author><surname>Miyashita</surname> <given-names>H</given-names> </author><author><surname>Shimada</surname> <given-names>K</given-names> </author><title>Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients</title><source>Hypertension</source><year>2009</year><volume>54</volume><fpage>716</fpage><lpage>723</lpage>
<author><surname>Fliser</surname> <given-names>D</given-names> </author><author><surname>Buchholz</surname> <given-names>K</given-names> </author><author><surname>Haller</surname> <given-names>H</given-names> </author><title>Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertension patients with microinflammation</title><source>Circulation</source><year>2004</year><volume>110</volume><fpage>1103</fpage><lpage>1107</lpage>
<author><surname>Smith</surname> <given-names>DH</given-names> </author><author><surname>Neutel</surname> <given-names>JM</given-names> </author><author><surname>Lacourci&#232;re</surname> <given-names>Y</given-names> </author><author><surname>Kempthorne-Rawson</surname> <given-names>J</given-names> </author><title>Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements</title><source>J Hypertens</source><year>2003</year><volume>21</volume><fpage>1291</fpage><lpage>1298</lpage>
<author><surname>Clegg</surname> <given-names>J</given-names> </author><author><surname>Murphy</surname> <given-names>E</given-names> </author><author><surname>Almack</surname> <given-names>K</given-names> </author><author><surname>Harvey</surname> <given-names>A</given-names> </author><title>Tensions around inclusion: reframing the moral horizon</title><source>Journal Applied Research in Intellectual Disabilities</source><year>2008</year><volume>21</volume><fpage>81</fpage><lpage>94</lpage>
<author><surname>Cummins</surname> <given-names>RA</given-names> </author><author><surname>Lau</surname> <given-names>ALD</given-names> </author><title>Community integration or community exposure? A review and discussion in relation to people with ID</title><source>Journal Applied Research in Intellectual Disabilities</source><year>2003</year><volume>16</volume><fpage>145</fpage><lpage>57</lpage>
Department of Health &amp; Social Security<source>Report of the Committee of Inquiry into Allegations of Ill-Treatement of Patients and Other Irregularities at the Ely Hospital, Cardiff</source><year>1969</year><other>London</other><publisher>HMSO</publisher>
<author><surname>Douglas</surname> <given-names>M</given-names> </author><source>Risk and Blame: Essays in Cultural Theory</source><year>1992</year><other>London</other><publisher>Routledge</publisher>
<author><surname>Felce</surname> <given-names>D</given-names> </author><title>Can person-centred planning fulfil a strategic planning role?</title><source>Journal Applied Research in Intellectual Disabilities</source><year>2004</year><volume>17</volume><fpage>27</fpage><lpage>30</lpage>
<author><surname>Forrester-Jones</surname> <given-names>R</given-names> </author><author><surname>Carpenter</surname> <given-names>J</given-names> </author><author><surname>Coolen-Schrijner</surname> <given-names>P</given-names> </author><author><surname>Cambridge</surname> <given-names>P</given-names> </author><author><surname>Tate</surname> <given-names>A</given-names> </author><author><surname>Beecham</surname> <given-names>J</given-names> </author><title>The social networks of people with ID living in the community 12 years after resettlement from long-stay hospitals</title><source>Journal Applied Research in Intellectual Disabilities</source><year>2006</year><volume>19</volume><fpage>285</fpage><lpage>95</lpage>
<author><surname>Gleeson</surname> <given-names>B</given-names> </author><author><surname>Kearns</surname> <given-names>R</given-names> </author><title>Remoralising landscapes of care</title><source>Environment and Planning D: Society and Space</source><year>2001</year><volume>19</volume><fpage>61</fpage><lpage>80</lpage>
<author><surname>Hallam</surname> <given-names>A</given-names> </author><author><surname>Beecham</surname> <given-names>J</given-names> </author><author><surname>Knapp</surname> <given-names>M</given-names> </author><author><surname>Carpenter</surname> <given-names>J</given-names> </author><author><surname>Cambridge</surname> <given-names>P</given-names> </author><author><surname>Forrester-Jones</surname> <given-names>R</given-names> </author><title>Service use and costs of support 12 years after leaving hospital</title><source>Journal Applied Research in Intellectual Disabilities</source><year>2006</year><volume>19</volume><fpage>296</fpage><lpage>308</lpage>
Healthcare Commission<source>Investigation into the service for people with learning disabilities provided by Sutton and Merton Primary Care Trust</source><year>2007a</year>Available at:
Healthcare Commission<source>Action plan by Sutton and Merton PCT in response to the Healthcare Commission's investigation into services for people with learning disabilities at the trust &#8211;&#8216;final version&#8217; 15 March 2007</source><year>2007b</year>Available at:
Healthcare Commission<source>Healthcare commission corporate plan 2007&#8211;8</source><year>2007c</year>Available at:
<author><surname>O'Brien</surname> <given-names>J</given-names> </author><editor>Wilcox B , Bellamy GT</editor><title>A guide to lifestyle planning</title><source>A Comprehensive Guide to the Activities Catalog</source><year>1987</year><other>Baltimore, MD</other><publisher>Paul H. Brookes</publisher><fpage>175</fpage><lpage>189</lpage>
<author><surname>Poncelas</surname> <given-names>A</given-names> </author><author><surname>Murphy</surname> <given-names>G</given-names> </author><title>Accessible information for people with intellectual disabilities: do symbols really help?</title><source>Journal Applied Research in Intellectual Disabilities</source><year>2007</year><volume>20</volume><fpage>466</fpage><lpage>74</lpage>
<author><surname>Power</surname> <given-names>M</given-names> </author><source>The Audit Society: Rituals of Verification</source><year>1997</year><other>Oxford</other><publisher>Oxford University Press</publisher>
Public Expenditure Statistical Analysis<source>Trends in public expenditure</source><year>2008</year>Available at:
<author><surname>Stronach</surname> <given-names>I</given-names> </author><editor>Vaughan M</editor><title>Inspection and justice: HMI and Summerhill school</title><source>Summerhill &amp; A.S.Neill</source><year>2006</year><other>Maidenhead</other><publisher>Open University Press</publisher><fpage>118</fpage><lpage>136</lpage>
<author><surname>Thomson</surname> <given-names>M</given-names> </author><source>The Problem of Mental Deficiency: Eugenics, Democracy and Social Policy in Britain c1870&#8211;1959</source><year>1998</year><other>Oxford</other><publisher>Clarendon Press</publisher>
<author><surname>Trent</surname> <given-names>JW</given-names> </author><source>Inventing the Feeble Mind: A History of Mental Retardation in the US</source><year>1994</year><other>Los Angeles, CA</other><publisher>University of California Press</publisher>
<author><surname>Wolfensberger</surname> <given-names>W</given-names> </author><author><surname>Glenn</surname> <given-names>L</given-names> </author><source>Program Analysis of Service Systems (PASS)</source><year>1972</year><other>Toronto</other><publisher>National Institute on Mental Retardation</publisher>
<author><surname>Porter</surname> <given-names>PL</given-names> </author><title>Global trends in breast cancer incidence and mortality</title><source>Salud P&#250;blica M&#233;x</source><year>2009</year><volume>51</volume><issue>Suppl 2</issue><fpage>s141</fpage><lpage>s146</lpage>
<author><surname>Travis</surname> <given-names>RC</given-names> </author><author><surname>Reeves</surname> <given-names>GK</given-names> </author><author><surname>Green</surname> <given-names>J</given-names> </author><title>Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study</title><source>Lancet</source><year>2010</year><volume>375</volume><issue>9732</issue><fpage>2143</fpage><lpage>2151</lpage>
<author><surname>Buck</surname> <given-names>MB</given-names> </author><author><surname>Knabbe</surname> <given-names>C</given-names> </author><title>TGF-&#946; signaling in breast cancer</title><source>Ann NY Acad Sci</source><year>2006</year><volume>1089</volume><fpage>119</fpage><lpage>126</lpage>
<author><surname>Dijke</surname> <given-names>P</given-names> </author><author><surname>Hill</surname> <given-names>CS</given-names> </author><title>New insights into TGF-&#946;-Smad signalling</title><source>Trends Biochem Sci</source><year>2004</year><volume>29</volume><issue>5</issue><fpage>265</fpage><lpage>273</lpage>
<author><surname>Moustakas</surname> <given-names>A</given-names> </author><author><surname>Heldin</surname> <given-names>CH</given-names> </author><title>Non-Smad TGF-&#946; signals</title><source>J Cell Sci</source><year>2005</year><volume>118</volume><issue>Pt 16</issue><fpage>3573</fpage><lpage>3584</lpage>
<author><surname>Zhang</surname> <given-names>YE</given-names> </author><title>Non-Smad pathways in TGF-&#946; signaling</title><source>Cell Res</source><year>2009</year><volume>19</volume><issue>1</issue><fpage>128</fpage><lpage>139</lpage>
<author><surname>Lee</surname> <given-names>MK</given-names> </author><author><surname>Pardoux</surname> <given-names>C</given-names> </author><author><surname>Hall</surname> <given-names>MC</given-names> </author><title>TGF-&#946; activates Erk MAP kinase signalling through direct phosphorylation of ShcA</title><source>EMBO J</source><year>2007</year><volume>26</volume><issue>17</issue><fpage>3957</fpage><lpage>3967</lpage>
<author><surname>Bhowmick</surname> <given-names>NA</given-names> </author><author><surname>Zent</surname> <given-names>R</given-names> </author><author><surname>Ghiassi</surname> <given-names>M</given-names> </author><title>Integrin &#946; 1 signaling is necessary for transforming growth factor-&#946; activation of p38MAPK and epithelial plasticity</title><source>J Biol Chem</source><year>2001</year><volume>276</volume><issue>50</issue><fpage>46707</fpage><lpage>46713</lpage>
<author><surname>Edlund</surname> <given-names>S</given-names> </author><author><surname>Landstrom</surname> <given-names>M</given-names> </author><author><surname>Heldin</surname> <given-names>CH</given-names> </author><title>Transforming growth factor-&#946;-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA</title><source>Mol Biol Cell</source><year>2002</year><volume>13</volume><issue>3</issue><fpage>902</fpage><lpage>914</lpage>
<author><surname>Wilkes</surname> <given-names>MC</given-names> </author><author><surname>Murphy</surname> <given-names>SJ</given-names> </author><author><surname>Garamszegi</surname> <given-names>N</given-names> </author><title>Cell-type-specific activation of PAK2 by transforming growth factor &#946; independent of Smad2 and Smad3</title><source>Mol Cell Biol</source><year>2003</year><volume>23</volume><issue>23</issue><fpage>8878</fpage><lpage>8889</lpage>
<author><surname>Barcellos-Hoff</surname> <given-names>MH</given-names> </author><author><surname>Akhurst</surname> <given-names>RJ</given-names> </author><title>Transforming growth factor-&#946; in breast cancer: too much, too late</title><source>Breast Cancer Res</source><year>2009</year><volume>11</volume><issue>1</issue><fpage>202</fpage>
<author><surname>Kleuser</surname> <given-names>B</given-names> </author><author><surname>Malek</surname> <given-names>D</given-names> </author><author><surname>Gust</surname> <given-names>R</given-names> </author><title>17-&#946;-estradiol inhibits transforming growth factor-&#946; signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30</title><source>Mol Pharmacol</source><year>2008</year><volume>74</volume><issue>6</issue><fpage>1533</fpage><lpage>1543</lpage>
<author><surname>Hinshelwood</surname> <given-names>RA</given-names> </author><author><surname>Huschtscha</surname> <given-names>LI</given-names> </author><author><surname>Melki</surname> <given-names>J</given-names> </author><title>Concordant epigenetic silencing of transforming growth factor-&#946; signaling pathway genes occurs early in breast carcinogenesis</title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>24</issue><fpage>11517</fpage><lpage>11527</lpage>
<author><surname>Akhurst</surname> <given-names>RJ</given-names> </author><author><surname>Derynck</surname> <given-names>R</given-names> </author><title>TGF-&#946; signaling in cancer&#8211;a double-edged sword</title><source>Trends Cell Biol</source><year>2001</year><volume>11</volume><issue>11</issue><fpage>S44</fpage><lpage>S51</lpage>
<author><surname>Turashvili</surname> <given-names>G</given-names> </author><author><surname>Bouchal</surname> <given-names>J</given-names> </author><author><surname>Baumforth</surname> <given-names>K</given-names> </author><title>Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis</title><source>BMC Cancer</source><year>2007</year><volume>7</volume><fpage>55</fpage>
<author><surname>Figueroa</surname> <given-names>JD</given-names> </author><author><surname>Flanders</surname> <given-names>KC</given-names> </author><author><surname>Garcia-Closas</surname> <given-names>M</given-names> </author><title>Expression of TGF-&#946; signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics</title><source>Breast Cancer Res Treat</source><year>2010</year><volume>121</volume><issue>3</issue><fpage>727</fpage><lpage>735</lpage>
<author><surname>Xu</surname> <given-names>J</given-names> </author><author><surname>Lamouille</surname> <given-names>S</given-names> </author><author><surname>Derynck</surname> <given-names>R</given-names> </author><title>TGF-&#946;-induced epithelial to mesenchymal transition</title><source>Cell Res</source><year>2009</year><volume>19</volume><issue>2</issue><fpage>156</fpage><lpage>172</lpage>
<author><surname>Miyazono</surname> <given-names>K</given-names> </author><title>Transforming growth factor-&#946; signaling in epithelial-mesenchymal transition and progression of cancer</title><source>Proc Jpn Acad B Phys Biol Sci</source><year>2009</year><volume>85</volume><issue>8</issue><fpage>314</fpage><lpage>323</lpage>
<author><surname>Massagu&#233;</surname> <given-names>J</given-names> </author><title>TGF&#946; in cancer</title><source>Cell</source><year>2008</year><volume>134</volume><issue>2</issue><fpage>215</fpage><lpage>230</lpage>
<author><surname>Dijke</surname> <given-names>P</given-names> </author><author><surname>Goumans</surname> <given-names>MJ</given-names> </author><author><surname>Pardali</surname> <given-names>E</given-names> </author><title>Endoglin in angiogenesis and vascular diseases</title><source>Angiogenesis</source><year>2008</year><volume>11</volume><issue>1</issue><fpage>79</fpage><lpage>89</lpage>
<author><surname>Flavell</surname> <given-names>RA</given-names> </author><author><surname>Sanjabi</surname> <given-names>S</given-names> </author><author><surname>Wrzesinski</surname> <given-names>SH</given-names> </author><title>The polarization of immune cells in the tumour environment by TGF-&#946;. Nature reviews</title><source>Immunology</source><year>2010</year><volume>10</volume><issue>8</issue><fpage>554</fpage><lpage>567</lpage>
<author><surname>Buijs</surname> <given-names>JT</given-names> </author><author><surname>Henriquez</surname> <given-names>NV</given-names> </author><author><surname>Overveld</surname> <given-names>PG</given-names> </author><title>Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer</title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>18</issue><fpage>8742</fpage><lpage>8751</lpage>
<author><surname>Bos</surname> <given-names>PD</given-names> </author><author><surname>Nguyen</surname> <given-names>DX</given-names> </author><author><surname>Massagu&#233;</surname> <given-names>J</given-names> </author><title>Modeling metastasis in the mouse</title><source>Curr Opin Pharmacol</source><year>2010</year><volume>10</volume><issue>5</issue><fpage>571</fpage><lpage>577</lpage>
<author><surname>Tsuji</surname> <given-names>T</given-names> </author><author><surname>Ibaragi</surname> <given-names>S</given-names> </author><author><surname>Hu</surname> <given-names>GF</given-names> </author><title>Epithelial-mesenchymal transition and cell cooperativity in metastasis</title><source>Cancer Res</source><year>2009</year><volume>69</volume><issue>18</issue><fpage>7135</fpage><lpage>7139</lpage>
<author><surname>Grunert</surname> <given-names>S</given-names> </author><author><surname>Jechlinger</surname> <given-names>M</given-names> </author><author><surname>Beug</surname> <given-names>H</given-names> </author><title>Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nature reviews</title><source>Molec Cell Biol</source><year>2003</year><volume>4</volume><issue>8</issue><fpage>657</fpage><lpage>665</lpage>
<author><surname>Padua</surname> <given-names>D</given-names> </author><author><surname>Zhang</surname> <given-names>XH</given-names> </author><author><surname>Wang</surname> <given-names>Q</given-names> </author><title>TGF-&#946; primes breast tumors for lung metastasis seeding through angiopoietin-like 4</title><source>Cell</source><year>2008</year><volume>133</volume><issue>1</issue><fpage>66</fpage><lpage>77</lpage>
<author><surname>Godde</surname> <given-names>NJ</given-names> </author><author><surname>Galea</surname> <given-names>RC</given-names> </author><author><surname>Elsum</surname> <given-names>IA</given-names> </author><title>Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions</title><source>J Mammary Gland Biol Neoplasia</source><year>2010</year><volume>15</volume><issue>2</issue><fpage>149</fpage><lpage>168</lpage>
<author><surname>Zavadil</surname> <given-names>J</given-names> </author><author><surname>Bottinger</surname> <given-names>EP</given-names> </author><title>TGF-&#946; and epithelial-to-mesenchymal transitions</title><source>Oncogene</source><year>2005</year><volume>24</volume><issue>37</issue><fpage>5764</fpage><lpage>5774</lpage>
<author><surname>Miettinen</surname> <given-names>PJ</given-names> </author><author><surname>Ebner</surname> <given-names>R</given-names> </author><author><surname>Lopez</surname> <given-names>AR</given-names> </author><title>TGF-&#946; induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors</title><source>J Cell Biol</source><year>1994</year><volume>127</volume><issue>6 Pt 2</issue><fpage>2021</fpage><lpage>2036</lpage>
<author><surname>Piek</surname> <given-names>E</given-names> </author><author><surname>Moustakas</surname> <given-names>A</given-names> </author><author><surname>Kurisaki</surname> <given-names>A</given-names> </author><title>TGF-(&#946;) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells</title><source>J Cell Sci</source><year>1999</year><volume>112</volume><issue>Pt 24</issue><fpage>4557</fpage><lpage>4568</lpage>
<author><surname>Lindley</surname> <given-names>LE</given-names> </author><author><surname>Briegel</surname> <given-names>KJ</given-names> </author><title>Molecular characterization of TGF&#946;-induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells</title><source>Biochem Biophys Res Commun</source><year>2010</year><volume>399</volume><issue>4</issue><fpage>659</fpage><lpage>664</lpage>
<author><surname>Jo</surname> <given-names>M</given-names> </author><author><surname>Lester</surname> <given-names>RD</given-names> </author><author><surname>Montel</surname> <given-names>V</given-names> </author><title>Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling</title><source>J Biol Chem</source><year>2009</year><volume>284</volume><issue>34</issue><fpage>22825</fpage><lpage>22833</lpage>
<author><surname>Trimboli</surname> <given-names>AJ</given-names> </author><author><surname>Fukino</surname> <given-names>K</given-names> </author><author><surname>Bruin</surname> <given-names>A</given-names> </author><title>Direct evidence for epithelial-mesenchymal transitions in breast cancer</title><source>Cancer Res</source><year>2008</year><volume>68</volume><issue>3</issue><fpage>937</fpage><lpage>945</lpage>
<author><surname>Turashvili</surname> <given-names>G</given-names> </author><author><surname>Bouchal</surname> <given-names>J</given-names> </author><author><surname>Ehrmann</surname> <given-names>J</given-names> </author><title>Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas</title><source>Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia</source><year>2007</year><volume>151</volume><issue>1</issue><fpage>59</fpage><lpage>64</lpage>
<author><surname>Micalizzi</surname> <given-names>DS</given-names> </author><author><surname>Farabaugh</surname> <given-names>SM</given-names> </author><author><surname>Ford</surname> <given-names>HL</given-names> </author><title>Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression</title><source>J Mammary Gland Biol Neoplasia</source><year>2010</year><volume>15</volume><issue>2</issue><fpage>117</fpage><lpage>134</lpage>
<author><surname>Christofori</surname> <given-names>G</given-names> </author><title>New signals from the invasive front</title><source>Nature</source><year>2006</year><volume>441</volume><issue>7092</issue><fpage>444</fpage><lpage>450</lpage>
<author><surname>Vincent</surname> <given-names>T</given-names> </author><author><surname>Neve</surname> <given-names>EP</given-names> </author><author><surname>Johnson</surname> <given-names>JR</given-names> </author><title>A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-&#946; mediated epithelial-mesenchymal transition</title><source>Nat Cell Biol</source><year>2009</year><volume>11</volume><issue>8</issue><fpage>943</fpage><lpage>950</lpage>
<author><surname>Thuault</surname> <given-names>S</given-names> </author><author><surname>Valcourt</surname> <given-names>U</given-names> </author><author><surname>Petersen</surname> <given-names>M</given-names> </author><title>Transforming growth factor-&#946; employs HMGA2 to elicit epithelial-mesenchymal transition</title><source>J Cell Biol</source><year>2006</year><volume>174</volume><issue>2</issue><fpage>175</fpage><lpage>183</lpage>
<author><surname>Viloria-Petit</surname> <given-names>AM</given-names> </author><author><surname>David</surname> <given-names>L</given-names> </author><author><surname>Jia</surname> <given-names>JY</given-names> </author><title>A role for the TGF&#946;-Par6 polarity pathway in breast cancer progression</title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><issue>33</issue><fpage>14028</fpage><lpage>14033</lpage>
<author><surname>Shirakihara</surname> <given-names>T</given-names> </author><author><surname>Horiguchi</surname> <given-names>K</given-names> </author><author><surname>Miyazawa</surname> <given-names>K</given-names> </author><title>TGF-&#946; regulates isoform switching of FGF receptors and epithelial-mesenchymal transition</title><source>EMBO J</source><year>2011</year><volume>30</volume><issue>4</issue><fpage>783</fpage><lpage>795</lpage>
<author><surname>Wendt</surname> <given-names>MK</given-names> </author><author><surname>Smith</surname> <given-names>JA</given-names> </author><author><surname>Schiemann</surname> <given-names>WP</given-names> </author><title>Transforming growth factor-&#946;-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression</title><source>Oncogene</source><year>2010</year><volume>29</volume><issue>49</issue><fpage>6485</fpage><lpage>6498</lpage>
<author><surname>Micalizzi</surname> <given-names>DS</given-names> </author><author><surname>Christensen</surname> <given-names>KL</given-names> </author><author><surname>Jedlicka</surname> <given-names>P</given-names> </author><title>The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-&#946; signaling</title><source>J Clin Invest</source><year>2009</year><volume>119</volume><issue>9</issue><fpage>2678</fpage><lpage>2690</lpage>
<author><surname>Micalizzi</surname> <given-names>DS</given-names> </author><author><surname>Wang</surname> <given-names>CA</given-names> </author><author><surname>Farabaugh</surname> <given-names>SM</given-names> </author><title>Homeoprotein Six1 increases TGF-&#946; Type I receptor and converts TGF-&#946; signaling from suppressive to supportive for tumor growth</title><source>Cancer Res</source><year>2010</year><volume>70</volume><issue>24</issue><fpage>10371</fpage><lpage>10380</lpage>
<author><surname>Deckers</surname> <given-names>M</given-names> </author><author><surname>Dinther</surname> <given-names>M</given-names> </author><author><surname>Buijs</surname> <given-names>J</given-names> </author><title>The tumor suppressor Smad4 is required for transforming growth factor &#946;-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells</title><source>Cancer Res</source><year>2006</year><volume>66</volume><issue>4</issue><fpage>2202</fpage><lpage>2209</lpage>
<author><surname>Thuault</surname> <given-names>S</given-names> </author><author><surname>Tan</surname> <given-names>EJ</given-names> </author><author><surname>Peinado</surname> <given-names>H</given-names> </author><title>HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition</title><source>J Biol Chem</source><year>2008</year><volume>283</volume><issue>48</issue><fpage>33437</fpage><lpage>33446</lpage>
<author><surname>Gregory</surname> <given-names>PA</given-names> </author><author><surname>Bert</surname> <given-names>AG</given-names> </author><author><surname>Paterson</surname> <given-names>EL</given-names> </author><title>The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1</title><source>Nat Cell Biol</source><year>2008</year><volume>10</volume><issue>5</issue><fpage>593</fpage><lpage>601</lpage>
<author><surname>Bakin</surname> <given-names>AV</given-names> </author><author><surname>Tomlinson</surname> <given-names>AK</given-names> </author><author><surname>Bhowmick</surname> <given-names>NA</given-names> </author><title>Phosphatidylinositol 3-kinase function is required for transforming growth factor &#946;-mediated epithelial to mesenchymal transition and cell migration</title><source>J Biol Chem</source><year>2000</year><volume>275</volume><issue>47</issue><fpage>36803</fpage><lpage>36810</lpage>
<author><surname>Graauw</surname> <given-names>M</given-names> </author><author><surname>Miltenburg</surname> <given-names>MH</given-names> </author><author><surname>Schmidt</surname> <given-names>MK</given-names> </author><title>Annexin A1 regulates TGF-&#946; signaling and promotes metastasis formation of basal-like breast cancer cells</title><source>Proc Natl Acad Sci USA</source><year>2010</year><volume>107</volume><issue>14</issue><fpage>6340</fpage><lpage>6345</lpage>
<author><surname>Araki</surname> <given-names>S</given-names> </author><author><surname>Eitel</surname> <given-names>JA</given-names> </author><author><surname>Batuello</surname> <given-names>CN</given-names> </author><title>TGF-&#946;1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer</title><source>J Clin Investig</source><year>2010</year><volume>120</volume><issue>1</issue><fpage>290</fpage><lpage>302</lpage>
<author><surname>Mareel</surname> <given-names>M</given-names> </author><author><surname>Oliveira</surname> <given-names>MJ</given-names> </author><author><surname>Madani</surname> <given-names>I</given-names> </author><title>Cancer invasion and metastasis: interacting ecosystems</title><source>Virchows Archiv: An International Journal of Pathology</source><year>2009</year><volume>454</volume><issue>6</issue><fpage>599</fpage><lpage>622</lpage>
<author><surname>Mareel</surname> <given-names>M</given-names> </author><author><surname>Leroy</surname> <given-names>A</given-names> </author><title>Clinical, cellular, and molecular aspects of cancer invasion</title><source>Physiol Rev</source><year>2003</year><volume>83</volume><issue>2</issue><fpage>337</fpage><lpage>376</lpage>
<author><surname>Hu</surname> <given-names>M</given-names> </author><author><surname>Yao</surname> <given-names>J</given-names> </author><author><surname>Carroll</surname> <given-names>DK</given-names> </author><title>Regulation of in situ to invasive breast carcinoma transition</title><source>Cancer Cell</source><year>2008</year><volume>13</volume><issue>5</issue><fpage>394</fpage><lpage>406</lpage>
<author><surname>Luo</surname> <given-names>YP</given-names> </author><author><surname>Zhou</surname> <given-names>H</given-names> </author><author><surname>Krueger</surname> <given-names>J</given-names> </author><title>The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression</title><source>Oncogene</source><year>2010</year><volume>29</volume><issue>5</issue><fpage>662</fpage><lpage>673</lpage>
<author><surname>Mandal</surname> <given-names>S</given-names> </author><author><surname>Johnson</surname> <given-names>KR</given-names> </author><author><surname>Wheelock</surname> <given-names>MJ</given-names> </author><title>TGF-&#946; induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways</title><source>Exp Cell Res</source><year>2008</year><volume>314</volume><issue>19</issue><fpage>3478</fpage><lpage>3493</lpage>
<author><surname>Giampieri</surname> <given-names>S</given-names> </author><author><surname>Manning</surname> <given-names>C</given-names> </author><author><surname>Hooper</surname> <given-names>S</given-names> </author><title>Localized and reversible TGF-&#946; signalling switches breast cancer cells from cohesive to single cell motility</title><source>Nat Cell Biol</source><year>2009</year><volume>11</volume><issue>11</issue><fpage>1287</fpage><lpage>1296</lpage>
<author><surname>McAllister</surname> <given-names>SS</given-names> </author><author><surname>Weinberg</surname> <given-names>RA</given-names> </author><title>Tumor-host interactions: a far-reaching relationship</title><source>J Clin Oncol: Official Journal of the American Society of Clinical Oncology</source><year>2010</year><volume>28</volume><issue>26</issue><fpage>4022</fpage><lpage>4028</lpage>
<author><surname>Park</surname> <given-names>CC</given-names> </author><author><surname>Bissell</surname> <given-names>MJ</given-names> </author><author><surname>Barcellos-Hoff</surname> <given-names>MH</given-names> </author><title>The influence of the microenvironment on the malignant phenotype</title><source>Mol Med Today</source><year>2000</year><volume>6</volume><issue>8</issue><fpage>324</fpage><lpage>329</lpage>
<author><surname>Mueller</surname> <given-names>MM</given-names> </author><author><surname>Fusenig</surname> <given-names>NE</given-names> </author><title>Friends or foes - bipolar effects of the tumour stroma in cancer</title><source>Nat Rev Cancer</source><year>2004</year><volume>4</volume><issue>11</issue><fpage>839</fpage><lpage>849</lpage>
<author><surname>Sieweke</surname> <given-names>MH</given-names> </author><author><surname>Bissell</surname> <given-names>MJ</given-names> </author><title>The tumor-promoting effect of wounding: a possible role for TGF-&#946;-induced stromal alterations</title><source>Crit Rev Oncog</source><year>1994</year><volume>5</volume><issue>2&#8211;3</issue><fpage>297</fpage><lpage>311</lpage>
<author><surname>Shekhar</surname> <given-names>MP</given-names> </author><author><surname>Pauley</surname> <given-names>R</given-names> </author><author><surname>Heppner</surname> <given-names>G</given-names> </author><title>Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast</title><source>Breast Cancer Res</source><year>2003</year><volume>5</volume><issue>3</issue><fpage>130</fpage><lpage>135</lpage>
<author><surname>Olsen</surname> <given-names>CJ</given-names> </author><author><surname>Moreira</surname> <given-names>J</given-names> </author><author><surname>Lukanidin</surname> <given-names>EM</given-names> </author><title>Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts</title><source>BMC Cancer</source><year>2010</year><volume>10</volume><fpage>444</fpage>
<author><surname>Stuelten</surname> <given-names>CH</given-names> </author><author><surname>Busch</surname> <given-names>JI</given-names> </author><author><surname>Tang</surname> <given-names>B</given-names> </author><title>Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-&#946; mediated mechanism in a mouse xenograft model of breast cancer</title><source>PLoS ONE</source><year>2010</year><volume>5</volume><issue>3</issue><fpage>e9832</fpage>
<author><surname>Karnoub</surname> <given-names>AE</given-names> </author><author><surname>Dash</surname> <given-names>AB</given-names> </author><author><surname>Vo</surname> <given-names>AP</given-names> </author><title>Mesenchymal stem cells within tumour stroma promote breast cancer metastasis</title><source>Nature</source><year>2007</year><volume>449</volume><issue>7162</issue><fpage>557</fpage><lpage>563</lpage>
<author><surname>Haviv</surname> <given-names>I</given-names> </author><author><surname>Polyak</surname> <given-names>K</given-names> </author><author><surname>Qiu</surname> <given-names>W</given-names> </author><title>Origin of carcinoma associated fibroblasts</title><source>Cell Cycle</source><year>2009</year><volume>8</volume><issue>4</issue><fpage>589</fpage><lpage>595</lpage>
<author><surname>Kojima</surname> <given-names>Y</given-names> </author><author><surname>Acar</surname> <given-names>A</given-names> </author><author><surname>Eaton</surname> <given-names>EN</given-names> </author><title>Autocrine TGF-&#946; and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts</title><source>Proc Natl Acad Sci USA</source><year>2010</year><volume>107</volume><issue>46</issue><fpage>20009</fpage><lpage>20014</lpage>
<author><surname>Bhowmick</surname> <given-names>NA</given-names> </author><author><surname>Chytil</surname> <given-names>A</given-names> </author><author><surname>Plieth</surname> <given-names>D</given-names> </author><title>TGF-&#946; signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia</title><source>Science</source><year>2004</year><volume>303</volume><issue>5659</issue><fpage>848</fpage><lpage>851</lpage>
<author><surname>Cheng</surname> <given-names>N</given-names> </author><author><surname>Bhowmick</surname> <given-names>NA</given-names> </author><author><surname>Chytil</surname> <given-names>A</given-names> </author><title>Loss of TGF-&#946; type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-&#945;-, MSP- and HGF-mediated signaling networks</title><source>Oncogene</source><year>2005</year><volume>24</volume><issue>32</issue><fpage>5053</fpage><lpage>5068</lpage>
<author><surname>Cheng</surname> <given-names>N</given-names> </author><author><surname>Chytil</surname> <given-names>A</given-names> </author><author><surname>Shyr</surname> <given-names>Y</given-names> </author><title>Transforming growth factor-&#946; signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion</title><source>Molec Cancer Res</source><year>2008</year><volume>6</volume><issue>10</issue><fpage>1521</fpage><lpage>1533</lpage>
<author><surname>Barcellos-Hoff</surname> <given-names>MH</given-names> </author><author><surname>Ravani</surname> <given-names>SA</given-names> </author><title>Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells</title><source>Cancer Res</source><year>2000</year><volume>60</volume><issue>5</issue><fpage>1254</fpage><lpage>1260</lpage>
<author><surname>Barcellos-Hoff</surname> <given-names>MH</given-names> </author><title>Radiation-induced transforming growth factor &#946; and subsequent extracellular matrix reorganization in murine mammary gland</title><source>Cancer Res</source><year>1993</year><volume>53</volume><issue>17</issue><fpage>3880</fpage><lpage>3886</lpage>
<author><surname>Casey</surname> <given-names>TM</given-names> </author><author><surname>Eneman</surname> <given-names>J</given-names> </author><author><surname>Crocker</surname> <given-names>A</given-names> </author><title>Cancer associated fibroblasts stimulated by transforming growth factor &#946;1 (TGF-&#946;1) increase invasion rate of tumor cells: a population study</title><source>Breast Cancer Res Treat</source><year>2008</year><volume>110</volume><issue>1</issue><fpage>39</fpage><lpage>49</lpage>
<author><surname>Mantovani</surname> <given-names>A</given-names> </author><author><surname>Marchesi</surname> <given-names>F</given-names> </author><author><surname>Porta</surname> <given-names>C</given-names> </author><title>Inflammation and cancer: breast cancer as a prototype</title><source>Breast</source><year>2007</year><volume>16</volume><issue>Suppl 2</issue><fpage>S27</fpage><lpage>S33</lpage>
<author><surname>Bierie</surname> <given-names>B</given-names> </author><author><surname>Moses</surname> <given-names>HL</given-names> </author><title>TGF-&#946; and cancer</title><source>Cytokine Growth Factor Rev</source><year>2006</year><volume>17</volume><issue>1&#8211;2</issue><fpage>29</fpage><lpage>40</lpage>
<author><surname>Marigo</surname> <given-names>I</given-names> </author><author><surname>Dolcetti</surname> <given-names>L</given-names> </author><author><surname>Serafini</surname> <given-names>P</given-names> </author><title>Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells</title><source>Immunol Rev</source><year>2008</year><volume>222</volume><fpage>162</fpage><lpage>179</lpage>
<author><surname>Gallina</surname> <given-names>G</given-names> </author><author><surname>Dolcetti</surname> <given-names>L</given-names> </author><author><surname>Serafini</surname> <given-names>P</given-names> </author><title>Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells</title><source>J Clin Investig</source><year>2006</year><volume>116</volume><issue>10</issue><fpage>2777</fpage><lpage>2790</lpage>
<author><surname>Yang</surname> <given-names>L</given-names> </author><author><surname>Huang</surname> <given-names>J</given-names> </author><author><surname>Ren</surname> <given-names>X</given-names> </author><title>Abrogation of TGF-&#946; signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis</title><source>Cancer Cell</source><year>2008</year><volume>13</volume><issue>1</issue><fpage>23</fpage><lpage>35</lpage>
<author><surname>Oliveira</surname> <given-names>MJ</given-names> </author><author><surname>Damme</surname> <given-names>J</given-names> </author><author><surname>Lauwaet</surname> <given-names>T</given-names> </author><title>&#946;-casein-derived peptides, produced by bacteria, stimulate cancer cell invasion and motility</title><source>EMBO J</source><year>2003</year><volume>22</volume><issue>22</issue><fpage>6161</fpage><lpage>6173</lpage>
<author><surname>Leask</surname> <given-names>A</given-names> </author><author><surname>Abraham</surname> <given-names>DJ</given-names> </author><title>TGF-&#946; signaling and the fibrotic response</title><source>FASEB J: Official Publication of the Federation of American Societies for Experimental Biology</source><year>2004</year><volume>18</volume><issue>7</issue><fpage>816</fpage><lpage>827</lpage>
<author><surname>Kang</surname> <given-names>Y</given-names> </author><author><surname>He</surname> <given-names>W</given-names> </author><author><surname>Tulley</surname> <given-names>S</given-names> </author><title>Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway</title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><issue>39</issue><fpage>13909</fpage><lpage>13914</lpage>
<author><surname>Alarmo</surname> <given-names>EL</given-names> </author><author><surname>Parssinen</surname> <given-names>J</given-names> </author><author><surname>Ketolainen</surname> <given-names>JM</given-names> </author><title>BMP7 influences proliferation, migration, and invasion of breast cancer cells</title><source>Cancer Lett</source><year>2009</year><volume>275</volume><issue>1</issue><fpage>35</fpage><lpage>43</lpage>
<author><surname>Ketolainen</surname> <given-names>JM</given-names> </author><author><surname>Alarmo</surname> <given-names>EL</given-names> </author><author><surname>Tuominen</surname> <given-names>VJ</given-names> </author><title>Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4</title><source>Breast Cancer Res Treat</source><year>2010</year><volume>124</volume><issue>2</issue><fpage>377</fpage><lpage>386</lpage>
<author><surname>Alarmo</surname> <given-names>EL</given-names> </author><author><surname>Korhonen</surname> <given-names>T</given-names> </author><author><surname>Kuukasjarvi</surname> <given-names>T</given-names> </author><title>Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas</title><source>Ann Oncol: Official Journal of the European Society for Medical Oncology/ESMO</source><year>2008</year><volume>19</volume><issue>2</issue><fpage>308</fpage><lpage>314</lpage>
<author><surname>Blair</surname> <given-names>HC</given-names> </author><author><surname>Athanasou</surname> <given-names>NA</given-names> </author><title>Recent advances in osteoclast biology and pathological bone resorption</title><source>Histol Histopathol</source><year>2004</year><volume>19</volume><issue>1</issue><fpage>189</fpage><lpage>199</lpage>
<author><surname>Henderson</surname> <given-names>MA</given-names> </author><author><surname>Danks</surname> <given-names>JA</given-names> </author><author><surname>Slavin</surname> <given-names>JL</given-names> </author><title>Parathyroid hormone-related protein localization in breast cancers predict improved prognosis</title><source>Cancer Res</source><year>2006</year><volume>66</volume><issue>4</issue><fpage>2250</fpage><lpage>2256</lpage>
<author><surname>Powell</surname> <given-names>GJ</given-names> </author><author><surname>Southby</surname> <given-names>J</given-names> </author><author><surname>Danks</surname> <given-names>JA</given-names> </author><title>Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites</title><source>Cancer Res</source><year>1991</year><volume>51</volume><issue>11</issue><fpage>3059</fpage><lpage>3061</lpage>
<author><surname>Guise</surname> <given-names>TA</given-names> </author><author><surname>Yin</surname> <given-names>JJ</given-names> </author><author><surname>Taylor</surname> <given-names>SD</given-names> </author><title>Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis</title><source>J Clin Investig</source><year>1996</year><volume>98</volume><issue>7</issue><fpage>1544</fpage><lpage>1549</lpage>
<author><surname>Yin</surname> <given-names>JJ</given-names> </author><author><surname>Selander</surname> <given-names>K</given-names> </author><author><surname>Chirgwin</surname> <given-names>JM</given-names> </author><title>TGF-&#946; signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development</title><source>J Clin Invest</source><year>1999</year><volume>103</volume><issue>2</issue><fpage>197</fpage><lpage>206</lpage>
<author><surname>Kakonen</surname> <given-names>SM</given-names> </author><author><surname>Selander</surname> <given-names>KS</given-names> </author><author><surname>Chirgwin</surname> <given-names>JM</given-names> </author><title>Transforming growth factor-&#946; stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways</title><source>J Biol Chem</source><year>2002</year><volume>277</volume><issue>27</issue><fpage>24571</fpage><lpage>24578</lpage>
<author><surname>Evtimova</surname> <given-names>V</given-names> </author><author><surname>Schwirzke</surname> <given-names>M</given-names> </author><author><surname>Tarbe</surname> <given-names>N</given-names> </author><title>Identification of breast cancer metastasis-associated genes by chip technology</title><source>Anticancer Res</source><year>2001</year><volume>21</volume><issue>6A</issue><fpage>3799</fpage><lpage>3806</lpage>
<author><surname>Watson</surname> <given-names>MA</given-names> </author><author><surname>Ylagan</surname> <given-names>LR</given-names> </author><author><surname>Trinkaus</surname> <given-names>KM</given-names> </author><title>Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients</title><source>Clin Cancer Res: An Official Journal of the American Association for Cancer Research</source><year>2007</year><volume>13</volume><issue>17</issue><fpage>5001</fpage><lpage>5009</lpage>
<author><surname>Lu</surname> <given-names>X</given-names> </author><author><surname>Wang</surname> <given-names>Q</given-names> </author><author><surname>Hu</surname> <given-names>G</given-names> </author><title>ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis</title><source>Genes Dev</source><year>2009</year><volume>23</volume><issue>16</issue><fpage>1882</fpage><lpage>1894</lpage>
<author><surname>Kang</surname> <given-names>Y</given-names> </author><author><surname>Massagu&#233;</surname> <given-names>J</given-names> </author><title>Epithelial-mesenchymal transitions: twist in development and metastasis</title><source>Cell</source><year>2004</year><volume>118</volume><issue>3</issue><fpage>277</fpage><lpage>279</lpage>
<author><surname>Dunn</surname> <given-names>LK</given-names> </author><author><surname>Mohammad</surname> <given-names>KS</given-names> </author><author><surname>Fournier</surname> <given-names>PG</given-names> </author><title>Hypoxia and TGF-&#946; drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment</title><source>PLoS ONE</source><year>2009</year><volume>4</volume><issue>9</issue><fpage>e6896</fpage>
<author><surname>Katoh</surname> <given-names>M</given-names> </author><title>Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGF&#946;, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors</title><source>Int J Oncol</source><year>2010</year><volume>36</volume><issue>2</issue><fpage>415</fpage><lpage>420</lpage>
<author><surname>Shimo</surname> <given-names>T</given-names> </author><author><surname>Kubota</surname> <given-names>S</given-names> </author><author><surname>Yoshioka</surname> <given-names>N</given-names> </author><title>Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer</title><source>J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research</source><year>2006</year><volume>21</volume><issue>7</issue><fpage>1045</fpage><lpage>1059</lpage>
<author><surname>Alarmo</surname> <given-names>EL</given-names> </author><author><surname>Kallioniemi</surname> <given-names>A</given-names> </author><title>Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?</title><source>Endocr-Relat Cancer</source><year>2010</year><volume>17</volume><issue>2</issue><fpage>R123</fpage><lpage>R139</lpage>
<author><surname>Johnson</surname> <given-names>RW</given-names> </author><author><surname>Nguyen</surname> <given-names>MP</given-names> </author><author><surname>Padalecki</surname> <given-names>SS</given-names> </author><title>TGF-&#946; promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical hedgehog signaling</title><source>Cancer Res</source><year>2011</year><volume>71</volume><issue>3</issue><fpage>822</fpage><lpage>831</lpage>
<author><surname>Futakuchi</surname> <given-names>M</given-names> </author><author><surname>Nannuru</surname> <given-names>KC</given-names> </author><author><surname>Varney</surname> <given-names>ML</given-names> </author><title>Transforming growth factor-&#946; signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation</title><source>Cancer Sci</source><year>2009</year><volume>100</volume><issue>1</issue><fpage>71</fpage><lpage>81</lpage>
<author><surname>Bierie</surname> <given-names>B</given-names> </author><author><surname>Stover</surname> <given-names>DG</given-names> </author><author><surname>Abel</surname> <given-names>TW</given-names> </author><title>Transforming growth factor-&#946; regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment</title><source>Cancer Res</source><year>2008</year><volume>68</volume><issue>6</issue><fpage>1809</fpage><lpage>1819</lpage>
<author><surname>Korpal</surname> <given-names>M</given-names> </author><author><surname>Yan</surname> <given-names>J</given-names> </author><author><surname>Lu</surname> <given-names>X</given-names> </author><title>Imaging transforming growth factor-&#946; signaling dynamics and therapeutic response in breast cancer bone metastasis</title><source>Nat Med</source><year>2009</year><volume>15</volume><issue>8</issue><fpage>960</fpage><lpage>966</lpage>
<author><surname>Petersen</surname> <given-names>M</given-names> </author><author><surname>Pardali</surname> <given-names>E</given-names> </author><author><surname>Horst</surname> <given-names>G</given-names> </author><title>Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis</title><source>Oncogene</source><year>2010</year><volume>29</volume><issue>9</issue><fpage>1351</fpage><lpage>1361</lpage>
<author><surname>Buijs</surname> <given-names>JT</given-names> </author><author><surname>Que</surname> <given-names>I</given-names> </author><author><surname>Lowik</surname> <given-names>CW</given-names> </author><title>Inhibition of bone resorption and growth of breast cancer in the bone microenvironment</title><source>Bone</source><year>2009</year><volume>44</volume><issue>2</issue><fpage>380</fpage><lpage>386</lpage>
<author><surname>Buijs</surname> <given-names>JT</given-names> </author><author><surname>Henriquez</surname> <given-names>NV</given-names> </author><author><surname>Overveld</surname> <given-names>PG</given-names> </author><title>TGF-&#946; and BMP7 interactions in tumour progression and bone metastasis</title><source>Clin Exp Metastasis</source><year>2007</year><volume>24</volume><issue>8</issue><fpage>609</fpage><lpage>617</lpage>
<author><surname>Buijs</surname> <given-names>JT</given-names> </author><author><surname>Kuijpers</surname> <given-names>CC</given-names> </author><author><surname>Pluijm</surname> <given-names>G</given-names> </author><title>Targeted therapy options for treatment of bone metastases; beyond bisphosphonates</title><source>Curr Pharm Des</source><year>2010</year><volume>16</volume><issue>27</issue><fpage>3015</fpage><lpage>3027</lpage>
<author><surname>Buijs</surname> <given-names>JT</given-names> </author><author><surname>Petersen</surname> <given-names>M</given-names> </author><author><surname>Horst</surname> <given-names>G</given-names> </author><title>Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis?</title><source>Curr Pharm Des</source><year>2010</year><volume>16</volume><issue>11</issue><fpage>1291</fpage><lpage>1300</lpage>
<author><surname>Kingsley</surname> <given-names>LA</given-names> </author><author><surname>Fournier</surname> <given-names>PG</given-names> </author><author><surname>Chirgwin</surname> <given-names>JM</given-names> </author><title>Molecular biology of bone metastasis</title><source>Mol Cancer Ther</source><year>2007</year><volume>6</volume><issue>10</issue><fpage>2609</fpage><lpage>2617</lpage>
<author><surname>McMahon</surname> <given-names>S</given-names> </author><author><surname>Charbonneau</surname> <given-names>M</given-names> </author><author><surname>Grandmont</surname> <given-names>S</given-names> </author><title>Transforming growth factor &#946;1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression</title><source>J Biol Chem</source><year>2006</year><volume>281</volume><issue>34</issue><fpage>24171</fpage><lpage>24181</lpage>
<author><surname>Pluijm</surname> <given-names>G</given-names> </author><author><surname>Sijmons</surname> <given-names>B</given-names> </author><author><surname>Vloedgraven</surname> <given-names>H</given-names> </author><title>Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases</title><source>J Bone Miner Res: The Official Journal of the American Society for Bone and Mineral Research</source><year>2001</year><volume>16</volume><issue>6</issue><fpage>1077</fpage><lpage>1091</lpage>
<author><surname>Davies</surname> <given-names>S</given-names> </author><author><surname>Jiang</surname> <given-names>WG</given-names> </author><title>ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis</title><source>Anticancer Res</source><year>2010</year><volume>30</volume><issue>4</issue><fpage>1163</fpage><lpage>1168</lpage>
<author><surname>Galaup</surname> <given-names>A</given-names> </author><author><surname>Cazes</surname> <given-names>A</given-names> </author><author><surname>Jan</surname> <given-names>S</given-names> </author><title>Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness</title><source>Proc Natl Acad Sci USA</source><year>2006</year><volume>103</volume><issue>49</issue><fpage>18721</fpage><lpage>18726</lpage>
<author><surname>Gupta</surname> <given-names>GP</given-names> </author><author><surname>Perk</surname> <given-names>J</given-names> </author><author><surname>Acharyya</surname> <given-names>S</given-names> </author><title>ID genes mediate tumor reinitiation during breast cancer lung metastasis</title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><issue>49</issue><fpage>19506</fpage><lpage>19511</lpage>
<author><surname>Sadej</surname> <given-names>R</given-names> </author><author><surname>Romanska</surname> <given-names>H</given-names> </author><author><surname>Kavanagh</surname> <given-names>D</given-names> </author><title>Tetraspanin CD151 regulates transforming growth factor &#946; signaling: implication in tumor metastasis</title><source>Cancer Res</source><year>2010</year><volume>70</volume><issue>14</issue><fpage>6059</fpage><lpage>6070</lpage>
<source>Human Gene Mutation Database</source><year>2011</year>
<author><surname>Veiga-da-Cunha</surname> <given-names>M</given-names> </author><author><surname>Gerin</surname> <given-names>I</given-names> </author><author><surname>Chen</surname> <given-names>YT</given-names> </author><title>A gene on chromosome 11q23 coding for a putative glucose-6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic</title><source>Am J Hum Genet</source><year>1998</year><volume>63</volume><fpage>976</fpage><lpage>983</lpage>
<author><surname>Visser</surname> <given-names>G</given-names> </author><author><surname>Rake</surname> <given-names>JP</given-names> </author><author><surname>Fernandes</surname> <given-names>J</given-names> </author><title>Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I</title><source>J Pediatr</source><year>2000</year><volume>137</volume><fpage>187</fpage><lpage>191</lpage>
<author><surname>Weston</surname> <given-names>BW</given-names> </author><author><surname>Lin</surname> <given-names>JU</given-names> </author><author><surname>Muenzer</surname> <given-names>J</given-names> </author><title>Glucose-6-Phosphatase Mutation G188R Confers an Atypical Glycogen Storage Disease Type 1b Phenotype</title><source>Pediatr Res</source><year>2000</year><volume>48</volume><fpage>329</fpage><lpage>334</lpage>
<author><surname>Launay-Vacher</surname> <given-names>V</given-names> </author><author><surname>Deray</surname> <given-names>G</given-names> </author><title>Hypertension and proteinuria: a class-effect of antiangiogenic therapies</title><source>Anticancer Drugs.</source><year>2009</year><volume>20</volume><issue>1</issue><fpage>81</fpage><lpage>82</lpage>
<author><surname>Chowdhury</surname> <given-names>S</given-names> </author><author><surname>Spicer</surname> <given-names>J</given-names> </author><author><surname>Harper</surname> <given-names>P</given-names> </author><title>Hypertension and targeted therapy: part 1. Bevacizumab</title><source>Targeted Oncology.</source><year>2006</year><volume>1</volume><issue>2</issue><fpage>104</fpage><lpage>108</lpage>
<author><surname>Chowdhury</surname> <given-names>S</given-names> </author><author><surname>Spicer</surname> <given-names>J</given-names> </author><author><surname>Harper</surname> <given-names>P</given-names> </author><title>Hypertension and targeted therapy: part 2. Small molecule inhibitors of VEGF</title><source>Targeted Oncology.</source><year>2006</year><volume>1</volume><issue>3</issue><fpage>172</fpage><lpage>178</lpage>
<author><surname>Roodhart</surname> <given-names>JM</given-names> </author><author><surname>Langenberg</surname> <given-names>MH</given-names> </author><author><surname>Witteveen</surname> <given-names>E</given-names> </author><title>The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway</title><source>Curr Clin Pharmacol.</source><year>2008</year><volume>3</volume><issue>2</issue><fpage>132</fpage><lpage>143</lpage>
<author><surname>Humphreys</surname> <given-names>BD</given-names> </author><author><surname>Atkins</surname> <given-names>MB</given-names> </author><title>Rapid development of hypertension by sorafenib: toxicity or target?</title><source>Clin Cancer Res.</source><year>2009</year><volume>15</volume><issue>19</issue><fpage>5947</fpage><lpage>5949</lpage>
<author><surname>Rixe</surname> <given-names>O</given-names> </author><author><surname>Billemont</surname> <given-names>B</given-names> </author><author><surname>Izzedine</surname> <given-names>H</given-names> </author><title>Hypertension as a predictive factor of sunitinib activity</title><source>Ann Oncol.</source><year>2007</year><volume>18</volume><issue>6</issue><fpage>1117</fpage>
<author><surname>Yang</surname> <given-names>R</given-names> </author><author><surname>Thomas</surname> <given-names>GR</given-names> </author><author><surname>Bunting</surname> <given-names>S</given-names> </author><title>Effects of vascular endothelial growth factor on hemodynamics and cardiac performance</title><source>J Cardiovasc Pharmacol.</source><year>1996</year><volume>27</volume><issue>6</issue><fpage>838</fpage><lpage>844</lpage>
<author><surname>Wei</surname> <given-names>W</given-names> </author><author><surname>Jin</surname> <given-names>H</given-names> </author><author><surname>Chen</surname> <given-names>ZW</given-names> </author><title>Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants</title><source>J Cardiovasc Pharmacol.</source><year>2004</year><volume>44</volume><issue>5</issue><fpage>615</fpage><lpage>621</lpage>
<author><surname>Steeghs</surname> <given-names>N</given-names> </author><author><surname>Gelderblom</surname> <given-names>H</given-names> </author><author><surname>Roodt</surname> <given-names>JO</given-names> </author><title>Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor</title><source>Clin Cancer Res.</source><year>2008</year><volume>14</volume><issue>11</issue><fpage>3470</fpage><lpage>3476</lpage>
<author><surname>Dechend</surname> <given-names>R</given-names> </author><author><surname>Luft</surname> <given-names>FC</given-names> </author><title>Angiogenesis factors and preeclampsia</title><source>Nature Med.</source><year>2008</year><volume>14</volume><issue>11</issue><fpage>1187</fpage><lpage>1188</lpage>
<author><surname>Motzer</surname> <given-names>RJ</given-names> </author><author><surname>Hutson</surname> <given-names>TE</given-names> </author><author><surname>Tomczak</surname> <given-names>P</given-names> </author><title>Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma</title><source>J Clin Oncol.</source><year>2009</year><volume>27</volume><issue>22</issue><fpage>3584</fpage><lpage>3590</lpage>
<title>Sunitinib malate (SUTENT&#174;) prescribing information. Revised July 2010</title>
<author><surname>Rini</surname> <given-names>BI</given-names> </author><author><surname>Schiller</surname> <given-names>JH</given-names> </author><author><surname>Fruehauf</surname> <given-names>JP</given-names> </author>Association of diastolic blood pressure (dBP) &gt;= 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). Poster presentation at the 44th annual meeting of the American Society of Clinical Oncology. Chicago, IL. May 30, 2008 to June 3, 2008. Abstract 3543
<author><surname>Bono</surname> <given-names>P</given-names> </author><author><surname>Elfving</surname> <given-names>H</given-names> </author><author><surname>Utriainen</surname> <given-names>T</given-names> </author><title>Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma</title><source>Ann Oncol.</source><year>2009</year><volume>20</volume><issue>2</issue><fpage>393</fpage><lpage>394</lpage>
<author><surname>Dahlberg</surname> <given-names>SE</given-names> </author><author><surname>Sandler</surname> <given-names>AB</given-names> </author><author><surname>Brahmer</surname> <given-names>JR</given-names> </author><author><surname>Schiller</surname> <given-names>JH</given-names> </author><author><surname>Johnson</surname> <given-names>DH</given-names> </author><title>Clinical course of advanced non&#8211;small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599</title><source>J Clin Oncol.</source><year>2010</year><volume>28</volume><issue>6</issue><fpage>949</fpage><lpage>954</lpage>
<author><surname>Friberg</surname> <given-names>G</given-names> </author><author><surname>Kasza</surname> <given-names>K</given-names> </author><author><surname>Vokes</surname> <given-names>EE</given-names> </author><title>Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G)</title><source>J Clin Oncol.</source><year>2005</year><volume>23</volume><issue>suppl</issue><fpage>196s</fpage>Abstract 3020
<author><surname>Scartozzi</surname> <given-names>M</given-names> </author><author><surname>Galizia</surname> <given-names>E</given-names> </author><author><surname>Chiorrini</surname> <given-names>S</given-names> </author><title>Arterial hypertension correlates with clinical outcome in colorectal cancer patients with first-line bevacizumab</title><source>Ann Oncol.</source><year>2009</year><volume>20</volume><issue>2</issue><fpage>227</fpage><lpage>230</lpage>
<author><surname>Gore</surname> <given-names>ME</given-names> </author><author><surname>Szczylik</surname> <given-names>C</given-names> </author><author><surname>Porta</surname> <given-names>C</given-names> </author><title>Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial</title><source>Lancet Oncol.</source><year>2009</year><volume>10</volume><issue>8</issue><fpage>757</fpage><lpage>763</lpage>
<author><surname>Motzer</surname> <given-names>RJ</given-names> </author><author><surname>Michaelson</surname> <given-names>MD</given-names> </author><author><surname>Redman</surname> <given-names>BG</given-names> </author><title>Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma</title><source>J Clin Oncol.</source><year>2006</year><volume>24</volume><issue>1</issue><fpage>16</fpage><lpage>24</lpage>
<author><surname>Motzer</surname> <given-names>RJ</given-names> </author><author><surname>Rini</surname> <given-names>BI</given-names> </author><author><surname>Bukowski</surname> <given-names>RM</given-names> </author><title>Sunitinib in patients with metastatic renal cell carcinoma</title><source>JAMA.</source><year>2006</year><volume>295</volume><issue>21</issue><fpage>2516</fpage><lpage>2524</lpage>
<author><surname>Motzer</surname> <given-names>RJ</given-names> </author><author><surname>Hutson</surname> <given-names>TE</given-names> </author><author><surname>Tomczak</surname> <given-names>P</given-names> </author><title>Sunitinib versus interferon alfa in metastatic renal-cell carcinoma</title><source>N Engl J Med.</source><year>2007</year><volume>356</volume><issue>2</issue><fpage>115</fpage><lpage>124</lpage>
<author><surname>Therasse</surname> <given-names>P</given-names> </author><author><surname>Arbuck</surname> <given-names>SG</given-names> </author><author><surname>Eisenhauer</surname> <given-names>EA</given-names> </author><title>New guidelines to evaluate the response to treatment in solid tumors</title><source>J Natl Cancer Inst.</source><year>2000</year><volume>92</volume><issue>3</issue><fpage>205</fpage><lpage>216</lpage>
<author><surname>Chobanian</surname> <given-names>AV</given-names> </author><author><surname>Bakris</surname> <given-names>GL</given-names> </author><author><surname>Black</surname> <given-names>HR</given-names> </author><title>Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</title><source>Hypertension.</source><year>2003</year><volume>42</volume><issue>6</issue><fpage>1206</fpage><lpage>1252</lpage>
<author><surname>Motzer</surname> <given-names>RJ</given-names> </author><author><surname>Bacik</surname> <given-names>J</given-names> </author><author><surname>Murphy</surname> <given-names>BA</given-names> </author><title>Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma</title><source>J Clin Oncol.</source><year>2002</year><volume>20</volume><issue>1</issue><fpage>289</fpage><lpage>296</lpage>
<author><surname>Heng</surname> <given-names>DY</given-names> </author><author><surname>Xie</surname> <given-names>W</given-names> </author><author><surname>Regan</surname> <given-names>MM</given-names> </author><title>Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study</title><source>J Clin Oncol.</source><year>2009</year><volume>27</volume><issue>34</issue><fpage>5794</fpage><lpage>5799</lpage>
<author><surname>Zhu</surname> <given-names>X</given-names> </author><author><surname>Stergiopoulos</surname> <given-names>K</given-names> </author><author><surname>Wu</surname> <given-names>S</given-names> </author><title>Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis</title><source>Acta Oncol.</source><year>2009</year><volume>48</volume><issue>1</issue><fpage>9</fpage><lpage>17</lpage>
<author><surname>Launay-Vacher</surname> <given-names>V</given-names> </author><author><surname>Ayllon</surname> <given-names>J</given-names> </author><author><surname>Janus</surname> <given-names>N</given-names> </author><title>Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma [published online ahead of print November 12, 2009]</title><source>Urol Oncol</source>
<author><surname>Maitland</surname> <given-names>ML</given-names> </author><author><surname>Bakris</surname> <given-names>GL</given-names> </author><author><surname>Black</surname> <given-names>HR</given-names> </author><title>Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors</title><source>J Natl Cancer Inst.</source><year>2010</year><volume>102</volume><issue>9</issue><fpage>596</fpage><lpage>604</lpage>
<author><surname>Langenberg</surname> <given-names>MH</given-names> </author><author><surname>van Herpen</surname> <given-names>CM</given-names> </author><author><surname>De Bono</surname> <given-names>J</given-names> </author><title>Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors</title><source>J Clin Oncol.</source><year>2009</year><volume>27</volume><issue>36</issue><fpage>6152</fpage><lpage>6159</lpage>
<author><surname>Bamias</surname> <given-names>A</given-names> </author><author><surname>Lainakis</surname> <given-names>G</given-names> </author><author><surname>Manios</surname> <given-names>E</given-names> </author><title>Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib</title><source>J Chemother.</source><year>2009</year><volume>21</volume><issue>3</issue><fpage>347</fpage><lpage>350</lpage>
<author><surname>Van Heeckeren</surname> <given-names>WJ</given-names> </author><author><surname>Ortiz</surname> <given-names>J</given-names> </author><author><surname>Cooney</surname> <given-names>MM</given-names> </author><title>Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?</title><source>J Clin Oncol.</source><year>2007</year><volume>25</volume><issue>21</issue><fpage>2993</fpage><lpage>2995</lpage>
<author><surname>Hood</surname> <given-names>JD</given-names> </author><author><surname>Meininger</surname> <given-names>CJ</given-names> </author><author><surname>Ziche</surname> <given-names>M</given-names> </author><title>VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells</title><source>Am J Physiol.</source><year>1998</year><volume>274</volume><issue>3, pt 2</issue><fpage>H1054</fpage><lpage>H1058</lpage>
<author><surname>van der Veldt</surname> <given-names>AA</given-names> </author><author><surname>de Boer</surname> <given-names>MP</given-names> </author><author><surname>Boven</surname> <given-names>E</given-names> </author><title>Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib</title><source>Anticancer Drugs.</source><year>2010</year><volume>21</volume><issue>4</issue><fpage>439</fpage><lpage>446</lpage>
<author><surname>Houk</surname> <given-names>BE</given-names> </author><author><surname>Bello</surname> <given-names>CL</given-names> </author><author><surname>Poland</surname> <given-names>B</given-names> </author><author><surname>Rosen</surname> <given-names>LS</given-names> </author><author><surname>Demetri</surname> <given-names>GD</given-names> </author><author><surname>Motzer</surname> <given-names>RJ</given-names> </author><title>Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis</title><source>Cancer Chemother Pharmacol.</source><year>2010</year><volume>66</volume><issue>2</issue><fpage>357</fpage><lpage>371</lpage>
<author><surname>Agaisse</surname> <given-names>H</given-names> </author><author><surname>Petersen</surname> <given-names>UM</given-names> </author><author><surname>Boutros</surname> <given-names>M</given-names> </author><author><surname>Mathey-Prevot</surname> <given-names>B</given-names> </author><author><surname>Perrimon</surname> <given-names>N</given-names> </author><title>Signaling role of hemocytes in Drosophila JAK/STAT-dependent response to septic injury</title><source>Dev Cell</source><year>2003</year><volume>5</volume><fpage>441</fpage><lpage>450</lpage>
<author><surname>Almudi</surname> <given-names>I</given-names> </author><author><surname>Stocker</surname> <given-names>H</given-names> </author><author><surname>Hafen</surname> <given-names>E</given-names> </author><author><surname>Corominas</surname> <given-names>M</given-names> </author><author><surname>Serras</surname> <given-names>F</given-names> </author><title>SOCS36E specifically interferes with Sevenless signaling during Drosophila eye development</title><source>Dev Biol</source><year>2009</year><volume>326</volume><fpage>212</fpage><lpage>223</lpage>
<author><surname>Amsen</surname> <given-names>D</given-names> </author><author><surname>Blander</surname> <given-names>JM</given-names> </author><author><surname>Lee</surname> <given-names>GR</given-names> </author><author><surname>Tanigaki</surname> <given-names>K</given-names> </author><author><surname>Honjo</surname> <given-names>T</given-names> </author><author><surname>Flavell</surname> <given-names>RA</given-names> </author><title>Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells</title><source>Cell</source><year>2004</year><volume>117</volume><fpage>515</fpage><lpage>526</lpage>
<author><surname>Arbouzova</surname> <given-names>NI</given-names> </author><author><surname>Zeidler</surname> <given-names>MP</given-names> </author><title>JAK/STAT signalling in Drosophila: insights into conserved regulatory and cellular functions</title><source>Development</source><year>2006</year><volume>133</volume><fpage>2605</fpage><lpage>2616</lpage>
<author><surname>Asano</surname> <given-names>H</given-names> </author><author><surname>Aonuma</surname> <given-names>M</given-names> </author><author><surname>Sanosaka</surname> <given-names>T</given-names> </author><author><surname>Kohyama</surname> <given-names>J</given-names> </author><author><surname>Namihira</surname> <given-names>M</given-names> </author><author><surname>Nakashima</surname> <given-names>K</given-names> </author><title>Astrocyte differentiation of neural precursor cells is enhanced by retinoic acid through a change in epigenetic modification</title><source>Stem Cells</source><year>2009</year><volume>27</volume><fpage>2744</fpage><lpage>2752</lpage>
<author><surname>Babst</surname> <given-names>M</given-names> </author><author><surname>Katzmann</surname> <given-names>DJ</given-names> </author><author><surname>Snyder</surname> <given-names>WB</given-names> </author><author><surname>Wendland</surname> <given-names>B</given-names> </author><author><surname>Emr</surname> <given-names>SD</given-names> </author><title>Endosome-associated complex, ESCRT-II, recruits transport machinery for protein sorting at the multivesicular body</title><source>Dev Cell</source><year>2002</year><volume>3</volume><fpage>283</fpage><lpage>289</lpage>
<author><surname>Bach</surname> <given-names>EA</given-names> </author><author><surname>Vincent</surname> <given-names>S</given-names> </author><author><surname>Zeidler</surname> <given-names>MP</given-names> </author><author><surname>Perrimon</surname> <given-names>N</given-names> </author><title>A sensitized genetic screen to identify novel regulators and components of the Drosophila janus kinase/signal transducer and activator of transcription pathway</title><source>Genetics</source><year>2003</year><volume>165</volume><fpage>1149</fpage><lpage>1166</lpage>
<author><surname>Bach</surname> <given-names>EA</given-names> </author><author><surname>Ekas</surname> <given-names>LA</given-names> </author><author><surname>Ayala-Camargo</surname> <given-names>A</given-names> </author><author><surname>Flaherty</surname> <given-names>MS</given-names> </author><author><surname>Lee</surname> <given-names>H</given-names> </author><author><surname>Perrimon</surname> <given-names>N</given-names> </author><author><surname>Baeg</surname> <given-names>GH</given-names> </author><title>GFP reporters detect the activation of the Drosophila JAK/STAT pathway in vivo</title><source>Gene Expr Patterns</source><year>2007</year><volume>7</volume><fpage>323</fpage><lpage>331</lpage>
<author><surname>Baonza</surname> <given-names>A</given-names> </author><author><surname>Freeman</surname> <given-names>M</given-names> </author><title>Notch signalling and the initiation of neural development in the Drosophila eye</title><source>Development</source><year>2001</year><volume>128</volume><fpage>3889</fpage><lpage>3898</lpage>
<author><surname>Baonza</surname> <given-names>A</given-names> </author><author><surname>Freeman</surname> <given-names>M</given-names> </author><title>Control of Drosophila eye specification by Wingless signalling</title><source>Development</source><year>2002</year><volume>129</volume><fpage>5313</fpage><lpage>5322</lpage>
<author><surname>Betz</surname> <given-names>A</given-names> </author><author><surname>Lampen</surname> <given-names>N</given-names> </author><author><surname>Martinek</surname> <given-names>S</given-names> </author><author><surname>Young</surname> <given-names>MW</given-names> </author><author><surname>Darnell</surname> <given-names>JE</given-names> <suffix>Jr</suffix> </author><title>A Drosophila PIAS homologue negatively regulates stat92E</title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>9563</fpage><lpage>9568</lpage>
<author><surname>Binari</surname> <given-names>R</given-names> </author><author><surname>Perrimon</surname> <given-names>N</given-names> </author><title>Stripe-specific regulation of pair-rule genes by hopscotch, a putative Jak family tyrosine kinase in Drosophila</title><source>Genes Dev</source><year>1994</year><volume>8</volume><fpage>300</fpage><lpage>312</lpage>
<author><surname>Bishop</surname> <given-names>N</given-names> </author><author><surname>Woodman</surname> <given-names>P</given-names> </author><title>TSG101/mammalian VPS23 and mammalian VPS28 interact directly and are recruited to VPS4-induced endosomes</title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>11735</fpage><lpage>11742</lpage>
<author><surname>Bonni</surname> <given-names>A</given-names> </author><author><surname>Sun</surname> <given-names>Y</given-names> </author><author><surname>Nadal-Vicens</surname> <given-names>M</given-names> </author><author><surname>Bhatt</surname> <given-names>A</given-names> </author><author><surname>Frank</surname> <given-names>DA</given-names> </author><author><surname>Rozovsky</surname> <given-names>I</given-names> </author><author><surname>Stahl</surname> <given-names>N</given-names> </author><author><surname>Yancopoulos</surname> <given-names>GD</given-names> </author><author><surname>Greenberg</surname> <given-names>ME</given-names> </author><title>Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway</title><source>Science</source><year>1997</year><volume>278</volume><fpage>477</fpage><lpage>483</lpage>
<author><surname>Boulay</surname> <given-names>JL</given-names> </author><author><surname>O'Shea</surname> <given-names>JJ</given-names> </author><author><surname>Paul</surname> <given-names>WE</given-names> </author><title>Molecular phylogeny within type I cytokines and their cognate receptors</title><source>Immunity</source><year>2003</year><volume>19</volume><fpage>159</fpage><lpage>163</lpage>
<author><surname>Bowman</surname> <given-names>T</given-names> </author><author><surname>Garcia</surname> <given-names>R</given-names> </author><author><surname>Turkson</surname> <given-names>J</given-names> </author><author><surname>Jove</surname> <given-names>R</given-names> </author><title>STATs in oncogenesis</title><source>Oncogene</source><year>2000</year><volume>19</volume><fpage>2474</fpage><lpage>2488</lpage>
<author><surname>Bromberg</surname> <given-names>JF</given-names> </author><author><surname>Wrzeszczynska</surname> <given-names>MH</given-names> </author><author><surname>Devgan</surname> <given-names>G</given-names> </author><author><surname>Zhao</surname> <given-names>Y</given-names> </author><author><surname>Pestell</surname> <given-names>RG</given-names> </author><author><surname>Albanese</surname> <given-names>C</given-names> </author><author><surname>Darnell</surname> <given-names>JE</given-names> <suffix>Jr</suffix> </author><title>Stat3 as an oncogene</title><source>Cell</source><year>1999</year><volume>98</volume><fpage>295</fpage><lpage>303</lpage>
<author><surname>Brown</surname> <given-names>S</given-names> </author><author><surname>Hu</surname> <given-names>N</given-names> </author><author><surname>Hombria</surname> <given-names>JC</given-names> </author><title>Identification of the first invertebrate interleukin JAK/STAT receptor, the Drosophila gene domeless</title><source>Curr Biol</source><year>2001</year><volume>11</volume><fpage>1700</fpage><lpage>1705</lpage>
<author><surname>Brown</surname> <given-names>S</given-names> </author><author><surname>Zeidler</surname> <given-names>MP</given-names> </author><title>Unphosphorylated STATs go nuclear</title><source>Curr Opin Genet Dev</source><year>2008</year><volume>18</volume><fpage>455</fpage><lpage>460</lpage>
<author><surname>Calo</surname> <given-names>V</given-names> </author><author><surname>Migliavacca</surname> <given-names>M</given-names> </author><author><surname>Bazan</surname> <given-names>V</given-names> </author><author><surname>Macaluso</surname> <given-names>M</given-names> </author><author><surname>Buscemi</surname> <given-names>M</given-names> </author><author><surname>Gebbia</surname> <given-names>N</given-names> </author><author><surname>Russo</surname> <given-names>A</given-names> </author><title>STAT proteins: from normal control of cellular events to tumorigenesis</title><source>J Cell Physiol</source><year>2003</year><volume>197</volume><fpage>157</fpage><lpage>168</lpage>
<author><surname>Cavodeassi</surname> <given-names>F</given-names> </author><author><surname>Diez Del Corral</surname> <given-names>R</given-names> </author><author><surname>Campuzano</surname> <given-names>S</given-names> </author><author><surname>Dominguez</surname> <given-names>M</given-names> </author><title>Compartments and organising boundaries in the Drosophila eye: the role of the homeodomain Iroquois proteins</title><source>Development</source><year>1999</year><volume>126</volume><fpage>4933</fpage><lpage>4942</lpage>
<author><surname>Chanut</surname> <given-names>F</given-names> </author><author><surname>Heberlein</surname> <given-names>U</given-names> </author><title>Role of the morphogenetic furrow in establishing polarity in the Drosophila eye</title><source>Development</source><year>1995</year><volume>121</volume><fpage>4085</fpage><lpage>4094</lpage>
<author><surname>Chao</surname> <given-names>JL</given-names> </author><author><surname>Tsai</surname> <given-names>YC</given-names> </author><author><surname>Chiu</surname> <given-names>SJ</given-names> </author><author><surname>Sun</surname> <given-names>YH</given-names> </author><title>Localized Notch signal acts through eyg and upd to promote global growth in Drosophila eye</title><source>Development</source><year>2004</year><volume>131</volume><fpage>3839</fpage><lpage>3847</lpage>
<author><surname>Cho</surname> <given-names>KO</given-names> </author><author><surname>Chern</surname> <given-names>J</given-names> </author><author><surname>Izaddoost</surname> <given-names>S</given-names> </author><author><surname>Choi</surname> <given-names>KW</given-names> </author><title>Novel signaling from the peripodial membrane is essential for eye disc patterning in Drosophila</title><source>Cell</source><year>2000</year><volume>103</volume><fpage>331</fpage><lpage>342</lpage>
<author><surname>Christova</surname> <given-names>R</given-names> </author><author><surname>Jones</surname> <given-names>T</given-names> </author><author><surname>Wu</surname> <given-names>PJ</given-names> </author><author><surname>Bolzer</surname> <given-names>A</given-names> </author><author><surname>Costa-Pereira</surname> <given-names>AP</given-names> </author><author><surname>Watling</surname> <given-names>D</given-names> </author><author><surname>Kerr</surname> <given-names>IM</given-names> </author><author><surname>Sheer</surname> <given-names>D</given-names> </author><title>P-STAT1 mediates higher-order chromatin remodelling of the human MHC in response to IFNgamma</title><source>J Cell Sci</source><year>2007</year><volume>120</volume><fpage>3262</fpage><lpage>3270</lpage>
<author><surname>Chung</surname> <given-names>CD</given-names> </author><author><surname>Liao</surname> <given-names>J</given-names> </author><author><surname>Liu</surname> <given-names>B</given-names> </author><author><surname>Rao</surname> <given-names>X</given-names> </author><author><surname>Jay</surname> <given-names>P</given-names> </author><author><surname>Berta</surname> <given-names>P</given-names> </author><author><surname>Shuai</surname> <given-names>K</given-names> </author><title>Specific inhibition of Stat3 signal transduction by PIAS3</title><source>Science</source><year>1997</year><volume>278</volume><fpage>1803</fpage><lpage>1805</lpage>
<author><surname>Classen</surname> <given-names>AK</given-names> </author><author><surname>Bunker</surname> <given-names>BD</given-names> </author><author><surname>Harvey</surname> <given-names>KF</given-names> </author><author><surname>Vaccari</surname> <given-names>T</given-names> </author><author><surname>Bilder</surname> <given-names>D</given-names> </author><title>A tumor suppressor activity of Drosophila Polycomb genes mediated by JAK-STAT signaling</title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>1150</fpage><lpage>1155</lpage>
<author><surname>Constantinescu</surname> <given-names>SN</given-names> </author><author><surname>Girardot</surname> <given-names>M</given-names> </author><author><surname>Pecquet</surname> <given-names>C</given-names> </author><title>Mining for JAK-STAT mutations in cancer</title><source>Trends Biochem Sci</source><year>2008</year><volume>33</volume><fpage>122</fpage><lpage>131</lpage>
<author><surname>Croker</surname> <given-names>BA</given-names> </author><author><surname>Kiu</surname> <given-names>H</given-names> </author><author><surname>Nicholson</surname> <given-names>SE</given-names> </author><title>SOCS regulation of the JAK/STAT signalling pathway</title><source>Semin Cell Dev Biol</source><year>2008</year><volume>19</volume><fpage>414</fpage><lpage>422</lpage>
<author><surname>D'Costa</surname> <given-names>A</given-names> </author><author><surname>Reifegerste</surname> <given-names>R</given-names> </author><author><surname>Sierra</surname> <given-names>S</given-names> </author><author><surname>Moses</surname> <given-names>K</given-names> </author><title>The Drosophila ramshackle gene encodes a chromatin-associated protein required for cell morphology in the developing eye</title><source>Mech Dev</source><year>2006</year><volume>123</volume><fpage>591</fpage><lpage>604</lpage>
<author><surname>de la Iglesia</surname> <given-names>N</given-names> </author><author><surname>Konopka</surname> <given-names>G</given-names> </author><author><surname>Puram</surname> <given-names>SV</given-names> </author><author><surname>Chan</surname> <given-names>JA</given-names> </author><author><surname>Bachoo</surname> <given-names>RM</given-names> </author><author><surname>You</surname> <given-names>MJ</given-names> </author><author><surname>Levy</surname> <given-names>DE</given-names> </author><author><surname>Depinho</surname> <given-names>RA</given-names> </author><author><surname>Bonni</surname> <given-names>A</given-names> </author><title>Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway</title><source>Genes Dev</source><year>2008</year><volume>22</volume><fpage>449</fpage><lpage>462</lpage>
<author><surname>Devergne</surname> <given-names>O</given-names> </author><author><surname>Ghiglione</surname> <given-names>C</given-names> </author><author><surname>Noselli</surname> <given-names>S</given-names> </author><title>The endocytic control of JAK/STAT signalling in Drosophila</title><source>J Cell Sci</source><year>2007</year><volume>120</volume><fpage>3457</fpage><lpage>3464</lpage>
<author><surname>Dominguez</surname> <given-names>M</given-names> </author><author><surname>de Celis</surname> <given-names>JF</given-names> </author><title>A dorsal/ventral boundary established by Notch controls growth and polarity in the Drosophila eye</title><source>Nature</source><year>1998</year><volume>396</volume><fpage>276</fpage><lpage>278</lpage>
<author><surname>Dominguez</surname> <given-names>M</given-names> </author><author><surname>Ferres-Marco</surname> <given-names>D</given-names> </author><author><surname>Gutierrez-Avino</surname> <given-names>FJ</given-names> </author><author><surname>Speicher</surname> <given-names>SA</given-names> </author><author><surname>Beneyto</surname> <given-names>M</given-names> </author><title>Growth and specification of the eye are controlled independently by Eyegone and Eyeless in Drosophila melanogaster</title><source>Nat Genet</source><year>2004</year><volume>36</volume><fpage>31</fpage><lpage>39</lpage>
<author><surname>Ekas</surname> <given-names>LA</given-names> </author><author><surname>Baeg</surname> <given-names>GH</given-names> </author><author><surname>Flaherty</surname> <given-names>MS</given-names> </author><author><surname>Ayala-Camargo</surname> <given-names>A</given-names> </author><author><surname>Bach</surname> <given-names>EA</given-names> </author><title>JAK/STAT signaling promotes regional specification by negatively regulating wingless expression in Drosophila</title><source>Development</source><year>2006</year><volume>133</volume><fpage>4721</fpage><lpage>4729</lpage>
<author><surname>Faivre</surname> <given-names>S</given-names> </author><author><surname>Kroemer</surname> <given-names>G</given-names> </author><author><surname>Raymond</surname> <given-names>E</given-names> </author><title>Current development of mTOR inhibitors as anticancer agents</title><source>Nat Rev Drug Discov</source><year>2006</year><volume>5</volume><fpage>671</fpage><lpage>688</lpage>
<author><surname>Flaherty</surname> <given-names>MS</given-names> </author><author><surname>Zavadil</surname> <given-names>J</given-names> </author><author><surname>Ekas</surname> <given-names>LA</given-names> </author><author><surname>Bach</surname> <given-names>EA</given-names> </author><title>Genome-wide expression profiling in the Drosophila eye reveals unexpected repression of notch signaling by the JAK/STAT pathway</title><source>Dev Dyn</source><year>2009</year><volume>238</volume><fpage>2235</fpage><lpage>2253</lpage>
<author><surname>Fonseca</surname> <given-names>BD</given-names> </author><author><surname>Smith</surname> <given-names>EM</given-names> </author><author><surname>Lee</surname> <given-names>VH</given-names> </author><author><surname>MacKintosh</surname> <given-names>C</given-names> </author><author><surname>Proud</surname> <given-names>CG</given-names> </author><title>PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex</title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>24514</fpage><lpage>24524</lpage>
<author><surname>Fu</surname> <given-names>W</given-names> </author><author><surname>Baker</surname> <given-names>NE</given-names> </author><title>Deciphering synergistic and redundant roles of Hedgehog, Decapentaplegic and Delta that drive the wave of differentiation in Drosophila eye development</title><source>Development</source><year>2003</year><volume>130</volume><fpage>5229</fpage><lpage>5239</lpage>
<author><surname>Ghiglione</surname> <given-names>C</given-names> </author><author><surname>Devergne</surname> <given-names>O</given-names> </author><author><surname>Georgenthum</surname> <given-names>E</given-names> </author><author><surname>Carballes</surname> <given-names>F</given-names> </author><author><surname>Medioni</surname> <given-names>C</given-names> </author><author><surname>Cerezo</surname> <given-names>D</given-names> </author><author><surname>Noselli</surname> <given-names>S</given-names> </author><title>The Drosophila cytokine receptor Domeless controls border cell migration and epithelial polarization during oogenesis</title><source>Development</source><year>2002</year><volume>129</volume><fpage>5437</fpage><lpage>5447</lpage>
<author><surname>Gilbert</surname> <given-names>MM</given-names> </author><author><surname>Weaver</surname> <given-names>BK</given-names> </author><author><surname>Gergen</surname> <given-names>JP</given-names> </author><author><surname>Reich</surname> <given-names>NC</given-names> </author><title>A novel functional activator of the Drosophila JAK/STAT pathway, unpaired2, is revealed by an in vivo reporter of pathway activation</title><source>Mech Dev</source><year>2005</year><volume>122</volume><fpage>939</fpage><lpage>948</lpage>
<author><surname>Gilbert</surname> <given-names>MM</given-names> </author><author><surname>Beam</surname> <given-names>CK</given-names> </author><author><surname>Robinson</surname> <given-names>BS</given-names> </author><author><surname>Moberg</surname> <given-names>KH</given-names> </author><title>Genetic interactions between the Drosophila tumor suppressor gene ept and the stat92E transcription factor</title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e7083</fpage>
<author><surname>Go</surname> <given-names>MJ</given-names> </author><author><surname>Eastman</surname> <given-names>DS</given-names> </author><author><surname>Artavanis-Tsakonas</surname> <given-names>S</given-names> </author><title>Cell proliferation control by Notch signaling in Drosophila development</title><source>Development</source><year>1998</year><volume>125</volume><fpage>2031</fpage><lpage>2040</lpage>
<author><surname>Greenwood</surname> <given-names>S</given-names> </author><author><surname>Struhl</surname> <given-names>G</given-names> </author><title>Progression of the morphogenetic furrow in the Drosophila eye: the roles of Hedgehog, Decapentaplegic and the Raf pathway</title><source>Development</source><year>1999</year><volume>126</volume><fpage>5795</fpage><lpage>5808</lpage>
<author><surname>Gutierrez-Avino</surname> <given-names>FJ</given-names> </author><author><surname>Ferres-Marco</surname> <given-names>D</given-names> </author><author><surname>Dominguez</surname> <given-names>M</given-names> </author><title>The position and function of the Notch-mediated eye growth organizer: the roles of JAK/STAT and four-jointed</title><source>EMBO Rep</source><year>2009</year><volume>10</volume><fpage>1051</fpage><lpage>1058</lpage>
<author><surname>Hanahan</surname> <given-names>D</given-names> </author><author><surname>Weinberg</surname> <given-names>RA</given-names> </author><title>The hallmarks of cancer</title><source>Cell</source><year>2000</year><volume>100</volume><fpage>57</fpage><lpage>70</lpage>
<author><surname>Hanratty</surname> <given-names>WP</given-names> </author><author><surname>Dearolf</surname> <given-names>CR</given-names> </author><title>The Drosophila Tumorous-lethal hematopoietic oncogene is a dominant mutation in the hopscotch locus</title><source>Mol Gen Genet</source><year>1993</year><volume>238</volume><fpage>33</fpage><lpage>37</lpage>
<author><surname>Hari</surname> <given-names>KL</given-names> </author><author><surname>Cook</surname> <given-names>KR</given-names> </author><author><surname>Karpen</surname> <given-names>GH</given-names> </author><title>The Drosophila Su(var)2-10 locus regulates chromosome structure and function and encodes a member of the PIAS protein family</title><source>Genes Dev</source><year>2001</year><volume>15</volume><fpage>1334</fpage><lpage>1348</lpage>
<author><surname>Harrison</surname> <given-names>DA</given-names> </author><author><surname>Binari</surname> <given-names>R</given-names> </author><author><surname>Nahreini</surname> <given-names>TS</given-names> </author><author><surname>Gilman</surname> <given-names>M</given-names> </author><author><surname>Perrimon</surname> <given-names>N</given-names> </author><title>Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects</title><source>EMBO J</source><year>1995</year><volume>14</volume><fpage>2857</fpage><lpage>2865</lpage>
<author><surname>Harrison</surname> <given-names>DA</given-names> </author><author><surname>McCoon</surname> <given-names>PE</given-names> </author><author><surname>Binari</surname> <given-names>R</given-names> </author><author><surname>Gilman</surname> <given-names>M</given-names> </author><author><surname>Perrimon</surname> <given-names>N</given-names> </author><title>Drosophila unpaired encodes a secreted protein that activates the JAK signaling pathway</title><source>Genes Dev</source><year>1998</year><volume>12</volume><fpage>3252</fpage><lpage>3263</lpage>
<author><surname>Hauck</surname> <given-names>B</given-names> </author><author><surname>Gehring</surname> <given-names>WJ</given-names> </author><author><surname>Walldorf</surname> <given-names>U</given-names> </author><title>Functional analysis of an eye specific enhancer of the eyeless gene in Drosophila</title><source>Proc Natl Acad Sci U S A</source><year>1999</year><volume>96</volume><fpage>564</fpage><lpage>569</lpage>
<author><surname>Hay</surname> <given-names>BA</given-names> </author><author><surname>Wolff</surname> <given-names>T</given-names> </author><author><surname>Rubin</surname> <given-names>GM</given-names> </author><title>Expression of baculovirus P35 prevents cell death in Drosophila</title><source>Development</source><year>1994</year><volume>120</volume><fpage>2121</fpage><lpage>2129</lpage>
<author><surname>Heberlein</surname> <given-names>U</given-names> </author><author><surname>Wolff</surname> <given-names>T</given-names> </author><author><surname>Rubin</surname> <given-names>GM</given-names> </author><title>The TGF beta homolog dpp and the segment polarity gene hedgehog are required for propagation of a morphogenetic wave in the Drosophila retina</title><source>Cell</source><year>1993</year><volume>75</volume><fpage>913</fpage><lpage>926</lpage>
<author><surname>Hennig</surname> <given-names>KM</given-names> </author><author><surname>Neufeld</surname> <given-names>TP</given-names> </author><title>Inhibition of cellular growth and proliferation by dTOR overexpression in Drosophila</title><source>Genesis</source><year>2002</year><volume>34</volume><fpage>107</fpage><lpage>110</lpage>
<author><surname>Heppner</surname> <given-names>GH</given-names> </author><title>Tumor heterogeneity</title><source>Cancer Res</source><year>1984</year><volume>44</volume><fpage>2259</fpage><lpage>2265</lpage>
<author><surname>Heslip</surname> <given-names>TR</given-names> </author><author><surname>Theisen</surname> <given-names>H</given-names> </author><author><surname>Walker</surname> <given-names>H</given-names> </author><author><surname>Marsh</surname> <given-names>JL</given-names> </author><title>Shaggy and dishevelled exert opposite effects on Wingless and Decapentaplegic expression and on positional identity in imaginal discs</title><source>Development</source><year>1997</year><volume>124</volume><fpage>1069</fpage><lpage>1078</lpage>
<author><surname>Hombria</surname> <given-names>JC</given-names> </author><author><surname>Brown</surname> <given-names>S</given-names> </author><title>The fertile field of Drosophila Jak/STAT signalling</title><source>Curr Biol</source><year>2002</year><volume>12</volume><fpage>R569</fpage><lpage>R575</lpage>
<author><surname>Hombria</surname> <given-names>JC</given-names> </author><author><surname>Brown</surname> <given-names>S</given-names> </author><author><surname>Hader</surname> <given-names>S</given-names> </author><author><surname>Zeidler</surname> <given-names>MP</given-names> </author><title>Characterisation of Upd2, a Drosophila JAK/STAT pathway ligand</title><source>Dev Biol</source><year>2005</year><volume>288</volume><fpage>420</fpage><lpage>433</lpage>
<author><surname>Hou</surname> <given-names>XS</given-names> </author><author><surname>Melnick</surname> <given-names>MB</given-names> </author><author><surname>Perrimon</surname> <given-names>N</given-names> </author><title>Marelle acts downstream of the Drosophila HOP/JAK kinase and encodes a protein similar to the mammalian STATs</title><source>Cell</source><year>1996</year><volume>84</volume><fpage>411</fpage><lpage>419</lpage>
<author><surname>Hou</surname> <given-names>SX</given-names> </author><author><surname>Zheng</surname> <given-names>Z</given-names> </author><author><surname>Chen</surname> <given-names>X</given-names> </author><author><surname>Perrimon</surname> <given-names>N</given-names> </author><title>The Jak/STAT pathway in model organisms: emerging roles in cell movement</title><source>Dev Cell</source><year>2002</year><volume>3</volume><fpage>765</fpage><lpage>778</lpage>
<author><surname>Huang</surname> <given-names>H</given-names> </author><author><surname>Rambaldi</surname> <given-names>I</given-names> </author><author><surname>Daniels</surname> <given-names>E</given-names> </author><author><surname>Featherstone</surname> <given-names>M</given-names> </author><title>Expression of the Wdr9 gene and protein products during mouse development</title><source>Dev Dyn</source><year>2003</year><volume>227</volume><fpage>608</fpage><lpage>614</lpage>
<author><surname>Ingham</surname> <given-names>PW</given-names> </author><author><surname>McMahon</surname> <given-names>AP</given-names> </author><title>Hedgehog signaling in animal development: paradigms and principles</title><source>Genes Dev</source><year>2001</year><volume>15</volume><fpage>3059</fpage><lpage>3087</lpage>
<author><surname>Jang</surname> <given-names>CC</given-names> </author><author><surname>Chao</surname> <given-names>JL</given-names> </author><author><surname>Jones</surname> <given-names>N</given-names> </author><author><surname>Yao</surname> <given-names>LC</given-names> </author><author><surname>Bessarab</surname> <given-names>DA</given-names> </author><author><surname>Kuo</surname> <given-names>YM</given-names> </author><author><surname>Jun</surname> <given-names>S</given-names> </author><author><surname>Desplan</surname> <given-names>C</given-names> </author><author><surname>Beckendorf</surname> <given-names>SK</given-names> </author><author><surname>Sun</surname> <given-names>YH</given-names> </author><title>Two Pax genes, eye gone and eyeless, act cooperatively in promoting Drosophila eye development</title><source>Development</source><year>2003</year><volume>130</volume><fpage>2939</fpage><lpage>2951</lpage>
<author><surname>Karsten</surname> <given-names>P</given-names> </author><author><surname>Hader</surname> <given-names>S</given-names> </author><author><surname>Zeidler</surname> <given-names>MP</given-names> </author><title>Cloning and expression of Drosophila SOCS36E and its potential regulation by the JAK/STAT pathway</title><source>Mech Dev</source><year>2002</year><volume>117</volume><fpage>343</fpage><lpage>346</lpage>
<author><surname>Karsten</surname> <given-names>P</given-names> </author><author><surname>Plischke</surname> <given-names>I</given-names> </author><author><surname>Perrimon</surname> <given-names>N</given-names> </author><author><surname>Zeidler</surname> <given-names>MP</given-names> </author><title>Mutational analysis reveals separable DNA binding and trans-activation of Drosophila STAT 92E</title><source>Cell Signal</source><year>2006</year><volume>18</volume><fpage>819</fpage><lpage>829</lpage>
<author><surname>Kile</surname> <given-names>BT</given-names> </author><author><surname>Alexander</surname> <given-names>WS</given-names> </author><title>The suppressors of cytokine signalling (SOCS)</title><source>Cell Mol Life Sci</source><year>2001</year><volume>58</volume><fpage>1627</fpage><lpage>1635</lpage>
<author><surname>Kinzler</surname> <given-names>KW</given-names> </author><author><surname>Vogelstein</surname> <given-names>B</given-names> </author><title>Lessons from hereditary colorectal cancer</title><source>Cell</source><year>1996</year><volume>87</volume><fpage>159</fpage><lpage>170</lpage>
<author><surname>Kisseleva</surname> <given-names>T</given-names> </author><author><surname>Bhattacharya</surname> <given-names>S</given-names> </author><author><surname>Braunstein</surname> <given-names>J</given-names> </author><author><surname>Schindler</surname> <given-names>CW</given-names> </author><title>Signaling through the JAK/STAT pathway, recent advances and future challenges</title><source>Gene</source><year>2002</year><volume>285</volume><fpage>1</fpage><lpage>24</lpage>
<author><surname>Klebes</surname> <given-names>A</given-names> </author><author><surname>Knust</surname> <given-names>E</given-names> </author><title>A conserved motif in Crumbs is required for E-cadherin localisation and zonula adherens formation in Drosophila</title><source>Curr Biol</source><year>2000</year><volume>10</volume><fpage>76</fpage><lpage>85</lpage>
<author><surname>Krebs</surname> <given-names>DL</given-names> </author><author><surname>Hilton</surname> <given-names>DJ</given-names> </author><title>SOCS proteins: negative regulators of cytokine signaling</title><source>Stem Cells</source><year>2001</year><volume>19</volume><fpage>378</fpage><lpage>387</lpage>
<author><surname>Kurata</surname> <given-names>S</given-names> </author><author><surname>Go</surname> <given-names>MJ</given-names> </author><author><surname>Artavanis-Tsakonas</surname> <given-names>S</given-names> </author><author><surname>Gehring</surname> <given-names>WJ</given-names> </author><title>Notch signaling and the determination of appendage identity</title><source>Proc Natl Acad Sci USA</source><year>2000</year><volume>97</volume><fpage>2117</fpage><lpage>2122</lpage>
<author><surname>Kurooka</surname> <given-names>H</given-names> </author><author><surname>Honjo</surname> <given-names>T</given-names> </author><title>Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5</title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>17211</fpage><lpage>17220</lpage>
<author><surname>Langer</surname> <given-names>JA</given-names> </author><author><surname>Cutrone</surname> <given-names>EC</given-names> </author><author><surname>Kotenko</surname> <given-names>S</given-names> </author><title>The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions</title><source>Cytokine Growth Factor Rev</source><year>2004</year><volume>15</volume><fpage>33</fpage><lpage>48</lpage>
<author><surname>Lee</surname> <given-names>T</given-names> </author><author><surname>Luo</surname> <given-names>L</given-names> </author><title>Mosaic analysis with a repressible cell marker for studies of gene function in neuronal morphogenesis</title><source>Neuron</source><year>1999</year><volume>22</volume><fpage>451</fpage><lpage>461</lpage>
<author><surname>Leong</surname> <given-names>KG</given-names> </author><author><surname>Karsan</surname> <given-names>A</given-names> </author><title>Recent insights into the role of Notch signaling in tumorigenesis</title><source>Blood</source><year>2006</year><volume>107</volume><fpage>2223</fpage><lpage>2233</lpage>
<author><surname>Levy</surname> <given-names>DE</given-names> </author><author><surname>Darnell</surname> <given-names>JE</given-names> <suffix>Jr</suffix> </author><title>Stats: transcriptional control and biological impact</title><source>Nat Rev Mol Cell Biol</source><year>2002</year><volume>3</volume><fpage>651</fpage><lpage>662</lpage>
<author><surname>Li</surname> <given-names>WX</given-names> </author><title>Canonical and non-canonical JAK-STAT signaling</title><source>Trends Cell Biol</source><year>2008</year><volume>18</volume><fpage>545</fpage><lpage>551</lpage>
<author><surname>Liu</surname> <given-names>B</given-names> </author><author><surname>Liao</surname> <given-names>J</given-names> </author><author><surname>Rao</surname> <given-names>X</given-names> </author><author><surname>Kushner</surname> <given-names>SA</given-names> </author><author><surname>Chung</surname> <given-names>CD</given-names> </author><author><surname>Chang</surname> <given-names>DD</given-names> </author><author><surname>Shuai</surname> <given-names>K</given-names> </author><title>Inhibition of Stat1-mediated gene activation by PIAS1</title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>10626</fpage><lpage>10631</lpage>
<author><surname>Lovegrove</surname> <given-names>B</given-names> </author><author><surname>Simoes</surname> <given-names>S</given-names> </author><author><surname>Rivas</surname> <given-names>ML</given-names> </author><author><surname>Sotillos</surname> <given-names>S</given-names> </author><author><surname>Johnson</surname> <given-names>K</given-names> </author><author><surname>Knust</surname> <given-names>E</given-names> </author><author><surname>Jacinto</surname> <given-names>A</given-names> </author><author><surname>Hombria</surname> <given-names>JC</given-names> </author><title>Coordinated control of cell adhesion, polarity, and cytoskeleton underlies Hox-induced organogenesis in Drosophila</title><source>Curr Biol</source><year>2006</year><volume>16</volume><fpage>2206</fpage><lpage>2216</lpage>
<author><surname>Lu</surname> <given-names>Y</given-names> </author><author><surname>Fukuyama</surname> <given-names>S</given-names> </author><author><surname>Yoshida</surname> <given-names>R</given-names> </author><author><surname>Kobayashi</surname> <given-names>T</given-names> </author><author><surname>Saeki</surname> <given-names>K</given-names> </author><author><surname>Shiraishi</surname> <given-names>H</given-names> </author><author><surname>Yoshimura</surname> <given-names>A</given-names> </author><author><surname>Takaesu</surname> <given-names>G</given-names> </author><title>Loss of SOCS3 gene expression converts STAT3 function from anti-apoptotic to pro-apoptotic</title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>36683</fpage><lpage>36690</lpage>
<author><surname>Luo</surname> <given-names>H</given-names> </author><author><surname>Hanratty</surname> <given-names>WP</given-names> </author><author><surname>Dearolf</surname> <given-names>CR</given-names> </author><title>An amino acid substitution in the Drosophila hopTum-l Jak kinase causes leukemia-like hematopoietic defects</title><source>EMBO J</source><year>1995</year><volume>14</volume><fpage>1412</fpage><lpage>1420</lpage>
<author><surname>Luo</surname> <given-names>H</given-names> </author><author><surname>Asha</surname> <given-names>H</given-names> </author><author><surname>Kockel</surname> <given-names>L</given-names> </author><author><surname>Parke</surname> <given-names>T</given-names> </author><author><surname>Mlodzik</surname> <given-names>M</given-names> </author><author><surname>Dearolf</surname> <given-names>CR</given-names> </author><title>The Drosophila Jak kinase hopscotch is required for multiple developmental processes in the eye</title><source>Dev Biol</source><year>1999</year><volume>213</volume><fpage>432</fpage><lpage>441</lpage>
<author><surname>Ma</surname> <given-names>C</given-names> </author><author><surname>Moses</surname> <given-names>K</given-names> </author><title>Wingless and patched are negative regulators of the morphogenetic furrow and can affect tissue polarity in the developing Drosophila compound eye</title><source>Development</source><year>1995</year><volume>121</volume><fpage>2279</fpage><lpage>2289</lpage>
<author><surname>Ma</surname> <given-names>C</given-names> </author><author><surname>Zhou</surname> <given-names>Y</given-names> </author><author><surname>Beachy</surname> <given-names>PA</given-names> </author><author><surname>Moses</surname> <given-names>K</given-names> </author><title>The segment polarity gene hedgehog is required for progression of the morphogenetic furrow in the developing Drosophila eye</title><source>Cell</source><year>1993</year><volume>75</volume><fpage>927</fpage><lpage>938</lpage>
<author><surname>Martinez</surname> <given-names>AM</given-names> </author><author><surname>Schuettengruber</surname> <given-names>B</given-names> </author><author><surname>Sakr</surname> <given-names>S</given-names> </author><author><surname>Janic</surname> <given-names>A</given-names> </author><author><surname>Gonzalez</surname> <given-names>C</given-names> </author><author><surname>Cavalli</surname> <given-names>G</given-names> </author><title>Polyhomeotic has a tumor suppressor activity mediated by repression of Notch signaling</title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>1076</fpage><lpage>1082</lpage>
<author><surname>McNeill</surname> <given-names>H</given-names> </author><author><surname>Yang</surname> <given-names>CH</given-names> </author><author><surname>Brodsky</surname> <given-names>M</given-names> </author><author><surname>Ungos</surname> <given-names>J</given-names> </author><author><surname>Simon</surname> <given-names>MA</given-names> </author><title>mirror encodes a novel PBX-class homeoprotein that functions in the definition of the dorsal-ventral border in the Drosophila eye</title><source>Genes Dev</source><year>1997</year><volume>11</volume><fpage>1073</fpage><lpage>1082</lpage>
<author><surname>Moberg</surname> <given-names>KH</given-names> </author><author><surname>Schelble</surname> <given-names>S</given-names> </author><author><surname>Burdick</surname> <given-names>SK</given-names> </author><author><surname>Hariharan</surname> <given-names>IK</given-names> </author><title>Mutations in erupted, the Drosophila ortholog of mammalian tumor susceptibility gene 101, elicit non-cell-autonomous overgrowth</title><source>Dev Cell</source><year>2005</year><volume>9</volume><fpage>699</fpage><lpage>710</lpage>
<author><surname>Mukherjee</surname> <given-names>T</given-names> </author><author><surname>Hombria</surname> <given-names>JC</given-names> </author><author><surname>Zeidler</surname> <given-names>MP</given-names> </author><title>Opposing roles for Drosophila JAK/STAT signalling during cellular proliferation</title><source>Oncogene</source><year>2005</year><volume>24</volume><fpage>2503</fpage><lpage>2511</lpage>
<author><surname>Mukherjee</surname> <given-names>T</given-names> </author><author><surname>Schafer</surname> <given-names>U</given-names> </author><author><surname>Zeidler</surname> <given-names>MP</given-names> </author><title>Identification of Drosophila genes modulating janus kinase/signal transducer and activator of transcription signal transduction</title><source>Genetics</source><year>2006</year><volume>172</volume><fpage>1683</fpage><lpage>1697</lpage>
<author><surname>Muller</surname> <given-names>P</given-names> </author><author><surname>Kuttenkeuler</surname> <given-names>D</given-names> </author><author><surname>Gesellchen</surname> <given-names>V</given-names> </author><author><surname>Zeidler</surname> <given-names>MP</given-names> </author><author><surname>Boutros</surname> <given-names>M</given-names> </author><title>Identification of JAK/STAT signalling components by genome-wide RNA interference</title><source>Nature</source><year>2005</year><volume>436</volume><fpage>871</fpage><lpage>875</lpage>
<author><surname>Nosaka</surname> <given-names>T</given-names> </author><author><surname>Kawashima</surname> <given-names>T</given-names> </author><author><surname>Misawa</surname> <given-names>K</given-names> </author><author><surname>Ikuta</surname> <given-names>K</given-names> </author><author><surname>Mui</surname> <given-names>AL</given-names> </author><author><surname>Kitamura</surname> <given-names>T</given-names> </author><title>STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells</title><source>EMBO J</source><year>1999</year><volume>18</volume><fpage>4754</fpage><lpage>4765</lpage>
<author><surname>Oldham</surname> <given-names>S</given-names> </author><author><surname>Hafen</surname> <given-names>E</given-names> </author><title>Insulin/IGF and target of rapamycin signaling: a TOR de force in growth control</title><source>Trends Cell Biol</source><year>2003</year><volume>13</volume><fpage>79</fpage><lpage>85</lpage>
<author><surname>Papayannopoulos</surname> <given-names>V</given-names> </author><author><surname>Tomlinson</surname> <given-names>A</given-names> </author><author><surname>Panin</surname> <given-names>VM</given-names> </author><author><surname>Rauskolb</surname> <given-names>C</given-names> </author><author><surname>Irvine</surname> <given-names>KD</given-names> </author><title>Dorsal-ventral signaling in the Drosophila eye</title><source>Science</source><year>1998</year><volume>281</volume><fpage>2031</fpage><lpage>2034</lpage>
<author><surname>Patterson</surname> <given-names>SG</given-names> </author><author><surname>Wei</surname> <given-names>S</given-names> </author><author><surname>Chen</surname> <given-names>X</given-names> </author><author><surname>Sallman</surname> <given-names>DA</given-names> </author><author><surname>Gilvary</surname> <given-names>DL</given-names> </author><author><surname>Zhong</surname> <given-names>B</given-names> </author><author><surname>Pow-Sang</surname> <given-names>J</given-names> </author><author><surname>Yeatman</surname> <given-names>T</given-names> </author><author><surname>Djeu</surname> <given-names>JY</given-names> </author><title>Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells</title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>6113</fpage><lpage>6122</lpage>
<author><surname>Perrimon</surname> <given-names>N</given-names> </author><author><surname>Mahowald</surname> <given-names>AP</given-names> </author><title>l(1)hopscotch, A larval-pupal zygotic lethal with a specific maternal effect on segmentation in Drosophila</title><source>Dev Biol</source><year>1986</year><volume>118</volume><fpage>28</fpage><lpage>41</lpage>
<author><surname>Ramos</surname> <given-names>VC</given-names> </author><author><surname>Vidal-Taboada</surname> <given-names>J</given-names> </author><author><surname>Bergonon</surname> <given-names>S</given-names> </author><author><surname>Egeo</surname> <given-names>A</given-names> </author><author><surname>Fisher</surname> <given-names>EM</given-names> </author><author><surname>Scartezzini</surname> <given-names>P</given-names> </author><author><surname>Oliva</surname> <given-names>R</given-names> </author><title>Characterisation and expression analysis of the WDR9 gene, located in the Down critical region-2 of the human chromosome 21</title><source>Biochim Biophys Acta</source><year>2002</year><volume>1577</volume><fpage>377</fpage><lpage>383</lpage>
<author><surname>Ready</surname> <given-names>DF</given-names> </author><author><surname>Hanson</surname> <given-names>TE</given-names> </author><author><surname>Benzer</surname> <given-names>S</given-names> </author><title>Development of the Drosophila retina, a neurocrystalline lattice</title><source>Dev Biol</source><year>1976</year><volume>53</volume><fpage>217</fpage><lpage>240</lpage>
<author><surname>Reifegerste</surname> <given-names>R</given-names> </author><author><surname>Ma</surname> <given-names>C</given-names> </author><author><surname>Moses</surname> <given-names>K</given-names> </author><title>A polarity field is established early in the development of the Drosophila compound eye</title><source>Mech Dev</source><year>1997</year><volume>68</volume><fpage>69</fpage><lpage>79</lpage>
<author><surname>Reynolds-Kenneally</surname> <given-names>J</given-names> </author><author><surname>Mlodzik</surname> <given-names>M</given-names> </author><title>Notch signaling controls proliferation through cell-autonomous and non-autonomous mechanisms in the Drosophila eye</title><source>Dev Biol</source><year>2005</year><volume>285</volume><fpage>38</fpage><lpage>48</lpage>
<author><surname>Royet</surname> <given-names>J</given-names> </author><author><surname>Finkelstein</surname> <given-names>R</given-names> </author><title>hedgehog, wingless and orthodenticle specify adult head development in Drosophila</title><source>Development</source><year>1996</year><volume>122</volume><fpage>1849</fpage><lpage>1858</lpage>
<author><surname>Sancak</surname> <given-names>Y</given-names> </author><author><surname>Thoreen</surname> <given-names>CC</given-names> </author><author><surname>Peterson</surname> <given-names>TR</given-names> </author><author><surname>Lindquist</surname> <given-names>RA</given-names> </author><author><surname>Kang</surname> <given-names>SA</given-names> </author><author><surname>Spooner</surname> <given-names>E</given-names> </author><author><surname>Carr</surname> <given-names>SA</given-names> </author><author><surname>Sabatini</surname> <given-names>DM</given-names> </author><title>PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase</title><source>Mol Cell</source><year>2007</year><volume>25</volume><fpage>903</fpage><lpage>915</lpage>
<author><surname>Schindler</surname> <given-names>C</given-names> </author><author><surname>Levy</surname> <given-names>DE</given-names> </author><author><surname>Decker</surname> <given-names>T</given-names> </author><title>JAK-STAT signaling: from interferons to cytokines</title><source>J Biol Chem</source><year>2007</year><volume>282</volume><fpage>20059</fpage><lpage>20063</lpage>
<author><surname>Schwartz</surname> <given-names>YB</given-names> </author><author><surname>Pirrotta</surname> <given-names>V</given-names> </author><title>Polycomb silencing mechanisms and the management of genomic programmes</title><source>Nat Rev Genet</source><year>2007</year><volume>8</volume><fpage>9</fpage><lpage>22</lpage>
<author><surname>Shi</surname> <given-names>S</given-names> </author><author><surname>Calhoun</surname> <given-names>HC</given-names> </author><author><surname>Xia</surname> <given-names>F</given-names> </author><author><surname>Li</surname> <given-names>J</given-names> </author><author><surname>Le</surname> <given-names>L</given-names> </author><author><surname>Li</surname> <given-names>WX</given-names> </author><title>JAK signaling globally counteracts heterochromatic gene silencing</title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>1071</fpage><lpage>1076</lpage>
<author><surname>Shi</surname> <given-names>M</given-names> </author><author><surname>Lin</surname> <given-names>TH</given-names> </author><author><surname>Appell</surname> <given-names>KC</given-names> </author><author><surname>Berg</surname> <given-names>LJ</given-names> </author><title>Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation</title><source>Immunity</source><year>2008a</year><volume>28</volume><fpage>763</fpage><lpage>773</lpage>
<author><surname>Shi</surname> <given-names>S</given-names> </author><author><surname>Larson</surname> <given-names>K</given-names> </author><author><surname>Guo</surname> <given-names>D</given-names> </author><author><surname>Lim</surname> <given-names>SJ</given-names> </author><author><surname>Dutta</surname> <given-names>P</given-names> </author><author><surname>Yan</surname> <given-names>SJ</given-names> </author><author><surname>Li</surname> <given-names>WX</given-names> </author><title>Drosophila STAT is required for directly maintaining HP1 localization and heterochromatin stability</title><source>Nat Cell Biol</source><year>2008b</year><volume>10</volume><fpage>489</fpage><lpage>496</lpage>
<author><surname>Shuai</surname> <given-names>K</given-names> </author><title>Regulation of cytokine signaling pathways by PIAS proteins</title><source>Cell Res</source><year>2006</year><volume>16</volume><fpage>196</fpage><lpage>202</lpage>
<author><surname>Smirnova</surname> <given-names>OV</given-names> </author><author><surname>Ostroukhova</surname> <given-names>TY</given-names> </author><author><surname>Bogorad</surname> <given-names>RL</given-names> </author><title>JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?</title><source>World J Gastroenterol</source><year>2007</year><volume>13</volume><fpage>6478</fpage><lpage>6491</lpage>
<author><surname>Song</surname> <given-names>MR</given-names> </author><author><surname>Ghosh</surname> <given-names>A</given-names> </author><title>FGF2-induced chromatin remodeling regulates CNTF-mediated gene expression and astrocyte differentiation</title><source>Nat Neurosci</source><year>2004</year><volume>7</volume><fpage>229</fpage><lpage>235</lpage>
<author><surname>Sotillos</surname> <given-names>S</given-names> </author><author><surname>Diaz-Meco</surname> <given-names>MT</given-names> </author><author><surname>Caminero</surname> <given-names>E</given-names> </author><author><surname>Moscat</surname> <given-names>J</given-names> </author><author><surname>Campuzano</surname> <given-names>S</given-names> </author><title>DaPKC-dependent phosphorylation of Crumbs is required for epithelial cell polarity in Drosophila</title><source>J Cell Biol</source><year>2004</year><volume>166</volume><fpage>549</fpage><lpage>557</lpage>
<author><surname>Sparmann</surname> <given-names>A</given-names> </author><author><surname>van Lohuizen</surname> <given-names>M</given-names> </author><title>Polycomb silencers control cell fate, development and cancer</title><source>Nat Rev Cancer</source><year>2006</year><volume>6</volume><fpage>846</fpage><lpage>856</lpage>
<author><surname>Staehling-Hampton</surname> <given-names>K</given-names> </author><author><surname>Jackson</surname> <given-names>PD</given-names> </author><author><surname>Clark</surname> <given-names>MJ</given-names> </author><author><surname>Brand</surname> <given-names>AH</given-names> </author><author><surname>Hoffmann</surname> <given-names>FM</given-names> </author><title>Specificity of bone morphogenetic protein-related factors: cell fate and gene expression changes in Drosophila embryos induced by decapentaplegic but not 60A</title><source>Cell Growth Differ</source><year>1994</year><volume>5</volume><fpage>585</fpage><lpage>593</lpage>
<author><surname>Stephanou</surname> <given-names>A</given-names> </author><author><surname>Latchman</surname> <given-names>DS</given-names> </author><title>Opposing actions of STAT-1 and STAT-3</title><source>Growth Factors</source><year>2005</year><volume>23</volume><fpage>177</fpage><lpage>182</lpage>
<author><surname>Subramaniam</surname> <given-names>PS</given-names> </author><author><surname>Torres</surname> <given-names>BA</given-names> </author><author><surname>Johnson</surname> <given-names>HM</given-names> </author><title>So many ligands, so few transcription factors: a new paradigm for signaling through the STAT transcription factors</title><source>Cytokine</source><year>2001</year><volume>15</volume><fpage>175</fpage><lpage>187</lpage>
<author><surname>Takizawa</surname> <given-names>T</given-names> </author><author><surname>Nakashima</surname> <given-names>K</given-names> </author><author><surname>Namihira</surname> <given-names>M</given-names> </author><author><surname>Ochiai</surname> <given-names>W</given-names> </author><author><surname>Uemura</surname> <given-names>A</given-names> </author><author><surname>Yanagisawa</surname> <given-names>M</given-names> </author><author><surname>Fujita</surname> <given-names>N</given-names> </author><author><surname>Nakao</surname> <given-names>M</given-names> </author><author><surname>Taga</surname> <given-names>T</given-names> </author><title>DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain</title><source>Dev Cell</source><year>2001</year><volume>1</volume><fpage>749</fpage><lpage>758</lpage>
<author><surname>Tepass</surname> <given-names>U</given-names> </author><author><surname>Theres</surname> <given-names>C</given-names> </author><author><surname>Knust</surname> <given-names>E</given-names> </author><title>crumbs encodes an EGF-like protein expressed on apical membranes of Drosophila epithelial cells and required for organization of epithelia</title><source>Cell</source><year>1990</year><volume>61</volume><fpage>787</fpage><lpage>799</lpage>
<author><surname>Thompson</surname> <given-names>BJ</given-names> </author><author><surname>Mathieu</surname> <given-names>J</given-names> </author><author><surname>Sung</surname> <given-names>HH</given-names> </author><author><surname>Loeser</surname> <given-names>E</given-names> </author><author><surname>Rorth</surname> <given-names>P</given-names> </author><author><surname>Cohen</surname> <given-names>SM</given-names> </author><title>Tumor suppressor properties of the ESCRT-II complex component Vps25 in Drosophila</title><source>Dev Cell</source><year>2005</year><volume>9</volume><fpage>711</fpage><lpage>720</lpage>
<author><surname>Timofeeva</surname> <given-names>OA</given-names> </author><author><surname>Plisov</surname> <given-names>S</given-names> </author><author><surname>Evseev</surname> <given-names>AA</given-names> </author><author><surname>Peng</surname> <given-names>S</given-names> </author><author><surname>Jose-Kampfner</surname> <given-names>M</given-names> </author><author><surname>Lovvorn</surname> <given-names>HN</given-names> </author><author><surname>Dome</surname> <given-names>JS</given-names> </author><author><surname>Perantoni</surname> <given-names>AO</given-names> </author><title>Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis</title><source>Oncogene</source><year>2006</year><volume>25</volume><fpage>7555</fpage><lpage>7564</lpage>
<author><surname>Treisman</surname> <given-names>JE</given-names> </author><author><surname>Rubin</surname> <given-names>GM</given-names> </author><title>wingless inhibits morphogenetic furrow movement in the Drosophila eye disc</title><source>Development</source><year>1995</year><volume>121</volume><fpage>3519</fpage><lpage>3527</lpage>
<author><surname>Tsai</surname> <given-names>YC</given-names> </author><author><surname>Sun</surname> <given-names>YH</given-names> </author><title>Long-range effect of upd, a ligand for Jak/STAT pathway, on cell cycle in Drosophila eye development</title><source>Genesis</source><year>2004</year><volume>39</volume><fpage>141</fpage><lpage>153</lpage>
<author><surname>Tsai</surname> <given-names>YC</given-names> </author><author><surname>Yao</surname> <given-names>JG</given-names> </author><author><surname>Chen</surname> <given-names>PH</given-names> </author><author><surname>Posakony</surname> <given-names>JW</given-names> </author><author><surname>Barolo</surname> <given-names>S</given-names> </author><author><surname>Kim</surname> <given-names>J</given-names> </author><author><surname>Sun</surname> <given-names>YH</given-names> </author><title>Upd/Jak/STAT signaling represses wg transcription to allow initiation of morphogenetic furrow in Drosophila eye development</title><source>Dev Biol</source><year>2007</year><volume>306</volume><fpage>760</fpage><lpage>771</lpage>
<author><surname>Ungureanu</surname> <given-names>D</given-names> </author><author><surname>Vanhatupa</surname> <given-names>S</given-names> </author><author><surname>Kotaja</surname> <given-names>N</given-names> </author><author><surname>Yang</surname> <given-names>J</given-names> </author><author><surname>Aittomaki</surname> <given-names>S</given-names> </author><author><surname>Janne</surname> <given-names>OA</given-names> </author><author><surname>Palvimo</surname> <given-names>JJ</given-names> </author><author><surname>Silvennoinen</surname> <given-names>O</given-names> </author><title>PIAS proteins promote SUMO-1 conjugation to STAT1</title><source>Blood</source><year>2003</year><volume>102</volume><fpage>3311</fpage><lpage>3313</lpage>
<author><surname>Vaccari</surname> <given-names>T</given-names> </author><author><surname>Bilder</surname> <given-names>D</given-names> </author><title>The Drosophila tumor suppressor vps25 prevents nonautonomous overproliferation by regulating notch trafficking</title><source>Dev Cell</source><year>2005</year><volume>9</volume><fpage>687</fpage><lpage>698</lpage>
<author><surname>Vander Haar</surname> <given-names>E</given-names> </author><author><surname>Lee</surname> <given-names>SI</given-names> </author><author><surname>Bandhakavi</surname> <given-names>S</given-names> </author><author><surname>Griffin</surname> <given-names>TJ</given-names> </author><author><surname>Kim</surname> <given-names>DH</given-names> </author><title>Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40</title><source>Nat Cell Biol</source><year>2007</year><volume>9</volume><fpage>316</fpage><lpage>323</lpage>
<author><surname>Wang</surname> <given-names>YH</given-names> </author><author><surname>Huang</surname> <given-names>ML</given-names> </author><title>Reduction of Lobe leads to TORC1 hypoactivation that induces ectopic Jak/STAT signaling to impair Drosophila eye development</title><source>Mech Dev</source><year>2009</year><volume>126</volume><fpage>781</fpage><lpage>790</lpage>
<author><surname>Weichhart</surname> <given-names>T</given-names> </author><author><surname>Costantino</surname> <given-names>G</given-names> </author><author><surname>Poglitsch</surname> <given-names>M</given-names> </author><author><surname>Rosner</surname> <given-names>M</given-names> </author><author><surname>Zeyda</surname> <given-names>M</given-names> </author><author><surname>Stuhlmeier</surname> <given-names>KM</given-names> </author><author><surname>Kolbe</surname> <given-names>T</given-names> </author><author><surname>Stulnig</surname> <given-names>TM</given-names> </author><author><surname>Horl</surname> <given-names>WH</given-names> </author><author><surname>Hengstschlager</surname> <given-names>M</given-names> </author><author><surname>Muller</surname> <given-names>M</given-names> </author><author><surname>Saemann</surname> <given-names>MD</given-names> </author><title>The TSC-mTOR signaling pathway regulates the innate inflammatory response</title><source>Immunity</source><year>2008</year><volume>29</volume><fpage>565</fpage><lpage>577</lpage>
<author><surname>Wicking</surname> <given-names>C</given-names> </author><author><surname>McGlinn</surname> <given-names>E</given-names> </author><title>The role of hedgehog signalling in tumorigenesis</title><source>Cancer Lett</source><year>2001</year><volume>173</volume><fpage>1</fpage><lpage>7</lpage>
<author><surname>Williams</surname> <given-names>JG</given-names> </author><title>STAT signalling in cell proliferation and in development</title><source>Curr Opin Genet Dev</source><year>2000</year><volume>10</volume><fpage>503</fpage><lpage>507</lpage>
<author><surname>Wolff</surname> <given-names>T</given-names> </author><author><surname>Ready</surname> <given-names>DF</given-names> </author><title>The beginning of pattern formation in the Drosophila compound eye: the morphogenetic furrow and the second mitotic wave</title><source>Development</source><year>1991</year><volume>113</volume><fpage>841</fpage><lpage>850</lpage>
<author><surname>Xu</surname> <given-names>T</given-names> </author><author><surname>Rubin</surname> <given-names>GM</given-names> </author><title>Analysis of genetic mosaics in developing and adult Drosophila tissues</title><source>Development</source><year>1993</year><volume>117</volume><fpage>1223</fpage><lpage>1237</lpage>
<author><surname>Yan</surname> <given-names>R</given-names> </author><author><surname>Small</surname> <given-names>S</given-names> </author><author><surname>Desplan</surname> <given-names>C</given-names> </author><author><surname>Dearolf</surname> <given-names>CR</given-names> </author><author><surname>Darnell</surname> <given-names>JE</given-names> <suffix>Jr</suffix> </author><title>Identification of a Stat gene that functions in Drosophila development</title><source>Cell</source><year>1996</year><volume>84</volume><fpage>421</fpage><lpage>430</lpage>
<author><surname>Zeidler</surname> <given-names>MP</given-names> </author><author><surname>Perrimon</surname> <given-names>N</given-names> </author><author><surname>Strutt</surname> <given-names>DI</given-names> </author><title>Polarity determination in the Drosophila eye: a novel role for unpaired and JAK/STAT signaling</title><source>Genes Dev</source><year>1999</year><volume>13</volume><fpage>1342</fpage><lpage>1353</lpage>
<author><surname>Proper</surname> <given-names>KI</given-names> </author><author><surname>Hildebrandt</surname> <given-names>VH</given-names> </author><author><surname>Van der Beek</surname> <given-names>AJ</given-names> </author><author><surname>Twisk</surname> <given-names>JW</given-names> </author><author><surname>Van Mechelen</surname> <given-names>W</given-names> </author><title>Effect of individual counseling on physical activity fitness and health: a randomized controlled trial in a workplace setting</title><source>Am J Prev Med</source><other>4</other><year>2003</year><volume>24</volume><issue>3</issue><fpage>218</fpage><lpage>226</lpage>
<author><surname>Church</surname> <given-names>TS</given-names> </author><author><surname>Martin</surname> <given-names>CK</given-names> </author><author><surname>Thompson</surname> <given-names>AM</given-names> </author><author><surname>Earnest</surname> <given-names>CP</given-names> </author><author><surname>Mikus</surname> <given-names>CR</given-names> </author><author><surname>Blair</surname> <given-names>SN</given-names> </author><title>Changes in weight, waist circumference and compensatory responses with different doses of exercise among sedentary, overweight postmenopausal women</title><source>PLoS One</source><year>2009</year><volume>4</volume><issue>2</issue><fpage>e4515</fpage>
<author><surname>Fairey</surname> <given-names>AS</given-names> </author><author><surname>Courneya</surname> <given-names>KS</given-names> </author><author><surname>Field</surname> <given-names>CJ</given-names> </author><title>Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial</title><source>Brain Behav Immun</source><year>2005</year><volume>19</volume><issue>5</issue><fpage>381</fpage><lpage>388</lpage>
<author><surname>Kasapis</surname> <given-names>C</given-names> </author><author><surname>Thompson</surname> <given-names>PD</given-names> </author><title>The effects of physical activity on serum C-reactive protein and inflammatory markers: a systematic review</title><source>J Am Coll Cardiol</source><year>2005</year><volume>45</volume><issue>10</issue><fpage>1563</fpage><lpage>1569</lpage>
<author><surname>Lokey</surname> <given-names>EA</given-names> </author><author><surname>Tran</surname> <given-names>ZV</given-names> </author><title>Effects of exercise training on serum lipid and lipoprotein concentrations in women: a meta-analysis</title><source>Int J Sports Med</source><year>1989</year><volume>10</volume><issue>6</issue><fpage>424</fpage><lpage>429</lpage>
<title>2008 physical activity guidelines for Americans</title>[Updated 4 November 2009]. Available from:
<author><surname>Greenland</surname> <given-names>P</given-names> </author><author><surname>Knoll</surname> <given-names>MD</given-names> </author><author><surname>Stamler</surname> <given-names>J</given-names> </author><title>Major risk factors as antecedents of fatal and nonfatal coronary heart disease events</title><source>JAMA</source><year>2003</year><volume>290</volume><issue>7</issue><fpage>891</fpage><lpage>897</lpage>
<author><surname>Bild</surname> <given-names>DE</given-names> </author><author><surname>Folsom</surname> <given-names>AR</given-names> </author><author><surname>Lowe</surname> <given-names>LP</given-names> </author><title>Prevalence and correlates of coronary calcification in black and white young adults: the Coronary Artery Risk Development in Young Adults (CARDIA) Study</title><source>Arterioscler Thromb Vasc Biol</source><year>2001</year><volume>21</volume><issue>5</issue><fpage>852</fpage><lpage>857</lpage>
<author><surname>Blair</surname> <given-names>SN</given-names> </author><author><surname>Kampert</surname> <given-names>JB</given-names> </author><author><surname>Kohl</surname> <given-names>HW</given-names> </author><title>Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women</title><source>JAMA</source><year>1996</year><volume>276</volume><issue>3</issue><fpage>205</fpage><lpage>210</lpage>
<author><surname>Tuomilehto</surname> <given-names>J</given-names> </author><author><surname>Rastenyte</surname> <given-names>D</given-names> </author><author><surname>Jousilahti</surname> <given-names>P</given-names> </author><author><surname>Sarti</surname> <given-names>C</given-names> </author><author><surname>Vartiainen</surname> <given-names>E</given-names> </author><title>Diabetes mellitus as a risk factor for death from stroke. Prospective study of the middle-aged Finnish population</title><source>Stroke</source><year>1996</year><volume>27</volume><issue>2</issue><fpage>210</fpage><lpage>215</lpage>
<author><surname>Wolf</surname> <given-names>PA</given-names> </author><author><surname>D&#8217;Agostino</surname> <given-names>RB</given-names> </author><author><surname>Belanger</surname> <given-names>AJ</given-names> </author><author><surname>Kannel</surname> <given-names>WB</given-names> </author><title>Probability of stroke: a risk profile from the Framingham Study</title><source>Stroke</source><year>1991</year><volume>22</volume><issue>3</issue><fpage>312</fpage><lpage>318</lpage>
<author><surname>Tudor-Locke</surname> <given-names>C</given-names> </author><author><surname>Bell</surname> <given-names>RC</given-names> </author><author><surname>Myers</surname> <given-names>AM</given-names> </author><title>Controlled outcome evaluation of the First Step Program: a daily physical activity intervention for individuals with type II diabetes</title><source>Int J Obes Relat Metab Disord</source><year>2004</year><volume>28</volume><issue>1</issue><fpage>113</fpage><lpage>119</lpage>
<author><surname>Ash</surname> <given-names>S</given-names> </author><author><surname>Reeves</surname> <given-names>M</given-names> </author><author><surname>Bauer</surname> <given-names>J</given-names> </author><title>A randomised control trial comparing lifestyle groups, individual counselling and written information in the management of weight and health outcomes over 12 months</title><source>Int J Obes(Lond)</source><year>2006</year><volume>30</volume><issue>10</issue><fpage>1557</fpage><lpage>1564</lpage>
<author><surname>Carr</surname> <given-names>LJ</given-names> </author><author><surname>Bartee</surname> <given-names>RT</given-names> </author><author><surname>Dorozynski</surname> <given-names>C</given-names> </author><author><surname>Broomfield</surname> <given-names>JF</given-names> </author><author><surname>Smith</surname> <given-names>ML</given-names> </author><author><surname>Smith</surname> <given-names>DT</given-names> </author><title>Internet-delivered behavior change program increases physical activity and improves cardiometabolic disease risk factors in sedentary adults: results of a randomized controlled trial</title><source>Prev Med</source><year>2008</year><volume>46</volume><issue>5</issue><fpage>431</fpage><lpage>438</lpage>
<author><surname>Norman</surname> <given-names>GJ</given-names> </author><author><surname>Zabinski</surname> <given-names>MF</given-names> </author><author><surname>Adams</surname> <given-names>MA</given-names> </author><author><surname>Rosenberg</surname> <given-names>DE</given-names> </author><author><surname>Yaroch</surname> <given-names>AL</given-names> </author><author><surname>Atienza</surname> <given-names>AA</given-names> </author><title>A review of eHealth interventions for physical activity and dietary behavior change</title><source>Am J Prev Med</source><year>2007</year><volume>33</volume><issue>4</issue><fpage>336</fpage><lpage>345</lpage>
<author><surname>De Greef</surname> <given-names>K</given-names> </author><author><surname>Deforche</surname> <given-names>B</given-names> </author><author><surname>Tudor-Locke</surname> <given-names>C</given-names> </author><author><surname>De Bourdeaudhuij</surname> <given-names>I</given-names> </author><title>A cognitive-behavioural pedometer-based group intervention on physical activity and sedentary behaviour in individuals with type 2 diabetes</title><source>Health Educ Res</source><year>2010</year><volume>25</volume><issue>5</issue><fpage>724</fpage><lpage>736</lpage>
<author><surname>Baker</surname> <given-names>G</given-names> </author><author><surname>Gray</surname> <given-names>SR</given-names> </author><author><surname>Wright</surname> <given-names>A</given-names> </author><title>The effect of a pedometer-based community walking intervention &#8220;Walking for Wellbeing in the West&#8221; on physical activity levels and health outcomes: a 12-week randomized controlled trial</title><source>Int J Behav Nutr Phys Act</source><year>2010</year><volume>7</volume><issue>1</issue><fpage>51</fpage>
<author><surname>Polzien</surname> <given-names>KM</given-names> </author><author><surname>Jakicic</surname> <given-names>JM</given-names> </author><author><surname>Tate</surname> <given-names>DF</given-names> </author><author><surname>Otto</surname> <given-names>AD</given-names> </author><title>The efficacy of a technology-based system in a short-term behavioral weight loss intervention</title><source>Obesity</source><year>2007</year><volume>15</volume><issue>4</issue><fpage>825</fpage><lpage>830</lpage>
<author><surname>Bravata</surname> <given-names>DM</given-names> </author><author><surname>Smith-Spangler</surname> <given-names>C</given-names> </author><author><surname>Sundaram</surname> <given-names>V</given-names> </author><title>Using pedometers to increase physical activity and improve health: a systematic review</title><source>JAMA</source><year>2007</year><volume>298</volume><issue>19</issue><fpage>2296</fpage><lpage>2304</lpage>
<author><surname>Stefanick</surname> <given-names>ML</given-names> </author><title>Physical activity for preventing and treating obesity-related dyslipoproteinemias</title><source>Med Sci Sports Exerc</source><year>1999</year><volume>31</volume><issue>11 Suppl</issue><fpage>S609</fpage><lpage>S618</lpage>
<author><surname>Barry</surname> <given-names>VW</given-names> </author><author><surname>McClain</surname> <given-names>AC</given-names> </author><author><surname>Shuger</surname> <given-names>S</given-names> </author><title>Using a technology-based intervention to promote weight loss in sedentary overweight or obese adults: a randomized controlled trial study design</title><source>Diabetes Metab Syndr Obes</source><year>2011</year><volume>4</volume><fpage>67</fpage><lpage>77</lpage>
<author><surname>Sharma</surname> <given-names>M</given-names> </author><title>Behavioural interventions for preventing and treating obesity in adults</title><source>Obes Rev</source><year>2007</year><volume>8</volume><issue>5</issue><fpage>441</fpage><lpage>449</lpage>
<author><surname>Clark</surname> <given-names>MM</given-names> </author><author><surname>Niaura</surname> <given-names>R</given-names> </author><author><surname>King</surname> <given-names>TK</given-names> </author><author><surname>Pera</surname> <given-names>V</given-names> </author><title>Depression, smoking, activity level, and health status: pretreatment predictors of attrition in obesity treatment</title><source>Addict Behav</source><year>1996</year><volume>21</volume><issue>4</issue><fpage>509</fpage><lpage>513</lpage>
<author><surname>Chobanian</surname> <given-names>AV</given-names> </author><author><surname>Bakris</surname> <given-names>GL</given-names> </author><author><surname>Black</surname> <given-names>HR</given-names> </author><title>The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report</title><source>JAMA</source><year>2003</year><volume>289</volume><issue>19</issue><fpage>2560</fpage><lpage>2572</lpage>
<author><surname>Blair</surname> <given-names>S</given-names> </author><author><surname>Dunn</surname> <given-names>A</given-names> </author><author><surname>Marcus</surname> <given-names>B</given-names> </author><author><surname>Carpenter</surname> <given-names>R</given-names> </author><source>Active Living Every Day: 20 weeks to lifelong vitality</source><other>Champaign</other><publisher>Human Kinetics</publisher><year>2001</year>
<author><surname>Carpenter</surname> <given-names>R</given-names> </author><author><surname>Finley</surname> <given-names>C</given-names> </author><source>Healthy Eating Every Day</source><other>Champaign</other><publisher>Human Kinetics</publisher><year>2005</year>
<author><surname>Prochaska</surname> <given-names>JO</given-names> </author><author><surname>Norcross</surname> <given-names>JC</given-names> </author><author><surname>DiClemente</surname> <given-names>CC</given-names> </author><source>Changing for good: A revolutionary six-stage program for overcoming bad habits and moving your life positively forward</source><other>New York, NY</other><publisher>Avon Books Inc.</publisher><year>1994</year>
<author><surname>Bandura</surname> <given-names>A</given-names> </author><source>Social foundations of thought and action: A social cognitive theory</source><other>Englewood Cliffs, NJ</other><publisher>Prentice Hall</publisher><year>1986</year>
<author><surname>Albright</surname> <given-names>A</given-names> </author><author><surname>Franz</surname> <given-names>M</given-names> </author><author><surname>Hornsby</surname> <given-names>G</given-names> </author><title>American College of Sports Medicine position stand. Exercise and type 2 diabetes</title><source>Med Sci Sports Exerc</source><year>2000</year><volume>32</volume><issue>7</issue><fpage>1345</fpage><lpage>1360</lpage>
<author><surname>Butryn</surname> <given-names>ML</given-names> </author><author><surname>Phelan</surname> <given-names>S</given-names> </author><author><surname>Hill</surname> <given-names>JO</given-names> </author><author><surname>Wing</surname> <given-names>RR</given-names> </author><title>Consistent self-monitoring of weight: a key component of successful weight loss maintenance</title><source>Obesity(Silver Spring)</source><year>2007</year><volume>15</volume><issue>12</issue><fpage>3091</fpage><lpage>3096</lpage>
<author><surname>van Baak</surname> <given-names>MA</given-names> </author><author><surname>Borghouts</surname> <given-names>LB</given-names> </author><title>Relationships with physical activity</title><source>Nutr Rev</source><year>2000</year><volume>58</volume><issue>3 Pt 2</issue><fpage>S16</fpage><lpage>S18</lpage>
<author><surname>Borghouts</surname> <given-names>LB</given-names> </author><author><surname>Keizer</surname> <given-names>HA</given-names> </author><title>Exercise and insulin sensitivity: a review</title><source>Int J Sports Med</source><year>2000</year><volume>21</volume><issue>1</issue><fpage>1</fpage><lpage>12</lpage>
<author><surname>Kraniou</surname> <given-names>GN</given-names> </author><author><surname>Cameron-Smith</surname> <given-names>D</given-names> </author><author><surname>Hargreaves</surname> <given-names>M</given-names> </author><title>Effect of short-term training on GLUT-4 mRNA and protein expression in human skeletal muscle</title><source>Exp Physiol</source><year>2004</year><volume>89</volume><issue>5</issue><fpage>559</fpage><lpage>563</lpage>
<author><surname>Ren</surname> <given-names>JM</given-names> </author><author><surname>Semenkovich</surname> <given-names>CF</given-names> </author><author><surname>Gulve</surname> <given-names>EA</given-names> </author><author><surname>Gao</surname> <given-names>J</given-names> </author><author><surname>Holloszy</surname> <given-names>JO</given-names> </author><title>Exercise induces rapid increases in GLUT4 expression, glucose transport capacity, and insulin-stimulated glycogen storage in muscle</title><source>J Biol Chem</source><year>1994</year><volume>269</volume><issue>20</issue><fpage>14396</fpage><lpage>14401</lpage>
<author><surname>Anderson</surname> <given-names>JW</given-names> </author><author><surname>Konz</surname> <given-names>EC</given-names> </author><title>Obesity and disease management: effects of weight loss on comorbid conditions</title><source>Obes Res</source><year>2001</year><volume>9</volume><issue>Suppl 4</issue><fpage>326S</fpage><lpage>334S</lpage>
<author><surname>Blumenthal</surname> <given-names>JA</given-names> </author><author><surname>Sherwood</surname> <given-names>A</given-names> </author><author><surname>Gullette</surname> <given-names>ECD</given-names> </author><title>Exercise and weight loss reduce blood pressure in men and women with mild hypertension: effects on cardiovascular, metabolic, and hemodynamic functioning</title><source>Arch Intern Med</source><year>2000</year><volume>160</volume><issue>13</issue><fpage>1947</fpage><lpage>1958</lpage>
<author><surname>Bytzer</surname> <given-names>P.</given-names> </author><author><surname>Talley</surname> <given-names>N.J.</given-names> </author><author><surname>Leemon</surname> <given-names>M.</given-names> </author><author><surname>Young</surname> <given-names>L.J.</given-names> </author><author><surname>Jones</surname> <given-names>M.P.</given-names> </author><author><surname>Horowitz</surname> <given-names>M.</given-names> </author><title>Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults</title><source>Arch Intern Med.</source><year>2001</year><volume>161</volume><fpage>1989</fpage><lpage>1996</lpage>
<author><surname>Ricci</surname> <given-names>J.A.</given-names> </author><author><surname>Siddique</surname> <given-names>R.</given-names> </author><author><surname>Stewart</surname> <given-names>W.F.</given-names> </author><author><surname>Sandler</surname> <given-names>R.S.</given-names> </author><author><surname>Sloan</surname> <given-names>S.</given-names> </author><author><surname>Farup</surname> <given-names>C.E.</given-names> </author><title>Upper gastrointestinal symptoms in a US national sample of adults with diabetes</title><source>Scand J Gastroenterol.</source><year>2000</year><volume>35</volume><fpage>152</fpage><lpage>159</lpage>
<author><surname>Samsom</surname> <given-names>M.</given-names> </author><author><surname>Bharucha</surname> <given-names>A.</given-names> </author><author><surname>Gerich</surname> <given-names>J.E.</given-names> </author><title>Diabetes mellitus and gastric emptying: questions and issues in clinical practice</title><source>Diabetes Metab Res Rev.</source><year>2009</year><volume>25</volume><fpage>502</fpage><lpage>514</lpage>
<author><surname>Patrick</surname> <given-names>A.</given-names> </author><author><surname>Epstein</surname> <given-names>O.</given-names> </author><title>Review article: gastroparesis</title><source>Aliment Pharmacol Ther.</source><year>2008</year><volume>27</volume><fpage>724</fpage><lpage>740</lpage>
<author><surname>Frank</surname> <given-names>J.W.</given-names> </author><author><surname>Saslow</surname> <given-names>S.B.</given-names> </author><author><surname>Camilleri</surname> <given-names>M.</given-names> </author><author><surname>Thomforde</surname> <given-names>G.M.</given-names> </author><author><surname>Dinneen</surname> <given-names>S.</given-names> </author><author><surname>Rizza</surname> <given-names>R.A.</given-names> </author><title>Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus</title><source>Gastroenterology</source><year>1995</year><volume>109</volume><fpage>755</fpage><lpage>765</lpage>
<author><surname>Intagliata</surname> <given-names>N.</given-names> </author><author><surname>Koch</surname> <given-names>K.L.</given-names> </author><title>Gastroparesis in type 2 diabetes mellitus: prevalence, etiology, diagnosis, and treatment</title><source>Curr Gastroenterol Rep.</source><year>2007</year><volume>9</volume><fpage>270</fpage><lpage>279</lpage>
<author><surname>Barnett</surname> <given-names>J.L.</given-names> </author><author><surname>Owyang</surname> <given-names>C.</given-names> </author><title>Serum glucose concentration as a modulator of interdigestive gastric motility</title><source>Gastroenterology</source><year>1988</year><volume>94</volume><fpage>739</fpage><lpage>744</lpage>
<author><surname>Lysy</surname> <given-names>J.</given-names> </author><author><surname>Israeli</surname> <given-names>E.</given-names> </author><author><surname>Strauss-Liviatan</surname> <given-names>N.</given-names> </author><author><surname>Goldin</surname> <given-names>E.</given-names> </author><title>Relationships between hypoglycaemia and gastric emptying abnormalities in insulin-treated diabetic patients</title><source>Neurogastroenterol Motil.</source><year>2006</year><volume>18</volume><fpage>433</fpage><lpage>440</lpage>
<author><surname>Horowitz</surname> <given-names>M.</given-names> </author><author><surname>Jones</surname> <given-names>K.L.</given-names> </author><author><surname>Rayner</surname> <given-names>C.K.</given-names> </author><author><surname>Read</surname> <given-names>N.W.</given-names> </author><title>&#8220;Gastric&#8221; hypoglycaemia &#8212; an important concept in diabetes management</title><source>Neurogastroenterol Motil.</source><year>2006</year><volume>18</volume><fpage>405</fpage><lpage>407</lpage>
<author><surname>Ma</surname> <given-names>J.</given-names> </author><author><surname>Rayner</surname> <given-names>C.K.</given-names> </author><author><surname>Jones</surname> <given-names>K.L.</given-names> </author><author><surname>Horowitz</surname> <given-names>M.</given-names> </author><title>Diabetic gastroparesis: diagnosis and management</title><source>Drugs</source><year>2009</year><volume>69</volume><fpage>971</fpage><lpage>986</lpage>
<author><surname>Hejazi</surname> <given-names>R.</given-names> </author><author><surname>McCallum</surname> <given-names>R.</given-names> </author><title>Diabetic gastroparesis: a review of medical treatments</title><source>Pract Gastroenterol.</source><year>2009</year><volume>6</volume><fpage>10</fpage><lpage>20</lpage>
<author><surname>Forster</surname> <given-names>J.</given-names> </author><author><surname>Damjanov</surname> <given-names>I.</given-names> </author><author><surname>Lin</surname> <given-names>Z.</given-names> </author><author><surname>Sarosiek</surname> <given-names>I.</given-names> </author><author><surname>Wetzel</surname> <given-names>P.</given-names> </author><author><surname>McCallum</surname> <given-names>R.W.</given-names> </author><title>Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings</title><source>J Gastrointest Surg.</source><year>2005</year><volume>9</volume><fpage>102</fpage><lpage>108</lpage>
<author><surname>Lin</surname> <given-names>Z.</given-names> </author><author><surname>Sarosiek</surname> <given-names>I.</given-names> </author><author><surname>Forster</surname> <given-names>J.</given-names> </author><author><surname>Damjanov</surname> <given-names>I.</given-names> </author><author><surname>Hou</surname> <given-names>Q.</given-names> </author><author><surname>McCallum</surname> <given-names>R.W.</given-names> </author><title>Association of the status of interstitial cells of Cajal and electrogastrogram parameters, gastric emptying and symptoms in patients with gastroparesis</title><source>Neurogastroenterol Motil.</source><year>2009</year><volume>22</volume><fpage>56</fpage><lpage>61</lpage>
<author><surname>Pasricha</surname> <given-names>P.J.</given-names> </author><author><surname>Pehlivanov</surname> <given-names>N.</given-names> </author><author><surname>Sugumar</surname> <given-names>A.</given-names> </author><author><surname>Jankovic</surname> <given-names>J.</given-names> </author><title>Drug insight: from disturbed motility to disordered movement: a review of the clinical benefits and medicolegal risks of metoclopramide</title><source>Nat Clin Pract Gastroenterol Hepatol.</source><year>2006</year><volume>3</volume><fpage>138</fpage><lpage>148</lpage>
<author><surname>Fraser</surname> <given-names>R.J.</given-names> </author><author><surname>Horowitz</surname> <given-names>M.</given-names> </author><author><surname>Maddox</surname> <given-names>A.F.</given-names> </author><author><surname>Harding</surname> <given-names>P.E.</given-names> </author><author><surname>Chatterton</surname> <given-names>B.E.</given-names> </author><author><surname>Dent</surname> <given-names>J.</given-names> </author><title>Hyperglycaemia slows gastric emptying in type 1 (insulin.dependent) diabetes mellitus</title><source>Diabetologia</source><year>1990</year><volume>33</volume><fpage>675</fpage><lpage>680</lpage>
<author><surname>Sogabe</surname> <given-names>M.</given-names> </author><author><surname>Okahisa</surname> <given-names>T.</given-names> </author><author><surname>Tsujigami</surname> <given-names>K.</given-names> </author><title>Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control</title><source>J Gastroenterol.</source><year>2005</year><volume>40</volume><fpage>583</fpage><lpage>590</lpage>
<author><surname>Schvarcz</surname> <given-names>E.</given-names> </author><author><surname>Palm&#233;r</surname> <given-names>M.</given-names> </author><author><surname>Aman</surname> <given-names>J.</given-names> </author><author><surname>Lindkvist</surname> <given-names>B.</given-names> </author><author><surname>Beckman</surname> <given-names>K.W.</given-names> </author><title>Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus</title><source>Diabetic Med.</source><year>1993</year><volume>10</volume><fpage>660</fpage><lpage>663</lpage>
<author><surname>Schvarcz</surname> <given-names>E.</given-names> </author><author><surname>Palm&#233;r</surname> <given-names>M.</given-names> </author><author><surname>Aman</surname> <given-names>J.</given-names> </author><author><surname>Berne</surname> <given-names>C.</given-names> </author><title>Hypoglycemia increases the gastric emptying rate in healthy subjects</title><source>Diabetes Care</source><year>1995</year><volume>18</volume><fpage>674</fpage><lpage>676</lpage>
<author><surname>Miller</surname> <given-names>G.</given-names> </author><author><surname>Palmer</surname> <given-names>K.R.</given-names> </author><author><surname>Smith</surname> <given-names>B.</given-names> </author><author><surname>Ferrington</surname> <given-names>C.</given-names> </author><author><surname>Merrick</surname> <given-names>M.V.</given-names> </author><title>Smoking delays gastric emptying of solids</title><source>Gut</source><year>1989</year><volume>30</volume><fpage>50</fpage><lpage>53</lpage>
<author><surname>Jones</surname> <given-names>K.L.</given-names> </author><author><surname>Russo</surname> <given-names>A.</given-names> </author><author><surname>Stevens</surname> <given-names>J.E.</given-names> </author><author><surname>Wishart</surname> <given-names>J.M.</given-names> </author><author><surname>Berry</surname> <given-names>M.K.</given-names> </author><author><surname>Horowitz</surname> <given-names>M.</given-names> </author><title>Predictors of delayed gastric emptying in diabetes</title><source>Diabetes Care</source><year>2001</year><volume>24</volume><fpage>1264</fpage><lpage>1269</lpage>
<author><surname>Abell</surname> <given-names>T.L.</given-names> </author><author><surname>Camilleri</surname> <given-names>M.</given-names> </author><author><surname>Donohoe</surname> <given-names>K.</given-names> </author><title>Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine</title><source>J Nucl Med Technol.</source><year>2008</year><volume>36</volume><fpage>44</fpage><lpage>54</lpage>
<author><surname>Eliasson</surname> <given-names>B.</given-names> </author><author><surname>Bj&#246;rnsson</surname> <given-names>E.</given-names> </author><author><surname>Urbanavicius</surname> <given-names>V.</given-names> </author><title>Hyperinsulinaemia impairs gastrointestinal motility and slows carbohydrate absorption</title><source>Diabetologia</source><year>1995</year><volume>38</volume><fpage>79</fpage><lpage>85</lpage>
<author><surname>Watkins</surname> <given-names>C.C.</given-names> </author><author><surname>Sawa</surname> <given-names>A.</given-names> </author><author><surname>Jaffrey</surname> <given-names>S.</given-names> </author><title>Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy</title><source>J Clin Invest.</source><year>2000</year><volume>106</volume><fpage>373</fpage><lpage>384</lpage>
<author><surname>Bunck</surname> <given-names>M.C.</given-names> </author><author><surname>Diamant</surname> <given-names>M.</given-names> </author><author><surname>Corn&#233;r</surname> <given-names>A.</given-names> </author><title>One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial</title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>762</fpage><lpage>768</lpage>
<author><surname>Heine</surname> <given-names>R.J.</given-names> </author><author><surname>Gaal</surname> <given-names>L.F.</given-names> </author><author><surname>Johns</surname> <given-names>D.</given-names> </author><title>Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial</title><source>Ann Intern Med.</source><year>2005</year><volume>143</volume><fpage>559</fpage><lpage>569</lpage>
<author><surname>Little</surname> <given-names>T.J.</given-names> </author><author><surname>Pilichiewicz</surname> <given-names>A.N.</given-names> </author><author><surname>Russo</surname> <given-names>A.</given-names> </author><title>Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses</title><source>J Clin Endocrinol Metab.</source><year>2006</year><volume>91</volume><fpage>1916</fpage><lpage>1923</lpage>
<author><surname>Vella</surname> <given-names>A.</given-names> </author><author><surname>Lee</surname> <given-names>J.S.</given-names> </author><author><surname>Camilleri</surname> <given-names>M.</given-names> </author><title>Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus</title><source>Neurogastroenterol Motil.</source><year>2002</year><volume>14</volume><fpage>123</fpage><lpage>131</lpage>
<author><surname>Samsom</surname> <given-names>M.</given-names> </author><author><surname>Szarka</surname> <given-names>L.A.</given-names> </author><author><surname>Camilleri</surname> <given-names>M.</given-names> </author><author><surname>Vella</surname> <given-names>A.</given-names> </author><author><surname>Zinsmeister</surname> <given-names>A.R.</given-names> </author><author><surname>Rizza</surname> <given-names>R.A.</given-names> </author><title>Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition</title><source>Am J Physiol Gastrointest Liver Physiol.</source><year>2000</year><volume>278</volume><fpage>946</fpage><lpage>951</lpage>
<author><surname>Koch</surname> <given-names>C.A.</given-names> </author><author><surname>Uwaifo</surname> <given-names>G.I.</given-names> </author><title>Are gastrointestinal symptoms related to diabetes mellitus and glycemic control?</title><source>Eur J Gastroenterol Hepatol.</source><year>2008</year><volume>20</volume><fpage>822</fpage><lpage>825</lpage>
<author><surname>Heine</surname> <given-names>R.J.</given-names> </author><author><surname>Brodows</surname> <given-names>R.</given-names> </author><title>Diabetic gastroparesis</title><source>N Engl J Med.</source><year>2007</year><volume>357</volume><fpage>418</fpage><lpage>420</lpage>
<author><surname>Longstreth</surname> <given-names>G.F.</given-names> </author><author><surname>Malagelada</surname> <given-names>J.R.</given-names> </author><author><surname>Kelly</surname> <given-names>K.A.</given-names> </author><title>Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis</title><source>Ann Intern Med.</source><year>1977</year><volume>86</volume><fpage>195</fpage><lpage>196</lpage>
<author><surname>Perkel</surname> <given-names>M.S.</given-names> </author><author><surname>Moore</surname> <given-names>C.</given-names> </author><author><surname>Hersh</surname> <given-names>T.</given-names> </author><author><surname>Davidson</surname> <given-names>E.D.</given-names> </author><title>Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study</title><source>Dig Dis Sci.</source><year>1979</year><volume>24</volume><fpage>662</fpage><lpage>666</lpage>
<author><surname>Peringer</surname> <given-names>E.</given-names> </author><author><surname>Jenner</surname> <given-names>P.</given-names> </author><author><surname>Marsden</surname> <given-names>C.D.</given-names> </author><title>Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5-hydroxytryptamine</title><source>J Pharm Pharmacol.</source><year>1975</year><volume>27</volume><fpage>442</fpage><lpage>444</lpage>
<author><surname>Koch</surname> <given-names>K.</given-names> </author><title>Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and tretment</title><source>Dig Dis Sci.</source><year>1999</year><volume>44</volume><fpage>1061</fpage><lpage>1075</lpage>
<author><surname>Schade</surname> <given-names>R.R.</given-names> </author><author><surname>Dugas</surname> <given-names>M.C.</given-names> </author><author><surname>Lhotsky</surname> <given-names>D.M.</given-names> </author><author><surname>Gavaler</surname> <given-names>J.S.</given-names> </author><author><surname>Thiel</surname> <given-names>D.H.</given-names> </author><title>Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis</title><source>Dig Dis Sci.</source><year>1985</year><volume>30</volume><fpage>10</fpage><lpage>15</lpage>
<author><surname>Erbas</surname> <given-names>T.</given-names> </author><author><surname>Varoglu</surname> <given-names>E.</given-names> </author><author><surname>Erbas</surname> <given-names>B.</given-names> </author><author><surname>Tastekin</surname> <given-names>G.</given-names> </author><author><surname>Akalin</surname> <given-names>S.</given-names> </author><title>Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis</title><source>Diabetes Care</source><year>1993</year><volume>16</volume><fpage>1511</fpage><lpage>1514</lpage>
<author><surname>McCallum</surname> <given-names>R.W.</given-names> </author><author><surname>Ricci</surname> <given-names>D.A.</given-names> </author><author><surname>Rakatansky</surname> <given-names>H.</given-names> </author><title>A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis</title><source>Diabetes Care</source><year>1983</year><volume>6</volume><fpage>463</fpage><lpage>467</lpage>
<author><surname>Ricci</surname> <given-names>D.A.</given-names> </author><author><surname>Saltzman</surname> <given-names>M.B.</given-names> </author><author><surname>Meyer</surname> <given-names>C.</given-names> </author><author><surname>Callachan</surname> <given-names>C.</given-names> </author><author><surname>McCallum</surname> <given-names>R.W.</given-names> </author><title>Effect of metoclopramide in diabetic gastroparesis</title><source>J Clin Gastroenterol.</source><year>1985</year><volume>7</volume><fpage>25</fpage><lpage>32</lpage>
<author><surname>Snape</surname> <given-names>W.J.</given-names> <suffix>Jr.</suffix> </author><author><surname>Battle</surname> <given-names>W.M.</given-names> </author><author><surname>Schwartz</surname> <given-names>S.S.</given-names> </author><author><surname>Braunstein</surname> <given-names>S.N.</given-names> </author><author><surname>Goldstein</surname> <given-names>H.A.</given-names> </author><author><surname>Alavi</surname> <given-names>A.</given-names> </author><title>Metoclopramide to treat gastroparesis due to diabetes mellitus</title><source>Ann Intern Med.</source><year>1982</year><volume>96</volume><fpage>444</fpage><lpage>446</lpage>
<author><surname>Talley</surname> <given-names>N.</given-names> </author><title>Diabetic gastropathy and prokinetics</title><source>Am J Gastroenterol.</source><year>2003</year><volume>98</volume><fpage>264</fpage><lpage>271</lpage>
<author><surname>Tonini</surname> <given-names>M.</given-names> </author><author><surname>Cipolina</surname> <given-names>L.</given-names> </author><author><surname>Poluuzzi</surname> <given-names>E.</given-names> </author><title>Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics</title><source>Aliment Pharmacol Ther.</source><year>2004</year><volume>19</volume><fpage>379</fpage><lpage>390</lpage>
<author><surname>Parkman</surname> <given-names>H.P.</given-names> </author><title>American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis</title><source>Gastroenterology</source><year>2004</year><volume>127</volume><fpage>1592</fpage><lpage>1622</lpage>
<author><surname>Patterson</surname> <given-names>D.</given-names> </author><author><surname>Abell</surname> <given-names>T.</given-names> </author><author><surname>Rothstein</surname> <given-names>R.</given-names> </author><author><surname>Koch</surname> <given-names>K.</given-names> </author><author><surname>Barnett</surname> <given-names>J.</given-names> </author><title>A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis</title><source>Am J Gastroenterol.</source><year>1999</year><volume>94</volume><fpage>1230</fpage><lpage>1234</lpage>
<author><surname>Farup</surname> <given-names>C.E.</given-names> </author><author><surname>Leidy</surname> <given-names>N.K.</given-names> </author><author><surname>Murray</surname> <given-names>M.</given-names> </author><author><surname>Williams</surname> <given-names>G.R.</given-names> </author><author><surname>Helbers</surname> <given-names>L.</given-names> </author><author><surname>Quigley</surname> <given-names>E.M.</given-names> </author><title>Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis</title><source>Diabetes Care</source><year>1998</year><volume>21</volume><fpage>1699</fpage><lpage>1706</lpage>
<author><surname>Heer</surname> <given-names>M.</given-names> </author><author><surname>Muller-Duysing</surname> <given-names>W.</given-names> </author><author><surname>Benes</surname> <given-names>I.</given-names> </author><title>Diabetic gastroparesis: treatment with domperidone &#8212; a double-blind, placebo-controlled trial</title><source>Digestion</source><year>1983</year><volume>27</volume><fpage>214</fpage><lpage>217</lpage>
<author><surname>Champion</surname> <given-names>E.A.</given-names> </author><title>Domperidone (Motilium) improves symptoms and solid phase gastric emptying in diabetic gastroparesis</title><source>Gastroenterol.</source><year>1987</year><volume>82</volume><fpage>975</fpage>
<author><surname>Dumitrascu</surname> <given-names>D.L.</given-names> </author><author><surname>Weinbeck</surname> <given-names>M.</given-names> </author><title>Domperidone versus metoclopramide in the treatment of diabetic gastroparesis</title><source>Am J Gastroenterol.</source><year>2000</year><volume>95</volume><fpage>316</fpage><lpage>317</lpage>
<author><surname>Sugumar</surname> <given-names>A.</given-names> </author><author><surname>Singh</surname> <given-names>A.</given-names> </author><author><surname>Pasricha</surname> <given-names>P.J.</given-names> </author><title>A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis</title><source>Clin Gastroenterol Hepatol.</source><year>2008</year><volume>6</volume><fpage>726</fpage><lpage>733</lpage>
<author><surname>Camilleri</surname> <given-names>M.</given-names> </author><title>Clinical practice. Diabetic gastroparesis</title><source>N Engl J Med.</source><year>2007</year><volume>356</volume><fpage>820</fpage><lpage>829</lpage>
<author><surname>Richards</surname> <given-names>R.D.</given-names> </author><author><surname>Davenport</surname> <given-names>K.</given-names> </author><author><surname>McCallum</surname> <given-names>R.W.</given-names> </author><title>The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin</title><source>Am J Gastroenterol.</source><year>1993</year><volume>88</volume><fpage>203</fpage><lpage>207</lpage>
<author><surname>Janssens</surname> <given-names>J.</given-names> </author><author><surname>Peeters</surname> <given-names>T.L.</given-names> </author><author><surname>Vantrappen</surname> <given-names>G.</given-names> </author><title>Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies</title><source>N Engl J Med.</source><year>1990</year><volume>322</volume><fpage>1028</fpage><lpage>1031</lpage>
<author><surname>Dive</surname> <given-names>A.</given-names> </author><author><surname>Miesse</surname> <given-names>C.</given-names> </author><author><surname>Galanti</surname> <given-names>L.</given-names> </author><title>Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study</title><source>Crit Care Med.</source><year>1995</year><volume>23</volume><fpage>1356</fpage><lpage>1362</lpage>
<author><surname>Talley</surname> <given-names>N.J.</given-names> </author><author><surname>Verlinden</surname> <given-names>M.</given-names> </author><author><surname>Geenen</surname> <given-names>D.J.</given-names> </author><title>Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial</title><source>Gut</source><year>2001</year><volume>49</volume><fpage>395</fpage><lpage>401</lpage>
<author><surname>Talley</surname> <given-names>N.J.</given-names> </author><author><surname>Verlinden</surname> <given-names>M.</given-names> </author><author><surname>Snape</surname> <given-names>W.</given-names> </author><title>Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial</title><source>Aliment Pharmacol Ther.</source><year>2000</year><volume>14</volume><fpage>1653</fpage><lpage>1661</lpage>
<author><surname>McCallum</surname> <given-names>R.W.</given-names> </author><author><surname>Cynshi</surname> <given-names>O.</given-names> </author><title>Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis &#8212; a randomized, multicentre, placebo-controlled study</title><source>Aliment Pharmacol Ther.</source><year>2007</year><volume>26</volume><fpage>1121</fpage><lpage>1130</lpage>
<author><surname>Hawkyard</surname> <given-names>C.V.</given-names> </author><author><surname>Koerner</surname> <given-names>R.J.</given-names> </author><title>The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks</title><source>J Antimicrob Chemother.</source><year>2007</year><volume>59</volume><fpage>347</fpage><lpage>358</lpage>
<author><surname>McCallum</surname> <given-names>R.W.</given-names> </author><author><surname>Prakash</surname> <given-names>C.</given-names> </author><author><surname>Campoli-Richards</surname> <given-names>D.M.</given-names> </author><author><surname>Goa</surname> <given-names>K.L.</given-names> </author><title>Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal disorders</title><source>Drugs</source><year>1988</year><volume>36</volume><fpage>652</fpage><lpage>681</lpage>
<author><surname>Champion</surname> <given-names>M.C.</given-names> </author><title>Management of idiopathic, diabetic and miscellaneous gastroparesis with cisapride</title><source>Scand J Gastroenterol Suppl.</source><year>1989</year><volume>165</volume><fpage>44</fpage><lpage>52</lpage>
<author><surname>Horowitz</surname> <given-names>M.</given-names> </author><author><surname>Maddern</surname> <given-names>G.J.</given-names> </author><author><surname>Maddox</surname> <given-names>A.</given-names> </author><author><surname>Wishart</surname> <given-names>J.</given-names> </author><author><surname>Chatterton</surname> <given-names>B.E.</given-names> </author><author><surname>Shearman</surname> <given-names>D.J.</given-names> </author><title>Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis</title><source>Gastroenterology</source><year>1987</year><volume>93</volume><fpage>311</fpage><lpage>315</lpage>
<author><surname>Horowitz</surname> <given-names>M.</given-names> </author><author><surname>Maddox</surname> <given-names>A.</given-names> </author><author><surname>Harding</surname> <given-names>P.E.</given-names> </author><title>Effect of cisapride on gastric and esophageal emptying in insulin-dependent diabetes mellitus</title><source>Gastroenterology</source><year>1987</year><volume>92</volume><fpage>1899</fpage><lpage>1907</lpage>
<author><surname>McHugh</surname> <given-names>S.</given-names> </author><author><surname>Lico</surname> <given-names>S.</given-names> </author><author><surname>Diamant</surname> <given-names>N.E.</given-names> </author><title>Cisapride vs. metoclopramide</title><source>Dig Dis Sci.</source><year>1992</year><volume>37</volume><fpage>997</fpage><lpage>1001</lpage>
<author><surname>Havelund</surname> <given-names>T.</given-names> </author><author><surname>Oster-J&#248;rgensen</surname> <given-names>E.</given-names> </author><author><surname>Esh&#248;j</surname> <given-names>O.</given-names> </author><author><surname>Larsen</surname> <given-names>M.L.</given-names> </author><author><surname>Lauritsen</surname> <given-names>K.</given-names> </author><title>Effects of cisapride on gastroparesis in patients with insulin-dependent diabetes mellitus</title><source>Acta Medica Scandinavica</source><year>1987</year><volume>222</volume><fpage>339</fpage><lpage>343</lpage>
<author><surname>Takaya</surname> <given-names>K.</given-names> </author><author><surname>Ariyasu</surname> <given-names>H.</given-names> </author><author><surname>Kanamoto</surname> <given-names>N.</given-names> </author><title>Ghrelin strongly stimulates growth hormone release in humans</title><source>J Clin Endocrinol Metab.</source><year>2000</year><volume>85</volume><fpage>4908</fpage><lpage>4911</lpage>
<author><surname>Peino</surname> <given-names>R.</given-names> </author><author><surname>Baldelli</surname> <given-names>R.</given-names> </author><author><surname>Rodriguez-Garcia</surname> <given-names>J.</given-names> </author><title>Ghrelin-induced growth hormone secretion in humans</title><source>Eur J Endocrinol.</source><year>2000</year><volume>143</volume><fpage>R11</fpage><lpage>R14</lpage>
<author><surname>Date</surname> <given-names>Y.</given-names> </author><author><surname>Kojima</surname> <given-names>M.</given-names> </author><author><surname>Hosoda</surname> <given-names>H.</given-names> </author><title>Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans</title><source>Endocrinology</source><year>2000</year><volume>141</volume><fpage>4255</fpage><lpage>4261</lpage>
<author><surname>Kojima</surname> <given-names>M.</given-names> </author><author><surname>Hosoda</surname> <given-names>H.</given-names> </author><author><surname>Date</surname> <given-names>Y.</given-names> </author><author><surname>Nakazato</surname> <given-names>M.</given-names> </author><author><surname>Matsuo</surname> <given-names>H.</given-names> </author><author><surname>Kangawa</surname> <given-names>K.</given-names> </author><title>Ghrelin is a growth-hormone-releasing acylated peptide from stomach</title><source>Nature</source><year>1999</year><volume>402</volume><fpage>656</fpage><lpage>660</lpage>
<author><surname>Howard</surname> <given-names>A.D.</given-names> </author><author><surname>Feighner</surname> <given-names>S.D.</given-names> </author><author><surname>Cully</surname> <given-names>D.F.</given-names> </author><title>A receptor in pituitary and hypothalamus that functions in growth hormone release</title><source>Science</source><year>1996</year><volume>273</volume><fpage>974</fpage><lpage>977</lpage>
<author><surname>Tack</surname> <given-names>J.</given-names> </author><author><surname>Depoortere</surname> <given-names>I.</given-names> </author><author><surname>Bisschops</surname> <given-names>R.</given-names> </author><title>Influence of ghrelin on interdigestive gastrointestinal motility in humans</title><source>Gut</source><year>2006</year><volume>55</volume><fpage>327</fpage><lpage>333</lpage>
<author><surname>Wren</surname> <given-names>A.M.</given-names> </author><author><surname>Seal</surname> <given-names>L.J.</given-names> </author><author><surname>Cohen</surname> <given-names>M.A.</given-names> </author><title>Ghrelin enhances appetite and increases food intake in humans</title><source>J Clin Endocrinol Metab.</source><year>2001</year><volume>86</volume><fpage>5992</fpage>
<author><surname>Druce</surname> <given-names>M.R.</given-names> </author><title>Ghrelin increases food intake in obese as well as lean subjects</title><source>Int J Obes (Lond).</source><year>2005</year><volume>29</volume><fpage>1130</fpage><lpage>1136</lpage>
<author><surname>Strasser</surname> <given-names>F.</given-names> </author><author><surname>Lutz</surname> <given-names>T.A.</given-names> </author><author><surname>Maeder</surname> <given-names>M.T.</given-names> </author><title>Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study</title><source>Br J Cancer</source><year>2008</year><volume>98</volume><fpage>300</fpage><lpage>308</lpage>
<author><surname>Murray</surname> <given-names>C.D.</given-names> </author><author><surname>Martin</surname> <given-names>N.M.</given-names> </author><author><surname>Patterson</surname> <given-names>M.</given-names> </author><title>Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study</title><source>Gut</source><year>2005</year><volume>54</volume><fpage>1693</fpage><lpage>1698</lpage>
<author><surname>Popescu</surname> <given-names>I.</given-names> </author><author><surname>Fleshner</surname> <given-names>P.R.</given-names> </author><author><surname>Pezzullo</surname> <given-names>J.C.</given-names> </author><author><surname>Charlton</surname> <given-names>P.A.</given-names> </author><author><surname>Kosutic</surname> <given-names>G.</given-names> </author><author><surname>Senagore</surname> <given-names>A.J.</given-names> </author><title>The Ghrelin agonist TZP-101 for management of postoperative ileus after partial colectomy: a randomized, dose-ranging, placebo-controlled clinical trial</title><source>Dis Colon Rectum</source><year>2010</year><volume>53</volume><fpage>126</fpage><lpage>134</lpage>
<author><surname>Ejskjaer</surname> <given-names>N.</given-names> </author><author><surname>Vestergaard</surname> <given-names>E.T.</given-names> </author><author><surname>Hellstr&#246;m</surname> <given-names>P.M.</given-names> </author><title>Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis</title><source>Aliment Pharmacol Ther.</source><year>2009</year><volume>29</volume><fpage>1179</fpage><lpage>1187</lpage>
<author><surname>Lasseter</surname> <given-names>K.C.</given-names> </author><author><surname>Shaughnessy</surname> <given-names>L.</given-names> </author><author><surname>Cummings</surname> <given-names>D.</given-names> </author><title>Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study</title><source>J Clin Pharmacol.</source><year>2008</year><volume>48</volume><fpage>193</fpage><lpage>202</lpage>
<author><surname>Wang</surname> <given-names>C.P.</given-names> </author><author><surname>Kao</surname> <given-names>C.H.</given-names> </author><author><surname>Chen</surname> <given-names>W.K.</given-names> </author><author><surname>Lo</surname> <given-names>W.Y.</given-names> </author><author><surname>Hsieh</surname> <given-names>C.L.</given-names> </author><title>A single-blinded, randomized pilot study evaluating effects of electroacupuncture in diabetic patients with symptoms suggestive of gastroparesis</title><source>J Altern Complement Med.</source><year>2008</year><volume>14</volume><fpage>833</fpage><lpage>839</lpage>
<author><surname>Mearin</surname> <given-names>F.</given-names> </author><author><surname>Camilleri</surname> <given-names>M.</given-names> </author><author><surname>Malagelada</surname> <given-names>J.R.</given-names> </author><title>Pyloric dysfunction in diabetics with recurrent nausea and vomiting</title><source>Gastroenterology</source><year>1986</year><volume>90</volume><fpage>1919</fpage><lpage>1925</lpage>
<author><surname>Camilleri</surname> <given-names>M.</given-names> </author><author><surname>Brown</surname> <given-names>M.L.</given-names> </author><author><surname>Malagelada</surname> <given-names>J.R.</given-names> </author><title>Relationship between impaired gastric emptying and abnormal gastrointestinal motility</title><source>Gastroenterology</source><year>1986</year><volume>91</volume><fpage>94</fpage><lpage>99</lpage>
<author><surname>Jankovic</surname> <given-names>J.</given-names> </author><author><surname>Brin</surname> <given-names>M.F.</given-names> </author><title>Therapeutic uses of botulinum toxin</title><source>N Engl J Med.</source><year>1991</year><volume>324</volume><fpage>1186</fpage><lpage>1194</lpage>
<author><surname>Pehlivanov</surname> <given-names>N.</given-names> </author><author><surname>Pasricha</surname> <given-names>P.J.</given-names> </author><title>Achalasia: botox, dilatation or laparoscopic surgery in 2006</title><source>Neurogastroenterol Motil.</source><year>2006</year><volume>18</volume><fpage>799</fpage><lpage>804</lpage>
<author><surname>Park</surname> <given-names>M.I.</given-names> </author><author><surname>Camilleri</surname> <given-names>M.</given-names> </author><title>Gastroparesis: clinical update</title><source>Am J Gastroenterol</source><year>2006</year><volume>101</volume><fpage>1129</fpage><lpage>1139</lpage>
<author><surname>Arts</surname> <given-names>J.</given-names> </author><author><surname>Holvoet</surname> <given-names>L.</given-names> </author><author><surname>Caenepeel</surname> <given-names>P.</given-names> </author><title>Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis</title><source>Aliment Pharmacol Ther.</source><year>2007</year><volume>26</volume><fpage>1251</fpage><lpage>1258</lpage>
<author><surname>Friedenberg</surname> <given-names>F.K.</given-names> </author><author><surname>Palit</surname> <given-names>A.</given-names> </author><author><surname>Parkman</surname> <given-names>H.P.</given-names> </author><author><surname>Hanlon</surname> <given-names>A.</given-names> </author><author><surname>Nelson</surname> <given-names>D.B.</given-names> </author><title>Botulinum toxin A for the treatment of delayed gastric emptying</title><source>Am J Gastroenterol.</source><year>2008</year><volume>103</volume><fpage>416</fpage><lpage>423</lpage>
<url>http://www.nice.org.uk/nicemedia/live/11130/31200/31200.pdf</url>
<author><surname>Anand</surname> <given-names>C.</given-names> </author><author><surname>Al-Juburi</surname> <given-names>A.</given-names> </author><author><surname>Familoni</surname> <given-names>B.</given-names> </author><title>Gastric electrical stimulation is safe and effective: a long-term study in patients with drug-refractory gastroparesis in three regional centers</title><source>Digestion</source><year>2007</year><volume>75</volume><fpage>83</fpage><lpage>89</lpage>
<author><surname>Abell</surname> <given-names>T.L.</given-names> </author><author><surname>Malinowski</surname> <given-names>S.</given-names> </author><author><surname>Minocha</surname> <given-names>A.</given-names> </author><title>Nutrition aspects of gastroparesis and therapies for drug-refractory patients</title><source>Nutr Clin Pract.</source><year>2006</year><volume>21</volume><fpage>23</fpage><lpage>33</lpage>
<author><surname>Cutts</surname> <given-names>T.F.</given-names> </author><author><surname>Luo</surname> <given-names>J.</given-names> </author><author><surname>Starkebaum</surname> <given-names>W.</given-names> </author><author><surname>Rashed</surname> <given-names>H.</given-names> </author><author><surname>Abell</surname> <given-names>T.L.</given-names> </author><title>Is gastric electrical stimulation superior to standard pharmacologic therapy in improving GI symptoms, healthcare resources, and long-term health care benefits?</title><source>Neurogastroenterol Motil.</source><year>2005</year><volume>17</volume><fpage>35</fpage><lpage>43</lpage>
<author><surname>Maranki</surname> <given-names>J.</given-names> </author><author><surname>Parkman</surname> <given-names>H.P.</given-names> </author><title>Gastric electric stimulation for the treatment of gastroparesis</title><source>Curr Gastroenterol Rep.</source><year>2007</year><volume>9</volume><fpage>286</fpage><lpage>294</lpage>
<author><surname>Maranki</surname> <given-names>J.L.</given-names> </author><author><surname>Lytes</surname> <given-names>V.</given-names> </author><author><surname>Meilahn</surname> <given-names>J.E.</given-names> </author><title>Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis</title><source>Dig Dis Sci.</source><year>2008</year><volume>53</volume><fpage>2072</fpage><lpage>2078</lpage>
<author><surname>Jones</surname> <given-names>M.P.</given-names> </author><author><surname>Maganti</surname> <given-names>K.</given-names> </author><title>A systematic review of surgical therapy for gastroparesis</title><source>Am J Gastroenterol.</source><year>2003</year><volume>98</volume><fpage>2122</fpage><lpage>2129</lpage>
